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Abstract 
High-throughput discovery of inhibitors for DNA gyrase and 
DNA topoisomerase VI 
James Andrew Taylor 
DNA topoisomerases are important drug targets that have been 
successfully exploited to produce effective anticancer and 
antimicrobial agents. Unfortunately the increasing level of antibiotic 
resistance amongst pathogen strains has diminished the potency of 
existing antimicrobials. The discovery of novel inhibitors which 
target DNA topoisomerase would provide the basis for new 
antimicrobials effective against these resistant strains. However, 
such research has been limited by the low-throughput nature of 
traditional assays. Using a novel high-throughput assay I have 
screened a library of 960 compounds against Escherichia coli DNA 
gyrase and Methanosarcina mazei topoisomerase VI. The two novel 
hits produced from the E. coli DNA gyrase screen, mitoxanthrone 
and suramin, were tested for bactericidal activity against Gram-
negative and Gram-positive bacteria. Mitoxanthrone was found to 
inhibit the growth of the Gram-positive bacteria Mycobacterium 
smegmatis in liquid cultures. Their modes of inhibition were also 
investigated in vitro. Suramin was found to inhibit the enzyme by 
preventing it from binding to DNA, whilst mitoxanthrone was shown 
to stabilize enzyme-mediated double-strand breaks (the “cleavage 
complex”). The screen against M. mazei topo VI produced six hits, 
five of which were novel. The mechanism of these compounds was 
explored in vitro against both M. mazei topo VI and S. shibatae topo 
VI, although the exact details proved elusive. The hits from the M. 
mazei screen were tested against Arbadopsis thaliana topo VI in 
planta using a morphological screen. One hit, hexylresorcinol, 
exhibited herbicidal activity and produced a morphology similar to 
topoisomerase VI knock-out mutations in Arbadopsis. In addition, 
the mechanism of M. mazei topo VI was explored revealing that the 
enzyme strongly binds to DNA in the presence of ATP. It was found 
that the M. mazei enzyme complex is unusually robust; with the 
subunits remaining associated despite harsh buffer conditions, and 
appears to be resistant to proteinase K digest. Additionally, the 
limits of the traditional gel-based topoisomerase assay and the 
microtitre plate-assay were explored, and the potential for triplex-
affinity purification of DNA plasmids was investigated. 
iv 
 
Acknowledgments 
 
First and foremost I would like to thank my supervisor Prof. Tony Maxwell 
for all the support, advice and insight he has provided over the course of 
this project (as well as generally putting up with me!). I’d also like to thank 
my co-supervisor Prof. Rob Field for his helpful and down-to-earth 
comments and advice on the more chemical aspects of the project. I’ve 
learned so much from both of you. 
I’d like to thank my family, especially my parents, for their continued 
love and support over the years. You’ve always believed in me, and that 
means so much. 
Next I would like to thank all my collaborators and those who have 
contributed towards this work including: Daniel Mitrovic for his assistance 
with the triplex-affinity purification of DNA; Dr Kevin Corbett and Prof. 
James Berger for supplying the clones for the M. mazei topo VI enzyme 
(University of California Berkley); Danielle Gadelle and Patrick Forterre for 
providing the S. shibatae topoisomerase VI (University of Paris XI, Orsay); 
August Johansson and Dr Neil Thompson for the AFM imaging (University of 
Leeds); and Dr Mark Thompson for providing experimental antimalarial 
compounds (University of Sheffield). 
I’d like to thank all the mentors I’ve had over the years. In particular 
I’d like to thank Lesley Mitchenall for her exceptional experimental know-
how, Dr Nick Burton for his insights into the microtitre plate assay and 
baculovirus expression (amongst other things), Martin Stocks for his 
practical outlook and being on my supervisory committee, Nicola Stacey for 
training and advice with the Arabidopsis work, Dr Matthew Burrell for initial 
training on the microtitre plate-based assay, Dr Richard Bowater and Prof. 
Julea Butt for early encouragement, Dr Martin Rejzek for help with the 
Microsource Library and Dr Sandra Grieve for her inspirational pep-talks. In 
addition I’d like to thank all members of the Maxwell Group and Inspiralis 
Ltd., past and present, for help and insights. 
Lastly I’d like to thank all my friends who have stood by during this 
time. In particular I’d like to thank Daniel Mitrovic and Stacey Price for 
being exceptional house-mates, Grant Howitt and Mary Hamilton, Fay Ikin 
and Hannah Powell-Smith, Lauran Wheaton, and Lizzy Townsend. I’d also 
like to thank the other denizens of the student office: Stuart King, Tracey 
Holley, Dr Karl Syson, Dr Fredric Collin, Dr Marcus Edwards and Farzana 
Miah for fruitful conversations and generating a positive working 
environment. 
  
v 
 
Abbreviations 
ADP Adenosine 5'-diphosphate 
ADPNP 5′-Adenylyl β,γ-imidodiphosphate 
ATP Adenosine 5'-triphosphate 
bp Base pairs 
BSA Bovine serum albumin 
CARE Continuous affinity recycle extraction 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dsDNA Double stranded DNA 
dNTP Deoxyribonucleoside 5'-triphosphate 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
FCS Foetal calf serum 
G segment DNA gate segment 
GyrA Gyrase subunit A 
GyrB Gyrase subunit B  
IPTG Isopropyl-β-D-thiogalactopyranoside 
kb Kilobases 
kDa KiloDaltons 
LDH Lactate dehydrogenase 
Lin. Linear DNA plasmid 
M Molar 
MRSA Methicillin resistant Staphylococcus aureus 
NADH Nicotinamide adenine dinucleotide 
MmT6 Methanosarcina Mazei topoisomerase VI  
MOI Multiplicity of Infection 
vi 
 
  
OAc Acetate 
OC Open-circular DNA plasmid 
P1/P2 Viral titre from passage 1 or 2 
PCR Polymerase chain reaction 
PEP phosphoenolpyruvate 
PfTopo6A1 Hypothetical Plasmodium falciparum topoisomerse VI subunit 
A (PF10_0412)  
PfTopo6A2 Hypothetical Plasmodium falciparum topoisomerse VI subunit 
A (PFL0825c) 
PfTopo6B Hypothetical Plasmodium falciparum topoisomerse VI subunit 
B (MAL13P1.328) 
PK pyruvate kinase 
RNA Ribonucleic acid 
SC Supercoiled DNA plasmid 
SEM Scanning electron microscopy 
SDS Sodium dodecyl sulphate 
PAGE Polyacrylamide gel electrophoresis 
Tm DNA melting point  
TF buffer Triplex Forming buffer 
T segment DNA transfer segment 
Topo Topoisomerase 
Tris Tris(hydroxymethyl)aminomethane 
U Units of enzyme 
v/v Volume per volume 
w/v Weight per volume 
  
  
vii 
 
Table of Contents 
 
Statement .......................................................................................... ii 
Abstract ............................................................................................ iii 
Acknowledgments ............................................................................... iv 
Abbreviations ...................................................................................... v 
List of Figures ................................................................................... xii 
List of Tables .................................................................................... xv 
List of Equations ................................................................................ xv 
Dedication ....................................................................................... xvi 
1 General Introduction ........................................................................ 1 
1.1 Infectious diseases, antibiotics and the problem of antibiotic  
 resistance .................................................................................... 1 
1.2 Drug screening strategies .............................................................. 4 
1.3 Antimicrobial targets ..................................................................... 6 
1.4 DNA Topology .............................................................................. 7 
1.5 DNA topoisomerases ..................................................................... 9 
1.5.1 Overview ............................................................................... 9 
1.5.2 Type I topoisomerases ........................................................... 12 
1.5.3 Type II topoisomerases ......................................................... 15 
1.6 Topoisomerase VI ....................................................................... 19 
1.6.1 Biological roles of topoisomerase VI ........................................ 21 
1.6.2 Topoisomerase VI structure .................................................... 25 
1.6.3 Topoisomerase VI mechanism ................................................ 28 
1.6.4 Inhibitors of topoisomerase VI ................................................ 29 
1.7 DNA gyrase ............................................................................... 30 
1.7.1 The biological role of DNA gyrase ............................................ 31 
1.7.2 Structure of DNA gyrase ........................................................ 32 
1.7.3 Mechanism of DNA gyrase ...................................................... 34 
1.8 DNA gyrase inhibitors ................................................................. 36 
1.8.1 Quinolones ........................................................................... 36 
1.8.2 Aminocoumarins ................................................................... 39 
1.8.3 Other small molecule inhibitors of DNA gyrase .......................... 42 
1.9 A high-throughput assay for topoisomerase inhibitors ..................... 44 
viii 
 
1.10 Project aims .............................................................................. 48 
2 Materials and Methods .................................................................... 50 
2.1 Buffers and solutions .................................................................. 50 
2.2 Antibiotics ................................................................................. 52 
2.3 Microbiology .............................................................................. 52 
2.3.1 Strains and species ............................................................... 52 
2.3.2 Growth media ....................................................................... 52 
2.3.3 Preparation of chemically competent cells ................................ 54 
2.3.4 Halo assays .......................................................................... 55 
2.3.5 Slope assays ........................................................................ 55 
2.3.6 Liquid-culture growth assays .................................................. 55 
2.3.7 Colony counting assays .......................................................... 56 
2.4 Arabidopsis Methods ................................................................... 56 
2.4.1 Arabidopsis lines used ........................................................... 56 
2.4.2 Seed sterilization .................................................................. 56 
2.4.3 Hypocotyl extension assays .................................................... 56 
2.4.4 Flow cytometry experiments ................................................... 57 
2.4.5 Cryo- Scanning Electron Microscopy (SEM) on hypocotyls .......... 57 
2.5 Plasmids and oligonucleotides ...................................................... 58 
2.5.1 Oligonucleotides ................................................................... 58 
2.5.2 Substrate plasmids ................................................................ 58 
2.5.3 Small-scale preparation of plasmid DNA ................................... 58 
2.5.4 Large-scale preparation of plasmid DNA ................................... 58 
2.5.5 Preparation of relaxed pNO1 ................................................... 60 
2.5.6 Phenol: chloroform:isoamyl alcohol extraction .......................... 60 
2.5.7 Precipitation of DNA .............................................................. 60 
2.5.8 Determination of DNA concentrations ...................................... 61 
2.5.9 Polymerase Chain Reaction (PCR) ........................................... 61 
2.5.10 Restriction digests and ligations .............................................. 62 
2.5.11 Isolation of PCR products from agarose gels ............................. 62 
2.5.12 DNA Sequencing ................................................................... 63 
2.6 Protein preparation ..................................................................... 64 
2.6.1 Insect cell culture conditions .................................................. 64 
2.6.2 Escherichia coli GyrA ............................................................. 64 
ix 
 
2.6.3 Escherichia coli GyrB ............................................................. 65 
2.6.4 Methanosarcina mazei topoisomerase VI .................................. 66 
2.6.5 Plasmodium falciparum hypothetical topoisomerase VI .............. 67 
2.6.6 Chicken erythrocyte topoisomerase I ....................................... 69 
2.6.7 Wheat germ topoisomerase I .................................................. 69 
2.6.8 Protein concentration determination ........................................ 69 
2.6.9 SDS-PAGE ............................................................................ 69 
2.7 DNA topoisomerase assays .......................................................... 70 
2.7.1 Agarose gel electrophoresis assay ........................................... 70 
2.7.2 Cleavage-complex stab stabilization assay ............................... 70 
2.7.3 ATPase assay ....................................................................... 71 
2.7.4 Native gel-shift assay ............................................................ 71 
2.7.5 Microtitre plate-based assay ................................................... 71 
2.8 Screening of a compound library for topoisomerase inhibitors .......... 72 
2.8.1 Library used ......................................................................... 72 
2.8.2 Screening protocol ................................................................ 73 
2.8.3 Data processing, hit selection and hit validation ........................ 73 
3 Exploration of Topoisomerase Assays ............................................... 75 
3.1 Introduction ............................................................................... 75 
3.2 Results ...................................................................................... 77 
3.2.1 Lithium Acetate as a running buffer. ........................................ 77 
3.2.2 Resolution of a second band from supercoiled plasmid  
 with LAE. ............................................................................. 79 
3.2.3 Triplex affinity purification of supercoiled plasmid ..................... 80 
3.2.4 Performance of buffers 9 and 12 in the microtitre  
 plate-based assay ................................................................. 84 
3.3 Discussion ................................................................................. 85 
3.3.1 Lithium Acetate EDTA as an electrophoresis running buffer ........ 85 
3.3.2 Triplex-affinity purification of supercoiled plasmids .................... 87 
4 Escherichia coli DNA Gyrase Screen .................................................. 89 
4.1 Introduction ............................................................................... 89 
4.2 Results ...................................................................................... 90 
4.2.1 Initial screening .................................................................... 90 
4.2.2 Intrinsic fluorescence of the library.......................................... 93 
x 
 
4.2.3 Elimination of false positives................................................... 93 
4.2.4 Statistical evaluation of screen ............................................... 97 
4.2.5 Quinacrine and 9-aminoacridine as activators of DNA gyrase ...... 98 
4.2.6 Mitoxanthrone and suramin as novel DNA gyrase inhibitors ...... 100 
4.2.7 Effect on growth of Gram-negative and Gram-positive  
 bacteria. ............................................................................ 103 
4.3 Discussion ............................................................................... 108 
4.3.1 Performance of the screen.................................................... 108 
4.3.2 9-aminoacridine and quinacrine as DNA gyrase activators ........ 109 
4.3.3 Mitoxanthrone and suramin as novel DNA gyrase inhibitors ...... 110 
4.3.4 Mitoxanthrone as an antimicrobial compound ......................... 111 
5 Methanosarcina mazei topoisomerase VI screen ............................... 113 
5.1 Introduction ............................................................................. 113 
5.2 Results .................................................................................... 115 
5.2.1 Characterisation of M. mazei topo VI ..................................... 115 
5.2.2 Inhibition of M. mazei topo VI by radicicol .............................. 123 
5.2.3 Screening against M. mazei topo VI ....................................... 125 
5.2.4 Elimination of false positives................................................. 129 
5.2.5 Statistical evaluation of screen ............................................. 132 
5.2.6 Characterisation of novel topo VI inhibitors in vitro ................. 133 
5.2.7 Cross-reactivity of M. mazei topo VI and E. coli DNA  
 gyrase hits ......................................................................... 141 
5.2.8 Inhibition of S. shibatae topo VI by the M. mazei  
 topo VI hits. ....................................................................... 143 
5.2.9 Testing against Arabidopsis topo VI in vivo ............................. 145 
5.2.10 Expression trials with P. falciparum topo VI ............................ 154 
5.2.11 Activities of anti-malarial compounds against M. mazei  
 topo VI .............................................................................. 161 
5.3 Discussion ............................................................................... 163 
5.3.1 M. mazei topo VI ATPase activity and DNA cleavage ................ 163 
5.3.2 Unusual topoisomers produced by M. mazei topo VI ................ 164 
5.3.3 Performance of the screen.................................................... 166 
5.3.4 Novel inhibitors of M. mazei topo VI ...................................... 166 
5.3.5 Cross-reactivity of M. mazei topo VI and E. coli gyrase  
xi 
 
 screen hits ......................................................................... 168 
5.3.6 Mechanism of action for screen hits ....................................... 169 
5.3.7 Hexylresorcinol as an inhibitor of Arabidopsis  
 endoreduplication................................................................ 171 
5.3.8 Expression of P. falciparum topo VI ....................................... 174 
5.3.9 P. falciparum topo VI as a drug target ................................... 176 
6 General Discussion ....................................................................... 178 
6.1 Introduction ............................................................................. 178 
6.2 Characteristics of M. mazei topo VI ............................................. 179 
6.3 The suitability of the microtitre plate-based assay for screening ..... 180 
6.4 Perspectives on screen hits ........................................................ 183 
6.5 Concluding remarks .................................................................. 186 
7 Appendix .................................................................................... 187 
7.1 High-Throughput Microtitre Plate-Based Assay for  
 DNA Topoisomerases ................................................................ 189 
7.1.1 2.1 Buffers and Solutions ..................................................... 191 
7.2 Screening data ......................................................................... 206 
7.2.1 E. coli DNA gyrase screen .................................................... 206 
7.2.2 M. mazei topoisomerase VI screen ........................................ 211 
8 References .................................................................................. 214 
 
  
xii 
 
List of Figures 
 
Figure 1.1 Number of deaths attributable to MRSA in the UK.. ................... 2 
Figure 1.2 The number of antibacterial agents approved by the  
USA FDA. ........................................................................... 3 
Figure 1.3 The effect in a change in Lk upon the twist and writhe of a 
restrained DNA molecule.. .................................................... 9 
Figure 1.4 DNA topoisomers interconvertible by DNA  
 topoisomerases.. ............................................................... 11 
Figure 1.5 Summary of reactions catalysed by specific  
 topoisomerases. ................................................................ 11 
Figure 1.6 Mechanism of action for type IA topoisomerases.. .................. 12 
Figure 1.7 Mechanism of action for type IB topoisomerases .................... 14 
Figure 1.8 General structure of type IIA topoisomerases.. ...................... 16 
Figure 1.9 Mechanism of action for type IIA topoisomerases. .................. 17 
Figure 1.10 Formation of catenated DNA during termination of  
 replication. ....................................................................... 21 
Figure 1.11 Morphology of topo VI knock-out mutants. .......................... 23 
Figure 1.12 Schizogony in the Plasmodium life cycle. ............................. 24 
Figure 1.13 Domain structure of S. shibatae and M. mazei topo VI  
 subunits. .......................................................................... 25 
Figure 1.14 Structure of Sulfolobus shibatae topo VI. ............................. 26 
Figure 1.15 Structure of Methanosarcina mazei topo VI. ......................... 26 
Figure 1.16 Mechanism of topo VI........................................................ 28 
Figure 1.17 Structures of S. shibatae topo VI inhibitors. ......................... 30 
Figure 1.18 The effect of replication on the supercoiling state  
of DNA.. ......................................................................... 32 
Figure 1.19 Domain structure of DNA gyrase subunits ............................ 33 
Figure 1.20 Crystal structures of DNA gyrase domains ........................... 34 
Figure 1.21 DNA wrapping and strand passage by DNA gyrase. ............... 35 
Figure 1.22 Structures of selected quinolones. ...................................... 37 
Figure 1.23 Binding of moxifloxacin to topo IV breakage-reunion  
 domain.. .......................................................................... 38 
Figure 1.24 Structures of the three natural aminocoumarins.. ................. 40 
Figure 1.25 The overlapping binding sites of ADPNP and  
novobiocin.. .................................................................... 41 
Figure 1.26 Structure of simocyclinone D8. ........................................... 43 
Figure 1.27 Motifs for DNA triplex formation. ........................................ 45 
Figure 1.28 Graphical depiction of the agarose and microtitre  
 plate-based assays.. ........................................................ 47 
Figure 1.29 General outline of project.. ................................................ 49 
Figure 3.1 Running relaxed and SC pNO1 in lithium acetate buffer. .......... 78 
Figure 3.2 Running LAE gels at high voltages. ....................................... 78 
Figure 3.3 SC plasmid run for long periods on an LAE gel... .................... 79 
Figure 3.4 Triplex-affinity column chromatography of DNA. ..................... 80 
Figure 3.5 Triplex-affinity purification with TF or buffer 9.. ...................... 81 
Figure 3.6 Buffers 9 and 12 as triplex forming buffers in the  
Microtitre plate assay. ........................................................ 85 
Figure 4.1 Results of E. coli gyrase screen. ........................................... 91 
xiii 
 
Figure 4.2 Percentage inhibition for Genplus plate 8 against E. coli DNA 
gyrase with hits labelled. .................................................... 92 
Figure 4.3 Intrinsic fluorescence of Genplus library ................................ 93 
Figure 4.4 Example of validation assay for putative E. coli gyrase screen 
hits.. ................................................................................ 94 
Figure 4.5 Example of testing the ability of false positives to  
interfere with the assay. ..................................................... 95 
Figure 4.6 Comparing harmalol library stock to fresh preparation. ........... 96 
Figure 4.7 Histogram of Z' values for the E. coli gyrase screen ................ 98 
Figure 4.8 Testing the effects of merbromin and quinacrine on the  
 microtitre plate-based assay.. ............................................. 99 
Figure 4.9 DNA gyrase activation in the presence of quinacrine ............. 100 
Figure 4.10 Effect of 2 µM quinacrine on the migration of relaxed  
and supercoiled pNO1.. .................................................. 101 
Figure 4.11 In vitro characterisation of mitoxanthrone and  
suramin. ....................................................................... 102 
Figure 4.12 Gel shift analysis of the binding DNA gyrase to DNA  
in the presence of suramin. ............................................. 103 
Figure 4.13 The effects of mitoxanthrone and suramin on  
bacterial growth on solid media.. ..................................... 104 
Figure 4.14 Bacterial growth in liquid media.. ...................................... 105 
Figure 4.15 Colony counting of M. smegmatis mc2155 in the  
presence of mitoxanthrone or suramin. ............................ 106 
Figure 4.16 M. smegmatis streaked on Middlebrooks 7H11 agar  
 containing 100 µM mitoxanthrone. ................................... 107 
Figure 4.17 Structures of novel DNA gyrase inhibitors from  
screen. ......................................................................... 110 
Figure 5.1 Activity of M. mazei topo VI. .............................................. 115 
Figure 5.2 Titration of M. mazei topo VI with relaxed or SC  
pNO1. ............................................................................ 116 
Figure 5.3 Processing of unusual products of topo VI by wheat germ 
topoisomerase I.. ............................................................ 118 
Figure 5.4 Time course reactions for M. mazei topo VI. ........................ 119 
Figure 5.5 Processing of unusual topo VI products by nicking  
 endonuclease Nb.BtsI.. .................................................... 120 
Figure 5.6 AFM images of M. mazei topo VI reaction products.. ............. 121 
Figure 5.7 Titration of radicicol with M. mazei topo VI in the  
agarose gel assay.. .......................................................... 123 
Figure 5.8 Titrations of novobiocin and radicicol with E. coli  
GyrB in the ATPase assay.. ............................................... 124 
Figure 5.9 Titrations of novobiocin and radicicol with M. mazei  
topo VI in the ATPase assay.. ............................................ 126 
Figure 5.10 Results of M. mazei topo VI screen. .................................. 127 
Figure 5.11 Percentage inhibition for Genplus plate 6 against  
M. mazei topo VI with hits labelled. .................................. 128 
Figure 5.12 Validation for putative M. mazei topo VI screen hits. ........... 130 
Figure 5.13 Titrations of quinacrine with wheat germ topo I or  
M. mazei topo VI. .......................................................... 131 
Figure 5.14 Histogram of Z' values for the M. mazei topo VI  
screen .......................................................................... 133 
Figure 5.15 Determination of IC50s for M. mazei topo VI hits.. ............... 134 
Figure 5.16 Native gel shift assays for the binding of M. mazei  
xiv 
 
topo VI to a 147 bp DNA fragment in the presence  
of screen hits.. .............................................................. 135 
Figure 5.17 Inhibition of the ATPase activity of M. mazei topo VI  
by screen hits. .............................................................. 136 
Figure 5.18 Pyruvate kinase assays with hexylresorcinol and  
 quinacrine. ................................................................... 138 
Figure 5.19 Activation of M. mazei topo VI ATPase activity by 
hexylresorcinol.. ............................................................ 139 
Figure 5.20 Testing cleavage conditions with M. mazei topo VI. ............. 140 
Figure 5.21 Cleavage complex stabilization assays with M. mazei  
topo VI hits. .................................................................. 141 
Figure 5.22 Mitoxanthrone as an inhibitor of M. mazei topo VI. ............. 142 
Figure 5.23 Testing M. mazei topo VI hits against S. shibatae  
topo VI.. ....................................................................... 144 
Figure 5.24 Cleavage protection assay for screen hits with  
S. shibatae topo VI.. ...................................................... 145 
Figure 5.25 Inhibition of Arabidopsis hypocotyl extension by hexylresorcinol.
 ................................................................................... 147 
Figure 5.26 Sample Arabidopsis seedlings from hypocotyl assay  
 grown on 40 µM hexylresorcinol. ..................................... 148 
Figure 5.27 Light-grown Arabidopsis grown on 40 µM hexylresorcinol.. .. 149 
Figure 5.28 Recovery of hexylresorcinol fed Arabidopsis plants. ............. 150 
Figure 5.29 SEM images of Arabidopsis seedling hypocotyls  
grown on hexylresorcinol.. .............................................. 152 
Figure 5.30 Flow cytometry of Arabidopsis plants grown on  
 hexylresorcinol. ............................................................. 153 
Figure 5.31 Cloning strategy for expression of P. falciparum 
topo VI A1 in E. coli. ...................................................... 155 
Figure 5.32 Expression of P. falciparum topo VI A1 and A2 in  
E. coli. .......................................................................... 156 
Figure 5.33 Cloning strategy for baculovirus expression of  
P. falciparum topo VI A1.. ............................................... 157 
Figure 5.34 Cloning of P. falciparum genes for baculovirus expression.. .. 158 
Figure 5.35 PCR analysis of bacmids containing P. falciparum  
topo VI genes.. ............................................................. 158 
Figure 5.36 Initial time course baculovirus expression of  
P. falciparum topo VI genes. ........................................... 159 
Figure 5.37 Expression of PfT6A1 and PfT6B in the baculovirus system... 160 
Figure 5.38 M. mazei topo VI with various anti-malarial  
compounds. .................................................................. 161 
Figure 5.39 Structures of experimental anti-malarial compounds.. ......... 162 
Figure 5.40 Testing putative anti-malarial compounds against  
M. mazei topo VI. .......................................................... 163 
Figure 5.41 Structures of M. mazei topo VI screen hits. ........................ 167 
Figure 5.42 Comparing hexylresorcinol “dwarf” morphology to  
topo VI knock-out mutants.. ........................................... 172 
Figure 5.43 Comparison of various anti-malarial compounds with  
 different scaffolds. ......................................................... 177 
Figure 6.1 Variation of standard deviation with increasing fluorescence 
signal. .......................................................................... 182 
xv 
 
List of Tables 
 
Table 1.1 Successfully exploited targets for antimicrobials. ....................... 7 
Table 1.2 Examples of each class of topoisomerase and the  
specific orthologs in this study. ........................................... 10 
Table 2.1 Commonly used buffers and solutions. ................................... 51 
Table 2.2 Summary of antibiotic stocks and working  
concentrations. ................................................................. 52 
Table 2.3 Summary of E. coli strains and genotypes. ............................. 53 
Table 2.4 Constant temperature PCR. .................................................. 62 
Table 2.5 Touchdown PCR program. ..................................................... 63 
Table 2.6 Program for BigDye 3.1 sequencing reactions. ........................ 64 
Table 3.1 Example of band quantification and data processing for  
TF and buffer 9.. ............................................................... 82 
Table 3.3 Compositions of triplex forming buffers tested. ........................ 83 
Table 3.2 Efficiencies of different buffers in triplex-affinity  
purification of SC plasmid.. ................................................. 83 
Table 4.1 Summary of compounds selected by the E. coli gyrase screen.. . 94 
Table 4.2 Table of control data and Z' values per plate for the  
E. coli gyrase screen .......................................................... 97 
Table 5.1 Summary of compounds selected by the M. mazei  
topo VI screen.. .............................................................. 129 
Table 5.2 Table of control data and Z' values per plate for the  
M. mazei topo VI screen.. ................................................. 132 
Table 5.3 IC50s for M. mazei topo VI hits. ........................................... 134 
Table 5.4 Table of compiled data from Arabidopsis hypocotyl  
assays with hexylresorcinol. .............................................. 146 
Table 5.5 BLAST search results for the putative P. falciparum  
topo VI B subunit in various protozoa. ................................ 154 
Table 6.1 Statistical summary of the two screens. ............................... 180 
Table 6.2 Summary of type II topoisomerase inhibition by  
screen hits.  .................................................................... 183 
List of Equations 
 
Equation 1.1 Calculating the theoretical linking number of closed circular 
DNA. .............................................................................. 8 
Equation 1.2 Calculating the difference between the theoretical an  
 observed linking number................................................... 8 
Equation 1.3 Calculating the specific superhelical density. ........................ 8 
Equation 1.4 The relationship between twist, writhe and linking number. .... 9 
Equation 2.1 The Beer-Lambert Law. ................................................... 61 
Equation 2.2 Equation to calculate the Z' of an assay. ............................ 74 
 
  
xvi 
 
 
 
 
 
 
Dedication  
 
This thesis is dedicated to my parents. 
Your faith in me is what has made this all possible. 
  
xvii 
 
 
 
 
"Nothing in life is to be feared. It is only to be understood." 
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Chapter 1 
1 General Introduction 
1.1 Infectious diseases, antibiotics and the 
problem of antibiotic resistance 
The development of antibiotics is one of the greatest achievements of 
medical science, responsible for saving the lives of countless people over 
the last sixty years. When penicillin was first manufactured in 1944 its 
speed and efficiency at curing previously fatal infections caused people to 
view it with awe and led to it being termed a ―wonder drug‖. Even though it 
is disputed that Dr. William H. Stewart, the US Surgeon General 1965-1969, 
actually made his now infamous pronouncement that ―It is time to close the 
book on infectious diseases, and declare the war against pestilence won‖ 
the statement certainly captured the attitude of the times (Spellberg, 
2008). 
 This level of optimism seems absurd these days with antibiotic 
resistant strains of bacteria such as Staphylococcus aureus generating 
apocalyptic headlines about the rise of ―superbugs‖. Although these articles 
are laden with hyperbole, the emergence of these resistant strains is a 
significant threat to public health. The emergence of S. aureus strains 
resistant to the penicillin derivative methicillin (MRSA) was reported soon 
after the introduction of the drug in 1960 (Eriksen, 1961). By the late 1960s 
strains resistant to multiple antibiotics had evolved (Grundmann et al, 
2006). It has been demonstrated that patients infected with these resistant 
strains have significantly increased mortality and morbidity rates than those 
afflicted with antibiotic susceptible strains (Kock et al, 2010). In the last two 
decades the number of infections reported to be caused by MRSA has 
increased rapidly, although has begun to drop in recent years (Figure 1.1). 
This is most likely due to improved awareness and hygiene (although a 
more sceptical view is that the disease is now being under-reported to 
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improve hospital statistics). Although S. aureus has been focused on here 
antibiotic resistance is also a problem for arguably more threatening 
diseases such as tuberculosis, which was thought to have infected a third of 
the world’s population and been responsible for around 2 million deaths in 
2009 (WHO 2010 report). The evolution of both multidrug-resistant 
Mycobacterium tuberculosis (resistant to one of two potent front line drugs) 
and extremely-drug resistant M. tuberculosis (resistant to several front-line 
and second-line drugs) is causing significant difficulties in treating this 
highly lethal disease. Nor is the development of drug resistance restricted to 
bacterial diseases, with the emergence of drug resistant strains of the 
malaria causing protozoa Plasmodium falciparum. Malaria was thought to 
infect around 200 million people and kill approximately one million in 2009 
(WHO 2010 report). Unfortunately several parasite strains have evolved 
which are resistant to some of the most commonly used and potent 
antimalarials (Farooq & Mahajan, 2004). 
 
Figure 1.1 The number of deaths attributable to MRSA in the UK. Figure from the 
National Statistics Department website (www. statistics.gov.uk). 
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 The public and professional misuse of antibiotics has been pivotal to 
the evolution and spread of these resistant strains of these pathogens (Rice, 
2003). Self-prescription, mis-prescription and over-prescription have 
exposed various human pathogens to sub-lethal levels of antibiotics. This 
has generated the selective pressure necessary for the evolution of resistant 
strains. Resistance puts its own fitness burden on strains bearing it, which 
in turn selects for compensatory mutations. The end result of these 
processes is the rapid evolution of stable resistant strains which will persist 
long after the misuse of antibiotics is curtailed (Andersson, 2003; Levy, 
1998; Projan, 2007). It is clear that although better management of how 
antibiotics are used and improving public awareness are very important 
they will do very little to help against existing resistant strains.  
New antibiotics with novel modes of action to which these strains are 
susceptible are necessary if we wish to keep our lead in the ―war on 
pestilence‖. However the number of new antimicrobials has been decreasing 
steadily over the last few decades (Figure 1.2). This is due to a number of 
 
Figure 1.2 The number of antibacterial agents approved by the USA FDA. Figure 
from Fox, 2006 and Spellberg et al, 2004. 
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factors including the high attrition rate for antimicrobial drugs in high-
throughput screens (which are about five-fold higher than similar screens 
for other diseases) and the lack of financial incentive for pharmaceutical 
companies (high attrition rates, the emergence of resistance, extensive 
clinical trials and short treatment courses all play their part here) (Payne et 
al, 2007). This vacuum caused by the withdrawal of the pharmaceutical 
companies from antibiotic research means that academic institutions and 
non-profit organisations must rise to meet the challenge of developing new 
antibacterial agents, preferably in coalition with the remaining industrial 
researchers in the area. 
1.2 Drug screening strategies 
The current paradigm for drug discovery is that of high-throughput 
biochemical or cell-based screening of rational targets, although the 
benefits of this approach over traditional pharmacological approaches are 
still debatable due to high attrition rates (Kola & Landis, 2004). This is 
partly due to increasing restrictions placed on the development of new 
drugs, but also due to the efficiency of the screening process itself. The 
overall performance of the screen is determined by the quality of the 
technology used, the assay optimisation, the data processing and the 
screened materials (Fischer, 2007).  
When screening for anti-infective agents one can either start with a 
specific target enzyme in mind which you are aiming to inhibit or assay 
compounds for their ability to kill the pathogen in cell-based assays. If the 
second approach is used it is common to then identify the target for any 
hits so that rational improvements can be easily made. Each of these two 
approaches has their own strengths and weaknesses, and there is no clearly 
superior strategy (Moore & Rees, 2001). The cell-based approach has 
pragmatism on its side: compounds which kill the pathogen will be selected 
by the screen. However there are a host of logistical issues including the 
maintenance and handling of the pathogen. Unless a non-pathogenic 
relative is used in the screen then a containment laboratory of the 
appropriate level is required. Cell-based assays also tend to have high 
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variability and report more false positives than target based screens. This is 
due to the difficulty in maintaining consistency of the reagents (i.e. the 
cells) over the course of the screen, the complexity of the cellular 
environment and the low level cytotoxic effects of solvents such as DMSO 
(especially after the extended exposure necessary in many cell-based 
assays) (Moore & Rees, 2001). Since the success of a screen is as much 
about statistics as it is about biochemistry this is a significant factor to 
consider when designing a screen. 
Target-based screening on the other hand is much simpler from a 
logistical stand point: large quantities of reagents can be produced and 
frozen to ensure consistency over the screen. Furthermore there are 
significantly fewer variables in a biochemical assay which results in a higher 
level of consistency. On the other hand there is no guarantee that a 
powerful in vitro inhibitor of a good target will make a successful 
antimicrobial. This can be for a range of reasons, including the compound 
not being able to enter the pathogen or the pathogen already possessing 
export or degradation pathways that target the compound. Target-based 
screening is simply impossible in some cases where the target cannot be 
successfully expressed and purified to the quantity and quality needed for 
screening. In short, neither of these screening strategies are perfect and in 
reality they are often used in concert (with hits from a cell-based screen 
being sub-screened against various targets or visa versa). 
Until 1996 80% of all medical drugs were derived from or inspired by 
natural products (Harvey, 2007). Despite this, there has been an increasing 
aversion to the use of natural products in screening for new drugs (Harvey, 
2007). This is because natural products are thought to be too structurally 
complex to make good drugs (Fischer, 2007). Also, the extensive extraction 
and purification procedures that are necessary to access natural products is 
thought not to be compatible with a high-throughput approach (Lam, 2007). 
However the success of natural products as leads for drug 
development cannot be denied and they offer a wealth of screening 
opportunities. They are highly structurally diverse, have been put under 
evolutionary pressures to acquire biological activity and often have activity 
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in a range of species due to protein homology (Harvey, 2007). Most of the 
natural products discovered thus far have not have had their biological 
activity tested, and new sources of compounds are constantly being 
discovered and catalogued (such as from marine organisms and exotic 
plants) (Harvey, 2007). 
Once a natural product with the desired activity has been identified, a 
combinatorial approach can be taken to further improve effectiveness. This 
can be rational, such as the addition of nitrogen groups to make the 
compound more ―drug-like‖ (Lopez et al, 2007) or random to generate a 
new library which can be screened (Pelish et al, 2001).  
An alternative approach to screen novel natural products is to screen 
existing drugs against new targets. This is appealing for a number of 
reasons (Chong & Sullivan, 2007): the pharmacokinetics and safety profiles 
of existing drugs are usually already well understood, and they have often 
already been approved for use by the regulatory authorities. This bypasses 
much of the time-consuming clinical trials as well as the much of the 
toxicological and pharmacokinetic evaluation, which is predicted to reduce 
the overall cost of production by 40% (DiMasi et al, 2003). Also existing 
drugs are known to have bioactivity, which greatly increases the chance of 
finding a biologically relevant inhibitor. This process of finding ―new uses for 
old drugs‖ has proven successful in the past, as demonstrated by the 
successful rebranding of the breast cancer drug miltefosine to treat visceral 
leishmaniasis (Sundar et al, 2002). 
1.3 Antimicrobial targets 
When screening for antimicrobial agents with a target lead approach one 
must first choose a target enzyme to screen against. A good target for 
antimicrobial drugs: is essential for pathogen viability, is present with high 
homology in several pathogens, has no or low homology to any human 
enzymes and occurs only as a single copy (Payne et al, 2007). The range of 
cellular processes that the currently successfully exploited antibacterial 
targets participate in is relatively limited (Table 1.1). This means that there 
are only a handful of these well validated targets. Attempts to discern new 
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targets via a genomic approach have had very little success, which is 
attributable in part to the difficulty in establishing the link between in vitro 
inhibition of a target and its ability to kill cells in vivo (Payne et al, 2007).  
As such it is much better to seek out compounds which inhibit a well 
validated target in novel ways. DNA topoisomerases, in particularly DNA 
gyrase, have been proven to be incredibly good targets for antimicrobial 
agents with a wide range of drugs targeting them now in clinical use. This is 
due in part to them satisfying the criteria for a good target as well as their 
unique mode of action (as discussed below). 
1.4 DNA Topology 
DNA topoisomerases are enzymes which are responsible for maintaining the 
topological state of DNA in the cell (Bates & Maxwell, 2005). As such a brief 
explanation of DNA topology is necessary before a detailed discussion on 
their mechanisms can take place.  
In relaxed B-form DNA the two strands of the double helix twist 
around their helical axis once per 10.5 base pairs. By dividing the number 
of base pairs in a DNA molecule by this value, the number of helical ―twists‖ 
can be determined. Interactions between proteins and DNA which require 
unwinding of the helix (such as during replication), can alter this value, 
which introduces stress into the molecule. In an unrestrained DNA molecule 
the mobility of the free ends allows this stress to easily dissipate. However 
Cellular process Example target Example antibiotic 
DNA replication DNA gyrase 
Topoisomerase IV 
Ciprofloxacin 
Cell wall synthesis Lipid II Ramoplanin 
Transcription RNA polymerase Rifampicin 
Translation 16S rRNA A site Tetracycline 
Fatty acid synthesis 2-trans-Enoyl ACP reductase Triclosan 
Cofactor synthesis Dihydrofolate reductase Trimethoprim 
Table 1.1 Successfully exploited targets for antimicrobials. Adapted from Bumann, 
2008. 
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if the DNA is constrained at either end by existing in a closed-circular form, 
or by interactions with proteins such as nucleosomes, then the DNA must 
find another way to relieve strain. It does so by contorting into superhelical 
turns (also called supercoils or writhe) (Bates & Maxwell, 2005).  
This relationship can be described mathematically using the concept 
of linking number (Lk) (Crick, 1976; Fuller, 1971), which represents the 
number of times the two strands of closed circular DNA are linked. The 
linking number of a hypothetical closed circular DNA molecule with no 
writhe (Lk°) can be calculated with the following equation: 
    
               
                      
 
Equation 1.1 Calculating the theoretical linking number of closed circular DNA. 
This number does not have to be an integer, but it is clear that fractional 
links do not exist in reality. The observed linking number Lk can be obtained 
by simply rounding of the Lk°. The difference between the hypothetical and 
observed linking numbers gives an indication of the intrinsic strain inside 
the molecule: 
           
Equation 1.2 Calculating the difference between the theoretical an observed linking 
number. 
Since smaller DNA molecules are less able to distribute this stress than 
larger ones, ΔLk is often scaled to the size of the DNA by dividing by Lko 
(which is determined by the number of base pairs). This gives the specific 
linking difference or superhelical density (σ): 
   
   
   
 
Equation 1.3 Calculating the specific superhelical density. 
The level of superhelical density can be used as an indication of the level of 
torsional strain, and hence the level of supercoiling, in a molecule. The sign 
of σ can be either negative or positive which indicates whether the DNA is 
negatively or positively supercoiled. Referring to the above observations, 
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the Lk can be related to the number of helical twists (Tw) and the 
superhelical writhes (Wr) with the following equation: 
         
Equation 1.4 The relationship between twist, writhe and linking number. 
Since Lk is an intrinsic property of restrained DNA, a change in either twist 
or writhe must result in an equal and opposite change in the other. This also 
implies that if Lk was to change, then both the twist and the writhe would 
change to compensate (Figure 1.3). This process can occur if the DNA 
molecule is broken, and either one or more strands passed through the 
break or if one strand is broken and rotated about the intact strand. In the 
cell, these processes are co-ordinated by DNA topoisomerases. 
1.5 DNA topoisomerases 
1.5.1 Overview 
Proper maintenance of a cell’s DNA is crucial to the stability of its genome, 
and hence its survival (Zhivotovsky & Kroemer, 2004). As a result of this a 
vast array of proteins and enzymes exist to package, repair, and replicate 
DNA. DNA topoisomerases are a class of enzymes whose function bridges all 
these processes, as they are responsible for managing the topological state 
 
Figure 1.3 The effect in a change in Lk upon the twist and writhe of a restrained 
DNA molecule. Note the double helix structure of the DNA has been simplified for 
clarity. The black boxes represent constraints placed upon the DNA, such as those 
imposed by chromatin or being in a closed-circular form. A. A break is formed in 
one strand and that strand rotated around the intact strand 360°. B. Either a 
negative or positive twist is introduced into the DNA, depending on whether the 
initial rotation was right-handed or left-handed. C. Change in twist converted into 
an opposite change in writhe. This increases the level of supercoiling in the DNA, 
and forms either a negative node (writhe -1) or a positive node (writhe +1). Figure 
adapted from Wheeler, R., 2007, Wikimedia commons. 
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of DNA. By covalently binding active site tyrosine residues to the 
phosphodiester backbone of either one or two strands of a DNA helix they 
produce controlled breaks in the DNA. They then utilise these breaks to 
unknot, decatenate or alter the supercoiling state of the helix via either 
strand passage or rotation (Figure 1.4). Topoisomerases are categorised by 
their mechanism, with type I topoisomerases nicking a single strand whilst 
type II topoisomerases form double-strand nicks (Bates & Maxwell, 1997). 
Which of these mechanisms a topoisomerase utilises dictates the range of 
reactions it can catalyse, for example a type I topoisomerase can only 
decatenate plasmids if a nick is present in one of the double-strands. As a 
general rule type I topoisomerases tend to be monomeric, whilst type II 
topoisomerases are either homodimers (A2) or heterotetramers (A2B2). 
These categories are further subdivided based on structure and mechanism: 
IA, IB or IC for type I topoisomerases and IIA or IIB for type II 
topoisomerase. A summary of the reactions catalysed by specific 
topoisomerase can be found in Figure 1.5. The specific enzymes used in this 
study can be found in Table 1.2.  
  
Type Example enzyme Ortholog in this study 
IA Bacterial topoisomerase I N/A 
IB Eukaryotic topoisomerase I Wheat germ 
IIA DNA gyrase Escherichia coli 
IIB Topoisomerase VI  Methanosarcina mazei 
 Sulfolobus shibatae 
 Plasmodium falciparum 
Table 1.2 Examples of each class of topoisomerase and the specific orthologs in 
this study. 
 Chapter 1 General Introduction 
 
  11 
 
  
 
Figure 1.4 DNA topoisomers interconvertible by DNA topoisomerases. The DNA 
double helix has been simplified to a single line in this diagram. 
 
Figure 1.5 Summary of reactions catalysed by specific topoisomerases. Figure from 
Schoeffler & Berger, 2008. 
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1.5.2 Type I topoisomerases 
Type I topoisomerases can be further subdivided into types IA, IB and IC 
based on the specifics of their structure and mechanism. 
1.5.2.1 Type IA topoisomerases 
Type IA topoisomerases have been found in both bacteria and eukaryotes. 
The majority of type IA topoisomerases are monomeric (Champoux, 2001) 
and require a divalent magnesium ion as a cofactor for carrying out 
relaxation (Domanico & Tse-Dinh, 1991). The binding of type IA 
topoisomerases to a double-stranded piece of DNA results in partial melting 
of the helix to form a short stretch of single-stranded DNA (Wang, 2002) 
(Figure 1.6). The topoisomerase then introduces a break into one of the 
single strands by catalysing reversible transesterfication between its active 
site tyrosine and the 5'-phosphate of the DNA. The less negatively 
supercoiled the DNA, the harder it is for the enzyme to unpair the bases to 
form this single-stranded region (Wang, 2002). This means that the enzyme 
can only relax the DNA to a certain level. After the nick has been generated 
the complementary strand is passed through the break into the interior of 
the enzyme. The nicked strand is then ligated, and the enzyme unbinds. 
This alters the linking number of the DNA by one (Bates & Maxwell, 2005). 
If a nick is already present in one of the two strands of a piece of double-
stranded DNA it is possible for a type IA topoisomerase to instead pass 
another double-stranded DNA molecule through the break, allowing it to 
catenate/decatenate or knot/unknot double-stranded DNA (Wang, 2002). 
 
Figure 1.6 The mechanism of action for type IA topoisomerases. The enzyme 
generates a single strand break by forming a covalent bond between its active site 
tyrosine and the 5'-phosphate of the DNA backbone. The intact strand is then 
passed through the break into the central cavity of the enzyme. This results in 
relaxation of the DNA by a linking number of one. Figure from Bates & Maxwell, 
2005. 
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Interestingly type IA enzymes cannot relax positively supercoiled DNA since 
they are unable to unpair the helix to produce a single-stranded region. 
However relaxation of positively supercoiled DNA can occur if a single-
stranded loop is present in the molecule (Kirkegaard & Wang, 1985) 
 Reverse gyrase is an unusual member of this class of enzymes. It is 
found in hyperthermophilic eubacteria and archaea such as Sulfolobus 
acidocaldarius, in which it was first discovered (Forterre et al, 1985; Kikuchi 
& Asai, 1984; Nakasu & Kikuchi, 1985), and is the only topoisomerases 
currently known to introduce positively supercoils into DNA in an ATP-
dependent manner (Forterre et al, 1985; Krah et al, 1996; Shibata et al, 
1987). It has been proposed that controlled unwinding by a helicase domain 
present in the enzyme is the cause of the enzymes supercoiling activity 
(Rodriguez, 2003). The introduction of positive supercoils into the genomes 
of hyperthermophilic archaea may help stabilize the DNA under the high 
temperatures at which they live. 
 Type IA topoisomerase have been found in bacteria but not in 
humans, fulfilling one of the criteria for a good drug target. However so far 
they have proven poor targets for antimicrobials. This may be due to 
redundancy of function within the bacterial cell which typically contains 
several different type IA topoisomerases and one or more type IIA 
topoisomerases capable of carrying out similar reactions. This is 
demonstrated by the fact that bacteria in which the genes for 
topoisomerase I (topo I), the most prevalent type IA topoisomerase in 
bacteria, has been knocked out are still viable when grown at 37°C without 
the need for compensatory mutations (Stupina & Wang, 2005). Since they 
are not essential for survival one can predict them to be poor antimicrobial 
targets, a hypothesis reinforced by the historic absence of drugs targeting 
them. Current research into type IA topoisomerases as drug targets focuses 
on stabilizing the covalent protein—DNA intermediate otherwise known as 
the ―cleavage complex‖, an aim which will be assisted by the recent crystal 
structure of the intact complex (Zhang et al, 2011). Bacteria containing 
mutations which lead to the accumulation of topo I cleavage complexes 
have been shown to have reduced viability, displaying SOS responses and 
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cell death (Tse-Dinh, 2009). Whether compounds can be found to replicate 
the effects of these mutations remains to be seen. 
1.5.2.2 Type IB topoisomerases 
Type IB topoisomerases are distinct from type IA topoisomerases in both 
their structure and mechanism. They are largely found in eukaryotes but 
have also been observed in viruses and archaea. Unlike type 1A, type 1B 
topoisomerases form a covalent bond between their active site tyrosine and 
the 3′-phosphate of the DNA (Wang, 2002). Unlike the type IAs they do not 
need to melt the DNA duplex in order to relax it, and as such their activity is 
not dependent on the supercoiling state of their substrate (Champoux, 
2001). Furthermore they do not require magnesium ions to cleave DNA and 
can relax both negative and positive supercoils (Champoux, 2001). The 
reason for these dramatic differences is that they do not facilitate relaxation 
by strand passage but by a ―controlled rotation‖ mechanism (Stewart et al, 
1998) (Figure 1.7). The two domains of the enzyme form a clamp around 
the DNA, completely encircling it (Champoux, 2001). After generating a 
single strand break by the formation of a covalent bond between its active 
site tyrosine and a phosphate in the DNA backbone the enzyme loosens its 
―grip‖ on the 5'-OH end of the broken strand. The broken strand is then free 
to rotate around the intact strand before being religated. 
 Since the type IB topoisomerases are found in humans and not 
bacteria they are useless as antimicrobial targets. They may have some 
mileage as an antiviral or antiprotozoal target, but it would be expected that 
any such compounds would have significant cross-reactivity with the human 
 
Figure 1.7 The mechanism of action for type IB topoisomerases. The enzyme 
clamps around the DNA double helix and makes a single-strand break by forming a 
covalent bond between its active site tyrosine and the 3'-phosphate of the DNA 
backbone. It then allows ―controlled rotation‖ of the 5'–hydroxyl side of the break 
before religation, resulting in relaxation. Figure from Bates & Maxwell, 2005. 
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enzyme. Currently human topo IB is used as a target for anticancer drugs 
such as camptothecin (Ulukan & Swaan, 2002; Wethington et al, 2008). 
1.5.2.3 Type IC topoisomerases 
Currently the only member of the type IC class of topoisomerases is 
topoisomerase V from the hyperthermophilic archaea Methanopyrus 
kandleri (Slesarev et al, 1993). Its mode of action is thought to be similar 
to that of the type IB topoisomerases. However it also possesses the ability 
to repair abasic regions in DNA, making it unique amongst the 
topoisomerases (Belova et al, 2001). Since the only reported type IC 
topoisomerase belongs to a non-pathogenic microbe it is not a viable target 
for therapeutics. 
1.5.3 Type II topoisomerases 
Type II topoisomerases are subdivided into type IIA and type IIB based on 
structural and mechanistic differences. Unlike different subtypes of the type 
I topoisomerases the reaction catalysed by type IIA and type IIB 
topoisomerases is very similar: the passage of one intact double-stranded 
DNA molecule through a double-strand break (Berger et al, 1996; Bergerat 
et al, 1994; Corbett et al, 2007; Roca & Wang, 1994). Type II 
topoisomerases are amongst the widest distributed class of enzyme being 
essential in all organisms currently known (Gadelle et al, 2003). 
1.5.3.1 Type IIA topoisomerases 
All type IIA topoisomerases possess two domains crucial for their activity: a 
DNA breakage-reunion domain and an ATPase domain. In eukaryotes these 
domains occur within a single subunit whilst prokaryotic enzymes split them 
between two subunits (A and B respectively). Eukaryotic enzymes therefore 
operate as symmetrical homodimers whilst the prokaryotic enzymes form 
symmetrical heterotetramers (A2B2) (Figure 1.8).  
The active site tyrosines are located on the A subunit (or the 
equivalent region of the eukaryotic homologue) within a 5Y- catabolite 
activator protein-like (CAP) domain, but the DNA breakage-reunion domain 
itself is spread across both the A and B subunits. This means that DNA 
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cleavage can only take place when the whole complex is assembled 
(Champoux, 2001; Corbett & Berger, 2004). 
The toprim (topoisomerase-primase) domain is common to types IA, 
IIA and IIB of topoisomerases as well as bacterial primases (Aravind et al, 
1998; Corbett & Berger, 2004). The domain contains a conserved glutamate 
thought to be important for religation of the DNA break in topoisomerases 
or nucleotide polymerisation in primases, as well as two aspartates 
necessary for coordinating the Mg2+ necessary for the activity of these two 
classes of enzyme (Aravind et al, 1998). 
The GHKL ATPase domain is located on the B subunit (or equivalent 
region for eukaryotic homologues) and contains an ATP-binding Bergerat 
fold (Bergerat et al, 1997; Dutta & Inouye, 2000). Although there appears 
 
Figure 1.8 The general structure of type IIA topoisomerases. The domains which 
comprise the A and B subunits of bacterial enzymes are indicated. The domains are 
coloured as follows: yellow, GHKL domain; orange, transducer; red, toprim; green 
5Y-CAP. Figure from Corbett & Berger, 2004. 
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to be a considerable degree of variation in the sequence of this region 
between type IIA topoisomerases there is a high degree of structural 
similarity, particularly in respect to the Bergerat fold (Dutta & Inouye, 
2000). 
The C-terminal domains of the A subunits of type IIA topoisomerases 
(or their equivalents in eukaryotic homologues) have little homology with 
one another and are believed to be important for substrate recognition, 
cellular targeting and interactions with other proteins (Champoux, 2001). 
The activity mechanism of type IIA topoisomerases can be described 
as proceeding by a ―three-gate‖ mechanism in which it binds two segments 
of DNA (Figure 1.9). The reaction cycle begins when the enzyme binds the 
first DNA segment (the G or gate segment) in its DNA breakage-reunion 
domain. The G segment can be acutely bent by the enzyme, with an angle 
 
Figure 1.9 The mechanism of action for type IIA topoisomerases. The different 
domains of the protein are coloured as follows: yellow, ATPase domain (B subunit 
N-terminus in prokaryotic enzymes); orange, B subunit C-terminus (or homologous 
region in homodimeric eukaryotic enzymes); blue, A subunit N-terminal breakage-
reunion domain (or homologue). The C-terminal domain of the A subunit is not 
shown. The G-segment (green), T-segment (red/pink) and the DNA, N- and C-gates 
are indicated. Movement of the T-segment is shown from the pink to the red 
position. Figure from Bates et al, 2011. 
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up to 150° (Dong & Berger, 2007). At this point the active site tyrosines 
can cleave the G segment by forming covalent bonds with the 5'-phosphate 
groups of the DNA backbone, generating a controlled double-strand break 
with a 4 base pair stagger (Sander & Hsieh, 1983). However the two ends 
of the break are held in close proximity, allowing for religation. The second 
segment (the T or transported segment) then enters the upper cavity of the 
enzyme. The T segment is then trapped by the ATP-induced dimerisation of 
the N-terminal domains of the B subunit forming the first of the three gates 
(the N gate). At the same time conformational changes brought about by 
ATP binding cause two sides of the double strand break in the G segment to 
be pulled apart (the DNA gate). The T segment is then passed through the 
open DNA gate, a process thought to be stimulated by narrowing of the 
upper cavity. The DNA gate then closes and the final gate formed by a 
protein interface of the A subunits (the C gate) opens to allow the exit of 
the T segment (Roca et al, 1996; Roca & Wang, 1994; Williams & Maxwell, 
1999b). ATP hydrolysis allows the enzyme to reset ready for subsequent 
rounds of reaction. This reaction results in either the linking number of the 
DNA changing by two if the G- and T-segments are in the same molecule 
(and an increase or decrease in supercoiling), or decatenation/catenation if 
the G and T segments are on different DNA molecules (Bates & Maxwell, 
2005). 
The essential nature of the type IIA topoisomerases makes them 
appealing drug targets. Furthermore, the stabilization of the protein—DNA 
intermediate (the ―cleavage complex‖) by compounds is exceptionally lethal 
in cells. This is because the stalled complexes act as ―roadblocks‖ for 
replication machinery. The collision between a replication fork and a 
stabilized cleavage-complex results in the formation of a double-strand DNA 
lesion, the accumulation of which rapidly leads to cell death (Drlica & Zhao, 
1997). The up-regulation of the human topoisomerase II in cancer cells has 
lead to its successful use as an anticancer drug target. Serendipitously, 
bacteria possess a unique type IIA topoisomerase which is absent in 
humans: DNA gyrase. DNA gyrase is one of the most successfully exploited 
antimicrobial targets known so far, and its structure, mechanism and 
inhibitors will be discussed in detail in a later section of this chapter. 
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1.5.3.2 Type IIB topoisomerase 
Type IIB topoisomerases catalyse a very similar reaction to the type IIA 
topoisomerases, but have significant structural and mechanistic differences. 
Most strikingly they only have two gates, lacking the C gate found in type 
IIAs (Corbett et al, 2007). Since topoisomerase VI is the only known 
member of this class, the structure and mechanism of the type IIB 
topoisomerases will be discussed in detail in the section below. 
1.6 Topoisomerase VI 
Topoisomerase VI (topo VI) is the only known member of the type IIB 
topoisomerases and has primarily been found in archaea, which are largely 
thought to be non-pathogenic. Consequently there have been relatively few 
studies of its structure and mechanism compared to the type IIA 
topoisomerases. Topo VI was first characterised from the thermophilic 
archaea Sulfolobus shibatae (Bergerat et al, 1997) and the majority of 
studies on the mechanism and structure of topo VI have been carried out on 
the S. shibatae enzyme. The topo VI from the methanogenic archaea 
Methanosarcina mazei has also been documented, but studies on this 
version of the enzyme have been limited and primarily focused on its 
structure (Corbett et al, 2007). 
Although no pathogenic archaea have been identified so far, they are 
present in the human body. In particular methanogenic archaea have been 
found in the human gut, vagina and mouth (Belay et al, 1988; Belay et al, 
1990; Eckburg et al, 2005). Studies have linked methanogenic archaea with 
the formation of periodontal tooth cavities (Lepp et al, 2004) as well as host 
of intestinal diseases including: Crohn’s disease, irritable bowel syndrome, 
colorectal cancer, diverticulosis, and obesity (Nakamura et al, 2010; 
Roccarina et al, 2010). Although the role of these archaea in these diseases 
is far from clear (and hotly disputed) the existence of pathogenic archaea is 
an interesting possibility. If their role in these diseases is confirmed 
antimicrobials targeting methanogenic archaea will suddenly become 
medically relevant, since topo VI appears to be the main type II 
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topoisomerase in many archaea (Gadelle et al, 2003) which in turn makes it 
a good drug target. 
 Topo VI has also been identified in some eukaryotes including plants, 
such as Arabidopsis thaliana (Hartung et al, 2002; Hartung & Puchta, 
2000), and genes hypothetically encoding for its subunits have been 
discovered in the genome of the malaria parasite Plasmodium falciparum 
(Aravind et al, 2003). These include two genes with homology for the topo 
VI A subunit (PF10_0412, abbreviated to PfTopo6A1; PFL0825c, abbreviated 
to PfTopo6A2) whilst one gene had homology for the topo VI B subunit 
(MAL13P1.328, abbreviated to PfTopo6B). Since it is absent in humans, 
validation of its presence in P. falciparum could lead to topo VI being a 
novel target for anti-malarial drugs. 
Inhibitors of the plant version of the enzyme may find uses as 
herbicides, as resistant strains have emerged for the most heavily used 
commercial herbicide glyphosate (Owen & Zelaya, 2005). One of the major 
reasons for the development of resistant weeds has been the lack of 
commercially viable alternatives to glyphosate, which is due to the lack of 
research and development in the area (Owen & Zelaya, 2005). Novel 
herbicides would provide farmers with alternatives to glyphosate and so 
elevate the selective pressure for resistant strains to develop. The 
development of herbicides has a different set of concerns compared to anti-
infectives including: cost of large scale spraying, environmental impact and 
the development of crops resistant to the herbicide. Since knockout mutants 
of topo VI in Arabidopsis thaliana have demonstrated severe dwarfism and 
do not live past five weeks it is likely a good target for herbicides (Hartung 
et al, 2002; Sugimoto-Shirasu et al, 2002). 
The potential for topo VI to serve as target for a range of medically 
and commercially useful compounds, as well as the relatively small body of 
research on it, make it an interesting candidate for inhibitor screening. 
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1.6.1 Biological roles of topoisomerase VI 
In archaea topo VI is thought to fulfil a similar role to the type IIA 
topoisomerases (which they often lack) (Gadelle et al, 2003): the regulation 
of the global level of supercoiling within the cell and the resolution of 
catenated DNA molecules during replication. During the replication of 
constrained DNA molecules (such as plasmids or genomic DNA) it is 
necessary for the DNA helix to be unwound (Postow et al, 2001). This 
causes positive and negative supercoils to be generated either side of the 
replication fork, which if not resolved result in a breakdown of the 
replication machinery. Additionally, when two replication forks converge 
catenated DNA can be formed if the daughter molecules are inter-wound, 
which can be lethal for the cell (Figure 1.10) (Wang, 1996). In E. coli this 
problem is resolved by a type IIA topoisomerase called topoisomerase IV, 
which if inactivated results in an increased amount of catenated DNA 
(Adams et al, 1992). Although these observations have all been carried out 
with type IIA topoisomerases in bacteria it is likely they hold true for topo 
VI due to the similarities between their mechanisms and the ubiquitous 
nature of these problems. 
 
Figure 1.10 The formation of catenated DNA during termination of replication. At 
the terminus of replication, converging replication forks (a), lead to the 
interwinding of daughter molecules and the formation of pre-catenanes (b). Upon 
completion of replication, the products are catenated DNA circles (c). Figure from 
Bates & Maxwell, 2005. 
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The only direct evidence for the biological role of topo VI in archaea 
has come from the inhibition of Haloferax volcanii growth by the topo VI 
inhibitor radicicol (Gadelle et al, 2005). As well as general inhibition of 
growth the archaeal cells were seen to grow much larger than normal, 
which may be indicative of replication without cell division. This would in 
turn imply that the genomes of the cells were catenated, which would be 
expected from topo VI inhibition if decatenation was a main role of the 
enzyme in vivo. 
 There is considerably more evidence for the role of topo VI in plants, 
although the enzyme is yet to be expressed in an active, soluble form. 
Knock-out mutations of the genes encoding for either Arabidopsis topo VIA 
or VIB subunits (Figure 1.11) results in plants with an extreme dwarf 
phenotype, yellowish leaves, reduced trichome (―leaf hair‖) size and 
reduced root hair size and frequency (Hartung et al, 2002; Sugimoto-
Shirasu et al, 2002). These plants die after 4-5 weeks of growth, which 
indicates the essential nature of topo VI in plants. The cells of these plants 
demonstrated an increased number of chromosome breaks, which supports 
the hypothesis that topo VI is involved with the resolution of catenanes 
during replication (Hartung et al, 2002). Furthermore, the cells 
demonstrated reduced cell size and a reduction in ploidy (chromosome 
number) (Hartung et al, 2002; Sugimoto-Shirasu et al, 2002). Plant cells 
are capable of adopting an alternative cell cycle called endoreduplication in 
which genome replication occurs but cell division does not, resulting in an 
increase in ploidy (Sugimoto-Shirasu & Roberts, 2003). This, through 
unknown mechanisms, leads to an increase in the size of the cell cytoplasm 
and therefore overall cell size. The inability of these mutants to induce high 
ploidy (above eight chromosome copies, or 8C) implies that topo VI is 
essential in the process of endoreduplication. 
 As well as the A and B subunits, three other proteins are thought to 
be part of the plant topo VI complex: BIN4, MIGET and RHL1 (Breuer et al, 
2007; Kirik et al, 2007; Sugimoto-Shirasu et al, 2005). All three of these 
proteins have been shown to interact with the topo VI subunits by yeast-
two-hybrid experiments and produce identical morphologies when 
inactivated to the subunit knock-out mutants. Furthermore, the double 
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Figure 1.11 The morphology of topo VI knock-out mutants. Morphologies of wild-
type (WT), topo VI A subunit knock-out (topo6a), topo VI B subunit knock-out 
(topo6b), or double knock-out shown. A. 7 day old dark-grown seedlings 
(hypocotyls indicated). B. 7 day old light-grown seedlings. C. 30 day old plants: 
mutants are only 10% of wild-type size. D. Mutants are unable to increase ploidy 
above 8C. E. Trichome of mutants smaller. F. Root hairs of mutants smaller and less 
frequent. Both trichomes and root hairs are single cells, so the size of these organs 
is directly linked to cell size. Figure adapted from Sugimoto-Shirasu et al, 2002. 
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knock-out mutants of the genes coding for these proteins and either of the 
topo VI subunits produced no additional characteristics. The role of these 
proteins is not known, but they are thought to play crucial roles in the 
regulation of topo VI activity. 
Although the presence of topo VI is yet to be confirmed in 
Plasmodium falciparum the biology of the parasite lends credibility to the 
idea. As part of the parasite’s life cycle it undergoes a process called 
schizogony, which bears similarities to endoreduplication in plants (Figure 
1.12). During the process of schizogony the parasite replicates its genome 
several times without cell division before budding daughter cells (Gantt et 
al, 1998; Sturm & Heussler, 2007). Since this step is a crucial part of the 
parasite’s life cycle, with several current antimalarial drugs thought to 
target it (Chauhan & Srivastava, 2001), it is likely that topo VI would make 
a good target if it was essential for this process. 
  
 
Figure 1.12 Schizogony in the Plasmodium life cycle. Plasmodium cytoplasm shown 
in blue and nuclei in red. Multiple rounds of genome replication occur during the 
schizont step without cell division. This is followed by rapid budding of mature 
parasites and rupturing of the host cell, leading to further proliferation of the 
pathogen. Figure adapted from Tuteja, 2007. 
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1.6.2 Topoisomerase VI structure 
Topo VI has been shown to be a symmetrical heterotetramer of two A and 
two B subunits (Figure 1.13). The B subunits of type IIA and type IIB 
topoisomerases are highly structurally related, and appear to share the 
same function in both type II subfamilies (Corbett & Berger, 2003) whereas 
the A subunits are only partially homologous (Corbett et al, 2007; Nichols et 
al, 1999). Unlike the type IIA topoisomerases crystal structures of the 
entire A2B2 complex have been solved for the S. shibatae (Graille et al, 
2008) and M. mazei (Corbett et al, 2007) orthologues of topo VI, both with 
a resolution of ~4 Å. These two structures appear to have captured the 
enzymes in different conformations, giving insight into the motions of topo 
VI during its reaction cycle (Figure 1.14 and Figure 1.15). In addition, a 
number of high-resolution structures have been solved for domains of the 
two subunits including: the DNA-binding core of the A subunit of 
 
Figure 1.13 The domain structure of S. shibatae and M. mazei topo VI subunits. The 
A subunit consists of a CAP domain containing the active site tyrosine 106 and a 
toprim domain. The domain structure of the A subunit is identical for the M. mazei 
ortholog. The B subunit consists of the GHKL ATPase domain, a helix-two-turn-helix 
domain and a transducer domain. The M. mazei ortholog also has a C-terminal 
domain of unknown function. 
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Methanococcus jannaschii topo VI (Nichols et al, 1999) and residues 1-470 
of the B subunit of S. shibatae topo VI (Corbett & Berger, 2003). All 
together these structures give an impressive level of detail about the 
architecture of the topo VI enzyme. 
  
 
Figure 1.14 The structure of Sulfolobus shibatae topo VI. Two different views of the 
enzyme are shown. B subunit: dark blue, GHKL ATPase domain; light blue, H2TH 
domain; and green, transducer domain. A subunit: red, WHD/CAP; and orange, 
toprim and scaffold domain. The ATP-binding pocket of both B subunits is coloured 
light blue; dotted circles represent the proposed binding sights for G- and T-
segment DNAs. Figure taken from Graille et al, 2008. 
 
Figure 1.15 The structure of Methanosarcina mazei topo VI. Three different views 
of the enzyme are shown. One A-B dimer is shaded grey whilst the other is 
coloured as follows. B subunit: yellow, GHKL ATPase domain; purple, H2TH domain; 
orange, transducer domain; and cyan, CTD. A subunit: green, WHD/CAP; and blue, 
toprim and scaffold domain. The ATP-binding pocket of both B subunits is coloured 
light blue; dotted circles represent the proposed binding sights for G- and T-
segment DNAs. Figure taken from Corbett et al, 2007. 
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 The A subunit is comprised of a CAP-like domain (also called a 
winged-helix domain, or WHD) and a toprim domain both of which are 
present in type IIA topoisomerases but in different arrangements (Nichols 
et al, 1999). The catalytic tyrosine is located in the CAP-like domain and 
forms the main point of contact with the B subunit. The toprim domain 
contains the conserved acidic residues necessary for the binding of Mg2+ 
which are positioned so that they form the ―DNA cleavage-reunion‖ site with 
the active site tyrosine (Nichols et al, 1999). Positively charged residues in 
both these domains form a 20 Å DNA binding saddle when the A subunit is 
dimerised (Corbett et al, 2007; Graille et al, 2008). The CAP-like domain of 
the M. mazei enzyme is thought to contain a disordered loop which may 
reach into the saddle and interact with the G-segment (Corbett et al, 2007). 
The most striking difference between the A subunit of topo VI and that of 
the type IIA subunits is the absence of the second dimer interface which 
makes up the C-gate in the type IIAs and the cavity it causes. 
 The B subunit is comprised of three core domains: the GHKL ATPase 
domain, the helix-two-turn-helix (H2TH) domain and the transducer 
domain. The GHKL domain has a similar function as when found in the type 
IIA topoisomerases, causing the B subunits to dimerise upon the binding of 
ATP (Corbett & Berger, 2003). The H2TH domain is entirely unique to topo 
VI, not being observed in any other topoisomerases. Its role is not currently 
known, but it is thought to be tangentially involved in binding of DNA 
glycosylases to DNA by positioning other domains in order to form the 
necessary interactions (Fromme & Verdine, 2002; Gilboa et al, 2002; Serre 
et al, 2002; Zharkov et al, 2002). The transducer domain is thought to 
―transduce‖ signals from the GHKL ATPase site to the DNA cleavage-reunion 
site in the A subunit (Corbett & Berger, 2003). It is expected to be flexible 
as it contains a hinge region about halfway down its length (Graille et al, 
2008). The M. mazei enzyme has been shown to contain an additional C-
terminal domain absent in the S. shibatae enzyme. This domain is only 
found in a small number of archaeal topo VI orthologs and is generally 
found in those species which also possess a DNA gyrase (Corbett et al, 
2007). It is postulated to be involved in protein—protein or protein—
carbohydrate interactions which may assist in targeting or regulating the 
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enzyme, but there is currently no direct evidence for its function (Corbett et 
al, 2007). 
1.6.3 Topoisomerase VI mechanism 
Topo VI has shown itself to be capable of a number of reactions, including 
the relaxation of negative and positive supercoiled DNA, unknotting and 
decatenation (Bergerat et al, 1994; Corbett et al, 2007). All of these 
reactions require ATP and Mg2+ (Bergerat et al, 1997; Corbett et al, 2007). 
The mechanism of topo VI is basically the same as type IIA topoisomerase 
(Schoeffler & Berger, 2008): a G-segment of DNA is bound by the A 
subunits, a T-segment is captured by binding of ATP and dimerisation of the 
B subunits, the G-segment is cleaved by the A subunits and the T-segment 
passed through the gap. ATP hydrolysis allows the enzyme to reset for 
further rounds of reaction.  
 Although the general reaction is very similar to the type IIA enzymes 
there are a number of specifics which differ. Unlike in type IIA enzymes the 
cleavage of the G-segment by topo VI is tightly linked to the binding of ATP 
(Buhler et al, 2001). Additionally the G-segment is cut with a two base pair 
stagger rather than the four base pair cut of the type IIA enzymes (Buhler 
 
Figure 1.16 The mechanism of topo VI. The domains are coloured as follows: 
yellow, B subunit ATPase and H2TH domains; orange, B subunit transducer domain; 
green, A subunit CAP-like domain; and blue, toprim domain. The G-segment is 
shown in pink whilst the T-segment is light blue. From Corbett et al, 2007. 
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et al, 2001). Finally the absence of the C-gate is thought to alter the range 
of relaxed topoisomers that the enzyme produces upon relaxing supercoiled 
DNA compared to type IIA enzymes but this is yet to be confirmed 
(Stuchinskaya et al, 2009). It is thought that the absence of the C-gate is 
compensated for by the tight coupling of DNA cleavage with ATP binding, 
which helps the complex maintain stability during strand passage (Bates et 
al, 2011). 
1.6.4 Inhibitors of topoisomerase VI 
There has been relatively little work looking into specific inhibitors of 
topoisomerase VI since it has been considered an archaeal curiosity, and 
therefore not medically or commercially useful. The S. shibatae enzyme was 
tested against a range of classic topoisomerase IIA inhibitors when it was 
first discovered (Bergerat et al, 1994). The enzyme was found to be 
resistant to both the coumarin and quinolone class of compound, both of 
which are potent inhibitors of DNA gyrase. It was however susceptible to 
several inhibitors of eukaryotic topoisomerase II used as anticancer drugs 
including: doxorubicin, ellipticine, m-amsacrine, and to a lesser extent o-
amsacrine. All these compounds inhibited S. shibatae topo VI at similar 
concentrations at which they inhibited eukaryotic topoisomerase II. The 
structures of these compounds can be found in Figure 1.17. 
 The Hsp90 inhibitor radicicol has also been shown to inhibit S. 
shibatae topo VI (Gadelle et al, 2005). The drug is a relatively weak 
inhibitor of the enzyme with an Inhibitory Concentration for 50% activity 
(IC50) of 250 µM. However it has not been reported to inhibit any type IIA 
topoisomerases, which makes it noteworthy compared to the other 
inhibitors of topo VI. The drug has been shown to specifically target the 
ATPase activity of the enzyme and to bind in a pocket near the ATP-binding 
site of the enzymes B subunit (Corbett & Berger, 2006; Graille et al, 2008). 
The binding of the compound does not cause dimerisation of the B subunits 
like ATP would, and it is thought that drug binds in such a way as to prevent 
the binding of ATP to the enzyme (Graille et al, 2008). 
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1.7 DNA gyrase 
DNA gyrase is unique among the type IIA topoisomerases since it can 
introduce negative supercoils into DNA in an ATP-dependent manner as well 
as relax positive supercoils with high efficiency (Bates et al, 1996; Gellert et 
al, 1976). Initially it was thought to be found exclusively in bacteria, but 
genes putatively encoding for both the A (GyrA) and B (GyrB) subunits have 
been since identified in plants as well as the malaria parasite Plasmodium 
falciparum (Garcia-Estrada et al, 2010; Raghu Ram et al, 2007; Wall et al, 
2004). The essential nature, unique mechanism amongst the type IIA 
topoisomerases and absence in humans have lead to DNA gyrase being an 
exceptional antimicrobial target. 
  
 
Figure 1.17 The structures of currently known S. shibatae topo VI inhibitors. 
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1.7.1 The biological role of DNA gyrase 
DNA gyrase is responsible for the global level of supercoiling inside the 
bacterial cell which is important for a number of reasons. The first is a 
matter of logistics: the length of a bacterial genome vastly exceeds the 
length of a bacterial cell. For example the E. coli genome is approximately 
1600 µm long whilst the bacterium is only ~1 µm in diameter and ~3-5 µm 
in length (Zimmerman, 2006). The introduction of negative supercoils is 
essential for compaction of this DNA into cellular bodies called nucleoids 
which occupy ~25% of the cell volume (Worcel & Burgi, 1972). 
The replication of bacterial plasmids requires the DNA to be 
negatively supercoiled to facilitate the unwinding of the target sequence 
(Schvartzman & Stasiak, 2004). Additionally, during DNA replication 
positive supercoils are generated ahead of the replication fork as it 
advances (Figure 1.18) (Sawitzke & Austin, 2000; Zechiedrich & Cozzarelli, 
1995). Failure to remove these supercoils can result in the formation of 
catenanes between the daughter duplexes (Zechiedrich & Cozzarelli, 1995) 
and the stalling of the replication machinery. 
 As well as its role in the process of DNA replication, DNA gyrase is 
also essential for the process of transcription. The transcription of many 
genes has been shown to be influenced by the global level of supercoiling in 
the cell (Bates & Maxwell, 2005). This is because supercoiling affects the 
binding of RNA polymerase and various promoter or suppressor proteins 
(Lilley et al, 1996). In addition it is thought that the interaction of the 
binding of RNA polymerase to DNA causes the DNA to rotate on its axis, 
allowing the enzyme to follow the helical path of the DNA strands (Liu & 
Wang, 1987). If the DNA is topologically constrained, for example bound to 
regulatory proteins, positive supercoils are formed ahead of the polymerase 
and whilst negative supercoils form behind. These supercoils are removed 
by DNA gyrase and bacterial topoisomerase I respectively (Lockshon & 
Morris, 1983; Pruss & Drlica, 1986). 
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1.7.2 Structure of DNA gyrase 
Like all bacterial type IIA topoisomerases DNA gyrases is a symmetrical 
heterotetramer of two GyrA and two GyrB subunits. Limited proteolysis 
experiments have further revealed both subunits are comprised of two 
domains (Kampranis & Maxwell, 1998; Reece & Maxwell, 1989) (Figure 
1.19). Although there is not currently a crystal structure for complete 
heterotetramers, crystal structures of the constituent domains have been 
solved (Figure 1.20). For the sake of convenience the subunit sizes and 
residue numbering in this section is for E. coli DNA gyrase, unless otherwise 
stated. 
The GyrA subunit is comprised of a 59 kDa N-terminal domain and a 
35 kDa C-terminal domain. The N-terminal domain contains the active site 
tyrosine and a DNA-binding saddle for the G-segment DNA when in its 
dimeric form. These features have led to it being known as the ―DNA 
breakage-reunion domain‖. As well as these features the structure of the N-
terminal domain causes a 30 Å cavity to form in the GyrA dimer between 
the major dimer interaction regions that is large enough to accommodate 
double-stranded DNA (Berger, 1998). The C-terminal domain is comprised 
of a novel β-pinwheel fold (which resembles a β-propeller fold). This roughly 
cylindrical structure possesses a band of positive charge around its diameter 
 
Figure 1.18 The effect of replication on the supercoiling state of DNA. The DNA has 
been separated into domains, indicated by the gold boxes. In the replicating 
domain, positive supercoils form in front of the replication fork and can diffuse 
behind to form pre-catenanes. Figure from Bates & Maxwell, 2005. 
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which could be used to wrap DNA (Corbett et al, 2004), a process essential 
for the mechanism of DNA gyrase. This is supported by the observation that 
mutants with the GyrA C-terminal domain deleted were no longer able to 
supercoil DNA, instead relaxing DNA in an ATP-dependent manner 
(Kampranis & Maxwell, 1998; Reece & Maxwell, 1989). 
 The GyrB subunit is comprised of a 43 kDa N-terminal domain and a 
47 kDa C-terminal domain. The N-terminal domain contains the GHKL 
ATPase domain (Wigley et al, 1991). When ATP (or a non-hydrolysable 
analogue such as ADPNP) is bound the N-terminal domain dimerises (Wigley 
et al, 1991). This dimer possesses a 20 Å cavity which is large enough to 
accommodate a DNA duplex (Wigley et al, 1991). The C-terminal domain 
contains both the Toprim domain necessary for DNA cleavage-religation 
(Noble & Maxwell, 2002) and a ―Tail‖ region thought to interact with DNA 
(Costenaro et al, 2007). Small angle x-ray scattering (SAXS) experiments 
suggest that the GyrB subunit is ―tadpole‖ shaped in solution with the N-
terminal domain forming the ―head‖ and the C-terminal the ―tail‖ 
(Costenaro et al, 2007). 
 
Figure 1.19 The domain structure of DNA gyrase subunits. The GyrA subunit 
consists of a N-terminal domain, which contains the Quinolone-Resistance 
Determining Region (QRDR) and the active site tyrosine 122, and a C-terminal 
domain responsible for DNA wrapping. The GyrB contains an N-terminal domain, 
containing the ATPase site, and a C-terminal domain which interacts with GyrA and 
DNA. 
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1.7.3 Mechanism of DNA gyrase 
DNA gyrases follows a similar reaction cycle to other type IIA 
topoisomerases (Section 1.5.3.1, Figure 1.9) with one important exception: 
it is able to introduce negative supercoils into DNA in an ATP dependent 
manner. It is thought that the C-terminal domain of the GyrA subunit is 
crucial for the supercoiling reaction, with its removal resulting in a loss of 
supercoiling activity (Corbett et al, 2004; Kampranis & Maxwell, 1996). 
Upon binding the G-segment DNA is wrapped around this C-terminal 
domain in a right-handed manner, resulting in DNA looping back across 
itself to form the T-segment (Figure 1.21)(Corbett et al, 2004; Wang, 
1998). The total amount of DNA wrapped in this manner by DNA gyrase is 
thought to be 120-150 bp (Champoux, 2001). 
 
Figure 1.20 The crystal structures of DNA gyrase domains. Structures have been 
solved for the N-terminal (Morais Cabral et al, 1997) and C-terminal domains 
(Ruthenburg et al, 2005) of E. coli GyrA, as well as the N-terminal domain of E. coli 
GyrB (Brino et al, 2000) and the C-terminal domain of M. tuberculosis GyrB (Fu et 
al, 2009). Structures presented in their approximate location in the intact DNA 
gyrase complex, but have not been drawn to exact scale. 
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Since the introduction of supercoils is not energetically favourable 
ATP hydrolysis is necessary to drive the reaction. The binding of ATP to the 
GyrB subunits causes their N-terminal domains to dimerise, clamping the T-
segment in place (Kampranis & Maxwell, 1996). It has been found that 
ATPase activity is stimulated by the cleavage of DNA by the GyrA subunit 
(Williams & Maxwell, 1999a). This G-segment is then cleaved on both its 
strands with a 4 bp stagger (Horowitz & Wang, 1987; Mizuuchi et al, 1980). 
Conformational changes occur which cause the break to widen enough to 
allow passage of the T-segment through this ―DNA gate‖ into the positively 
charged cavity formed by the GyrA N-terminal domains (Morais Cabral et al, 
1997). The T-segment can then exit the complex by the bottom gate of the 
GyrA N-terminal domains. Although it is not clear what drives the T-
segment to do this, it is thought that the closing of the DNA gate causes the 
GyrA N-terminal cavity to narrow and ―squeeze‖ T-segment out (Wang, 
1998). ATP hydrolysis allows the enzyme to reset, ready do another round 
of activity (Sugino et al, 1978). 
If ATP is replaced by a non-hydrolysable analogue such as ADPNP (5'-
 
Figure 1.21 DNA wrapping and strand passage by DNA gyrase. The different 
domains of the protein are coloured as follows: yellow, GyrB N-terminal (containing 
the ATPase domain); red, GyrB C-terminus (containing toprim and tail domains); 
dark blue, GyrA subunit N-terminal (containing the ―breakage-reunion‖ domain); 
green, GyrA C-terminal domain (responsible for DNA wrapping). The G-segment 
(purple), T-segment (light blue) and the DNA, N- and C-gates are indicated. Figure 
from Corbett et al, 2004. 
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adenylyl β,γ-imidodiphosphate) the T-segment can be captured by the GyrB 
subunits and the strand passage event can occur (Ali et al, 1993; Ali et al, 
1995; Lindsley & Wang, 1993; Roca & Wang, 1992). However the enzyme 
is unable to religate the double strand break and is trapped in an inactive 
state (Roca et al, 1996). 
DNA gyrase is also able to relax negatively supercoiled DNA in the 
absence of ATP, passing the T-segment in the opposite direction (Williams & 
Maxwell, 1999b). ATP is not necessary since the removal of negative 
supercoils is energetically favourable. This reaction is significantly less 
efficient than the enzyme’s supercoiling activity (Gellert et al, 1979; Higgins 
et al, 1978). DNA gyrase is capable of relaxing positive supercoils in the 
presence of ATP, a reaction which has enhanced activity over the enzyme’s 
negative supercoiling activity (Bates et al, 1996). This reaction is thought to 
happen in an identical manner to the negative supercoiling reaction. The 
catenation, decatenation and unknotting activities of DNA gyrase have all 
been described and are ATP-dependent (Kreuzer & Cozzarelli, 1980; Liu et 
al, 1980). 
1.8 DNA gyrase inhibitors 
Because of the essential nature of its function and its absence in humans 
DNA gyrase is a highly appealing drug target. A large number of antibiotics 
have been produced which target it (and its companion type IIA 
topoisomerase, topoisomerase IV) (Froelich-Ammon & Osheroff, 1995). The 
two biggest classes of these inhibitors are the quinolones and 
aminocoumarins. 
1.8.1 Quinolones 
The quinolones, which include the drug ciprofloxacin, are among the most 
successful classes of antimicrobials developed. The first quinolone, nalidixic 
acid, was discovered by accident as a by-product in the synthesis of the 
antimalarial drug chloroquine (Lesher et al, 1962). Subsequent 
modifications to the ring decoration have resulted in progressively more 
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potent second, third and fourth generation quinolones (Emmerson & Jones, 
2003; King et al, 2000). 
Quinolones are thought to operate by stabilisation of the cleavage-
complex formed during the topoisomerase reaction (Heddle et al, 2000). 
This converts the enzymes into physiological toxins that introduce high 
levels of breaks into the cell’s genome (Kreuzer & Cozzarelli, 1979), 
resulting in mutagenesis (Ripley, 1994) and cell death (Zhivotovsky & 
Kroemer, 2004). Their lethality is reflected in their low in vivo minimum 
inhibitory concentration for bacterial growth (MIC) compared to their in vitro 
IC50 values, as only a small number of breaks are required to disrupt the 
stability of the cell (Domagala et al, 1986; Gellert et al, 1977). What’s more 
they are highly effective against rapidly dividing cells, such as bacteria, 
since the presence of replication machinery greatly increases the number of 
breaks formed (Hsiang et al, 1989). However, the exact details of quinolone 
activity and binding have remained elusive. Several low resolution crystal 
structures have been published which show the stabilization of DNA 
cleavage by various quinolones with DNA gyrase or topoisomerase IV 
(Figure 1.23) (Bax et al, 2010; Laponogov et al, 2010; Laponogov et al, 
2009; Wohlkonig et al, 2010). In all these structures the DNA gate is 
closed, showing that gate opening is not necessary for quinolone binding or 
strand cleavage. This is consistent with previous biochemical studies 
 
Figure 1.22 Structures of selected quinolones. Figure from Drlica et al, 2008. 
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(Williams & Maxwell, 1999a). Although these structures show approximately 
where the binding sites for the quinolones are in this enzyme, low resolution 
and discrepancies between the structures means drawing conclusions about 
the exact interactions between drug, enzyme and DNA is not possible. The 
binding sites revealed in the crystal structures appear to overlap with the 
so-called Quinolone-Resistance-Determining-Region (QRDR) region of the 
GyrA subunit (Yoshida et al, 1990). 
 
Figure 1.23 The binding of moxifloxacin to topo IV breakage-reunion domain. 
Colouring as follows: blue, ParC (GyrA homologue) N-terminal domain; yellow, ParE 
(GyrB homologue) toprim domain; green, 34 bp DNA duplex; red, moxifloxacin; 
cyan, WHD or CAP-like domain; orange, ‗tower‘ domain; and silver, C-gate. The 
interface region between ParC and ParE subunits is in purple. Figure from 
Laponogov et al, 2009. 
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Despite their potency several bacterial strains which are resistant to 
the quinolones have emerged (Hooper, 1999). Some of these strains bear 
genes which prevent uptake of the drugs or encode for pumps which export 
them from the bacteria before they can kill the cell. Others have mutations 
within the gyrase genes, altering key interaction residues and preventing 
the drugs binding. The majority of these mutations occur in the QRDR 
region of the GyrA subunit, which lies near the dimer interface and active 
site tyrosine (Morais Cabral et al, 1997). The residues most commonly 
mutated in these resistant strains are Ser83 and Asp87 (Yoshida et al, 
1990). The mutation of these residues is thought to reduce the binding of 
quinolones (Willmott & Maxwell, 1993). In addition to these resistance-
conferring mutations of DNA gyrase, a plasmid-borne quinolone resistance 
gene has been identified in clinical isolates (Jacoby et al, 2003). The protein 
it encodes for, a pentapeptide repeat protein called Qnr (Bateman et al, 
1998), is thought to be a DNA mimic capable of inhibiting gyrase activity by 
binding to the enzyme instead of the G-segment (Hegde et al, 2005). 
Presumably, by lowering the activity of the enzyme in this way the bacteria 
reduce the number of DNA lesions generated by the drugs and therefore 
reduce their lethality. 
1.8.2 Aminocoumarins 
The aminocoumarin class of natural products have been known to inhibit 
nucleic acid synthesis in bacteria since the 1950s. There are three naturally 
occurring aminocoumarins produced by Streptomyces: novobiocin, 
clorobiocin and coumermycin A1 (Figure 1.24) (Maxwell & Lawson, 2003). 
All three of these compounds possess a 3-amino-4, 7-dihydroxycoumarin 
core (referred to as a coumarin ring), a L-noviosyl sugar and an aromatic 
acyl component attached to the amino group of the coumarin ring (Maxwell 
& Lawson, 2003). They have been shown to inhibit the ATPase activity of 
DNA gyrase by competing with ATP for binding to GyrB (Mizuuchi et al, 
1978; Sugino & Cozzarelli, 1980; Sugino et al, 1978). High resolution 
crystal structures (Holdgate et al, 1997; Lewis et al, 1996a; Lewis et al, 
1996b; Maxwell & Lawson, 2003) and biochemical studies (Gilbert & 
Maxwell, 1994) have revealed that they do not bind to the ATP binding site 
of the enzyme but rather to an overlapping site, with the noviose sugar of 
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the aminocoumarin overlapping with the adenine ring of ATP/ADPNP (Figure 
1.25). 
 Resistance to aminocoumarins usually arises due to mutations in the 
GyrB subunit. The most common of these mutations involve an Arg residue 
critical to aminocoumarin binding (Arg136 in E. coli) (Contreras & Maxwell, 
1992; del Castillo et al, 1991; Kampranis et al, 1999; Lewis et al, 1996a; 
Tsai et al, 1997). Mutations in other residues in the drug binding site have 
been reported such as Gly164 to Val, Asp73 to Glu, Gly77 to Ala or Ser, 
Ile78 to Ala or Leu and Thr165 to Ala or Val (Contreras & Maxwell, 1992; 
Gross et al, 2003). Some mutations have been shown to confer more 
selective resistance, such as Asp-89 to Gly and Ser-128 to Leu which make 
the enzyme resistant to novobiocin and not coumermycin A1 (Fujimoto-
 
Figure 1.24 The structures of the three natural aminocoumarins. Coumermycin A1 
is unusual, appearing to be a symmetrical dimer of the clorobiocin noviose sugar 
and coumarin ring linked by a pyrrole group. 
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Nakamura et al, 2005). Many of these mutations are detrimental to the 
activity of the enzyme, most likely due to their proximity to the ATPase 
active site (Contreras & Maxwell, 1992; Gross et al, 2003). This means that 
there is a possibly significant cost for the bacteria to develop resistance to 
these drugs, which is an appealing thought for developing clinical 
aminocoumarins. 
 However, although these compounds are potent DNA gyrase 
inhibitors they make poor clinical antimicrobials due to their poor solubility, 
high toxicity in humans and ineffectiveness against Gram-negative bacteria 
due to poor penetration of the bacterial cells (Maxwell & Lawson, 2003). 
Novobiocin has been used as a clinical antibiotic under the names albamycin 
and cathomycin but was withdrawn due to low potency and unpleasant side-
effects such as skin rashes and liver dysfunction. The mitigation of these 
flaws by chemical modification is now the main challenge for producing 
clinically relevant aminocoumarin drugs. 
  
 
Figure 1.25 The overlapping binding sites of ADPNP and novobiocin. ADPNP is 
shown in red and novobiocin in green. This image was produced by aligning the 
structures of the ADPNP-bound GyrB fragment (Brino et al, 2000)and novobiocin-
bound GyrB fragment (Holdgate et al, 1997).  
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1.8.3 Other small molecule inhibitors of DNA 
gyrase 
As well as the two major classes of inhibitors above a host of other 
compounds have been found that inhibit DNA gyrase. Many of these 
compounds have only been recently identified, and their modes of action 
still require further exploration. 
 The simocyclinones are hybrid antibiotics, produced by Streptomyces 
antibioticus Tü 6040, which target DNA gyrase (Flatman et al, 2005) that 
are mostly intermediates of simocyclinone D8 (SD8) (Theobald et al, 2000; 
Trefzer et al, 2002). These antibiotics possess both aminocoumarin and 
polyketide moieties linked by a tetraene dicarboxylic acid–olivose sugar 
linker (Figure 1.26). Although the aminocoumarin and polyketide moieties 
can inhibit DNA gyrase individually, their potency is much less than the 
intact antibiotic (Edwards et al, 2009). Surprisingly, the binding site for the 
aminocoumarin end of the molecule is not at the ATPase site of GyrB 
(Edwards et al, 2009; Flatman et al, 2006). A crystal structure of SD8 
bound to the GyrA N-terminal domain has revealed that both ends of the 
molecule bind to two different sites on the GyrA subunit at the GyrA—GyrB 
interface (Edwards et al, 2009). This is supported by the biochemical 
evidence that SD8 does not affect the ATPase activity of DNA gyrase, 
instead appearing to prevent the binding of the enzyme to DNA (Flatman et 
al, 2005). The crystal structure shows that four SD8 molecules stabilise a 
tetramer of GyrA subunits, with each SD8 binding one of its two heads to 
two different GyrA subunits. Since it is not clear if this mode of binding is 
physiologically relevant an alternative model, supported by mass 
spectrometry data, has been proposed in which one SD8 bridges the two 
sites on the same GyrA subunit (Edwards et al, 2011). Unfortunately SD8 
does not appear to be a good candidate for clinical use, having poor 
bactericidal activity and cytotoxicity against human cells (Richter et al, 
2010; Sadiq et al, 2010; Schimana et al, 2000). 
 Chapter 1 General Introduction 
 
  43 
 
 Cyclothialidine is a cyclic peptide with weak antibacterial activity 
produced by Streptomyces filipinensis (Goetschi et al, 1993; Nakada et al, 
1993). It has been shown to inhibit the ATPase activity of DNA gyrase 
(Goetschi et al, 1993; Nakada et al, 1994; Oram et al, 1996). Several 
analogues have been produced with enhanced activity (Angehrn et al, 2004; 
Goetschi et al, 1993), and the crystal structure of one of these compounds 
(GR122222X) shows that they bind to a site overlapping with the ATP-
binding site, like novobiocin (Nakada et al, 1995; Oram et al, 1996). These 
derivatives are yet to be tested clinically. 
 Cinodine is a natural product of the Norcardia spp. of bacteria that 
belongs to the glycocinnamoylspermidine antibiotic class (Martin et al, 
1978; Tresner et al, 1978). Three different forms have been discovered: β, 
γ1 and γ2. Cinodine has been shown to have bactericidal activity, inhibiting 
bacterial DNA synthesis (Greenstein et al, 1981). It has also been shown to 
have activity against gyrase in vitro and resistant mutants have been 
mapped to the A subunit (Osburne, 1995; Osburne et al, 1990). Other than 
this, its mode of action has not been explored. 
 As well as these natural product inspired inhibitors many synthetic 
inhibitors of DNA gyrase have been devised, often referred to as new 
bacterial topoisomerase inhibitors (NBTIs). NBTIs are generally compounds 
with antibacterial activity which do not belong to the quinolone class but 
have the same mode of action (stabilization of the cleavage complex) whilst 
remaining efficient against quinolone-resistant strains (Widdowson & 
 
Figure 1.26 The structure of simocyclinone D8. 
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Hennessy, 2010). One such compound is the potent DNA gyrase inhibitor 
GSK299423 which has had its structure solved bound to Staphylococcus 
aureus DNA gyrase (Bax et al, 2010). The compound binds in a site close, 
but distinct from, the quinolone binding site. However, the compound does 
not stabilize double-strand breaks, instead inducing single-strand breaks 
(Bax et al, 2010). This implies a novel mode of action which requires further 
exploration. 
1.9 A high-throughput assay for 
topoisomerase inhibitors 
All the above goes to demonstrate that DNA topoisomerases have made 
exceptional drug targets, and that the problem of resistance to 
antimicrobials targeting them necessitates the discovery of new inhibitors. 
However, the discovery of such novel inhibitors has been limited by the 
traditional assay for topoisomerase activity, which is based on the principle 
that different DNA topoisomers have different mobilities on an agarose gel. 
This assay is information-rich, but is also slow and requires intensive 
handling. As such it is not suitable for the high-throughput format necessary 
for large scale screening for novel inhibitors. To address the limitations of 
this assay, a microtitre plate-based assay was developed (Maxwell et al, 
2006) which is based on the formation of parallel-motif DNA triplexes. 
As well as its standard duplex structure DNA is capable of forming 
DNA triplexes under the correct conditions. The formation of DNA triplexes 
was first observed with polynucleotide strands in 1957 (Felsenfeld et al, 
1957), and later with triplex-forming oligos (or TFOs) with polypurine-
polypyrimidine sections of double-stranded DNA (Le Doan et al, 1987; 
Moser & Dervan, 1987) (Figure 1.27). The binding of the TFO is thought to 
occur in the major groove of the double-stranded DNA in either a parallel or 
antiparallel orientation relative to the purine strand (Fox, 2000; Vasquez & 
Glazer, 2002). Whether a TFO binds in one or another of these two motifs is 
dependent on its sequence. 
The antiparallel motif has had the least study of the two binding 
motifs. It is characterized by the formation of A•AT, T•AT and G•GC triplets 
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via reverse-Hoogsteen base pairing (Beal & Dervan, 1991; Chen, 1991) 
(DNA triplets are usually written in the form X•YZ, where the third strand 
base X interacts with an YZ base pair by forming hydrogen bonds to Y). The 
formation of antiparallel DNA triplexes is not dependent on pH (unlike the 
parallel motif, see below) but requires the presence of divalent metal ions 
(such as Mg2+) (Fox, 2000). Their stability is highly sequence specific which 
has made them difficult to predict. This sequence specificity is thought to 
arise from the non-isohelical nature of the triplets as well as the formation 
of unusual guanine-mediated inter and intra molecular structures (Fox, 
2000). 
The parallel motif usually requires a TFO containing CT repeats, 
forming T•AT and C+•GC triplets via two Hoogsteen hydrogen bonds. The 
formation of C+•GC triplets necessitates a low pH (<6.0) to protonate the 
third strand cytosine (Fox, 2000; Lee et al, 1979; Vasquez & Glazer, 2002). 
Triplet formation is still possible without this protonation, but is much 
 
Figure 1.27 The two motifs for DNA triplex formation. Triplex formation occurs at 
polypurine—polypyrimidine sites in duplex DNA. At such sites a third strand (the 
triplex forming oligo) can bind in either a: A. pyrimidine motif; or B. purine motif. 
Figure from Vasquez & Glazer, 2002. 
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weaker since it can form only one Hoogsteen hydrogen bond (Asensio et al, 
1998). Interestingly the difference in stability between the protonated and 
non-protonated forms is much greater than one would expect for a single 
hydrogen bond (Asensio et al, 1998). It is likely electrostatic interactions 
with the phosphate backbone or altered stacking with neighboring bases 
play a role, possibly as a result of favorable interactions between the 
positive charge and the  systems of these bases (Fox, 2000). Although the 
pKa of free cytosine is around 4.5, this may vary considerably when the 
base forms part of a DNA triplex with internal cytosines possessing much 
higher pKas (i.e. being more stable) than terminal ones (Asensio et al, 
1998). As well as pH a number of other factors affect the efficiency of 
parallel triplex formation including the valancey of cations present (Hampel 
et al, 1991; Rougee et al, 1992) and the ionic strength of the buffer 
(Rougee et al, 1992; Singleton & Dervan, 1993). Importantly for the high-
throughput microtitre plate-based assay, triplex formation has been shown 
to be enhanced by negative supercoiling of the double-stranded DNA 
(Hanvey et al, 1988; Sakamoto et al, 1996). 
The microtitre plate-based assay reactions are carried out in 
streptavidin-coated microtitre wells, which have had a single-stranded 
biotinylated CT-rich TFO immobilized on their surfaces. This oligo can form 
triplexes with a target plasmid by the addition of a low pH triplex formation 
buffer containing divalent metal ions, which also stops the topoisomerase 
reaction. Supercoiled DNA will be retained in the wells after washing, 
whereas relaxed, open circle and linear DNA will be removed. The amount 
of DNA retained can be quantified with a fluorescent dye, and directly 
correlates with the level of enzyme activity (Figure 1.28). 
 Chapter 1 General Introduction 
 
  47 
 
This assay has several advantages over the traditional assay for 
screening: it is much faster since it does not require a lengthy 
electrophoresis step, hundreds of reactions can be carried out 
simultaneously, the visualisation of DNA is quicker and simpler than the 
classic assay and there is less sample handling required by the operator. All 
these factors greatly speed up the assaying processes and open up the 
possibility for automation. However there are limits to the assay which need 
to be considered before it is used. Since the test compounds remain in the 
wells during the triplex formation step they may stimulate or inhibit triplex 
formation. This can result in the generation of false positives or negatives 
 
Figure 1.28 A graphical depiction of the agarose and microtitre plate-based assays. 
A. Sample agarose gel assay for increasing units of DNA gyrase with position of 
different topoisomers indicated. Relaxed DNA runs as a series of bands whilst 
supercoiled DNA runs as a single band. B. A cartoon representation of the 
equivalent experiment in the high-throughput assay. Each circle represents a well 
in a microtitre plate shaded to represent fluorescence intensity. C. Cartoon of the 
contents of the indicated wells (plasmid and TFO not drawn to scale). Conversion of 
relaxed to supercoiled DNA increases the amount of DNA retained in the well due to 
triplex formation and subsequently the intensity of the fluorescent signal after 
SBYR Gold staining. Figure adapted from Maxwell et al, 2006. 
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(depending on whether a supercoiling or relaxing enzyme is being assayed). 
This is a particular concern since many topoisomerase inhibitors interact 
with DNA as part of their mode of inhibition. 
1.10 Project aims 
Since the microtitre plate-assay had yet to be tested in a high-throughput 
format the initial aim of this project was to demonstrate that it could be 
used for such a purpose. It would begin by carrying out a screen using a 
small library of natural products and existing drugs (the Genplus library 
from Microsource) against the well characterised E. coli DNA gyrase. It 
would then investigate the mode of action of any hits and test them for 
bactericidal activity against Gram-negative and Gram-positive bacteria.  
The project would then move on to screening against the more exotic 
topoisomerase VI. Topo VI was chosen due to the relatively small number  
of studies conducted on it and the scarcity of specific inhibitors known for it. 
The M. mazei orthalogue was chosen to screen against since it is active at 
room temperature and is easily expressed. The the mode of action on any 
hits would then be explored and tested on the plant enzyme in vivo by 
carrying out a morphological screen with Arabidopsis hypocotyls. Towards 
the end of the project the possible existence of a hypothetical Plasmodium 
topo VI was discovered in the literature and an attempt was made to 
express the enzyme in order to test the archaeal topo VI hits against it. 
Along the way the traditional and microtitre-plate assays for 
topoisomerase activity were explored and optimised, and the M. mazei 
enzyme was characterised. 
A summary of the areas covered in the project can be found in Figure 1.29. 
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Figure 1.29 A general outline of project. E. coli DNA gyrase screen would be 
pursued first, followed by the M. mazei topo VI screen and the morphological 
screening of M. mazei topo VI screen hits against Arabidopsis seedlings. Other 
areas of study would be pursued as opportunity presented itself. 
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Chapter 2 
2 Materials and Methods 
2.1 Buffers and solutions 
Buffer/solution Details 
DNA gyrase dilution buffer 50 mM Tris·HCl (pH 7.5), 100 mM KCl, 2 mM 
DTT, 1 mM EDTA, 10% (w/v) glycerol. Store 
at -20°C. 
Calcium acetate 75 mM calcium acetate (pH 4.7). Filtered 
with 0.2 µm filter. Store at room 
temperature. 
Chicken erythrocyte 
topoisomerase I dilution buffer 
10 mM Tris·HCl (pH 7.5), 1 mM DTT, 1 mM 
EDTA, 50 % (v/v) glycerol, 100 mg/mL 
bovine serum albumin. 
Chicken erythrocyte 
topoisomerase I relaxation buffer 
20 mM Tris·HCl (pH 8), 200 mM NaCl, 0.25 
mM EDTA, 5% glycerol. The buffer is stored 
as a 10× concentrate at -20°C. 
DNA gyrase relaxation buffer 35 mM Tris·HCl (pH 7.5), 24 mM KCl, 4 mM 
MgCl2, 2 mM DTT, 6.5% (w/v) glycerol, 0.1 
mg/mL bovine serum albumin. The buffer is 
stored as a 5× concentrate at -20°C. 
DNA gyrase supercoiling buffer 35 mM Tris·HCl (pH 7.5), 24 mM KCl, 4 mM 
MgCl2, 2 mM DTT, 1.8 mM spermidine, 1 mM 
ATP, 6.5% (w/v) glycerol, 0.1 mg/mL bovine 
serum albumin. The buffer is stored as a 5× 
concentrate at -20°C. 
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Gel shift binding buffer (5x) 250 mM Tris∙HCl (pH 7.5), 500 mM KCl, 25 
mM MgCl2, 10 mM DTT, 50% w/v glycerol). 
STEB (x2) 40% sucrose, 100 mM Tris·HCl (pH 8.0), 
100 mM EDTA, 0.5 mg/mL bromophenol 
blue. 
T10E1 buffer 10 mM Tris·HCl (pH 8.0), 1 mM EDTA. 
Filtered with 0.2 µm filter. Store at room 
temperature. 
TAE 40 mM Tris·Acetate (pH 8.0), 1 mM EDTA. 
TBM 90 mM Tris∙Borate (pH 7.5), 4 mM MgCl2. 
Topoisomerase VI dilution buffer 20 mM HEPES pH 7.5, 10% (v/v) glycerol. 
Store at -20°C. 
Topoisomerase VI relaxation 
buffer 
20 mM bis-tris propane (pH 6.5), 100 mM 
potassium glutamate, 10 mM MgCl2, 1 mM 
DTT, and 1 mM ATP. The buffer is stored as 
a 5× concentrate at -20°C. 
Triplex formation (TF) buffer 75 mM magnesium acetate (pH 4.7). 
Filtered with 0.2 µm filter. Store at room 
temperature. 
Wash Buffer 20 mM Tris·HCl (pH 7.6), 137 mM NaCl, 
0.01% (w/v) bovine serum albumin 
(acetylated), 0.05% (v/v) Tween-20. 
Filtered with 0.2 µm filter. Store at 4°C. 
Wheat germ topoisomerase I 
dilution buffer 
50 mM Tris·HCl (pH7.9), 1 mM EDTA, 1 mM 
DTT, 50% (v/v) glycerol, 500 mM NaCl 
Wheat germ topoisomerase I 
relaxation buffer 
50 mM Tris·HCl (pH7.9), 1 mM EDTA, 1 mM 
DTT, 20% (v/v) glycerol, 50 mM NaCl 
Table 2.1 Commonly used buffers and solutions. 
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2.2 Antibiotics 
Stock solutions of antibiotics were prepared at the concentration detailed 
below (Table 2.2). All antibiotics were purchased from Sigma. Stock 
solutions were prepared with Milli-Q water; filter sterilized and stored at 
minus 20°C. 
2.3 Microbiology 
2.3.1 Strains and species 
The Escherichia coli strains used in this work are detailed below (Table 2.3). 
Mycobacterium smegmatis mc2155 (wild-type) was used for the M. 
smegmatis studies. 
2.3.2 Growth media 
 E. coli growth was carried out in a range of media as detailed below. All 
media was sterilized by autoclaving. When solid media was required 15 g of 
Bacto Agar per litre of media was added before autoclaving. Solid media 
was melted in a microwave prior to the pouring of plates, and allowed to 
cool to ~50 °C before any thermolabile substances were added (i.e. 
antibiotics).  
Antibiotic Stock concentration 
(mg/mL) 
Final concentration 
(µg/mL) 
Ampicillin* 100 100 
Chloramphenicol** 35 35 
Kanamycin* 50 50  
or 100 (in autoinduction medium) 
Neomycin* 5 5 
Penicillin* 5 5 
Streptomycin* 10 10 
Tetracycline* 10 10 
Gentamicin* 7 7 
Table 2.2 Summary of antibiotic stocks and working concentrations. * in Milli-Q water. 
** in 100% ethanol. 
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Auto Induction Medium (AIM): 0.1% (w/v) Tryptone, 0.05% (w/v) yeast 
extract, 0.0033% (NH4)2SO4 , 0.0068% (w/v) KH2PO4, 0.0071% (w/v) 
Na2HPO4, 0.0005% (w/v) glucose, 0.002% (w/v) α-lactose, 0.00015%, 
(w/v), MgSO4, 0.00003% (w/v), trace elements. 
Luria-Bertani (LB) medium: 1% w/v tryptone, 0.05% w/v yeast extract, 1% 
w/v NaCl, adjusted to pH 7 with 10 M NaOH. 
Middlebrook broth 7H9 (Difco): 0.05% (w/v) L-glutamic acid, 0.25% (w/v) 
Na2HPO4, 0.1% (w/v) NaH2PO4, 0.05% (w/v) (NH4)2SO4, 0.01% (w/v) 
sodium citrate, 0.004% (w/v) ferric ammonium citrate, 0.005% (w/v) 
MgSO4, 0.0001% (w/v) CuSO4, 0.0001% (w/v) pyridoxine, 0.0001% (w/v) 
  
Table 2.3 Summary of E. coli strains and genotypes. 
Strain Genotype 
BL21(DE3) 
(Studier & 
Moffatt, 1986) 
E. coli B F- dcm ompT hsdS(rB- mB-) gal [malB
+]K-12(λ
S) 
  
DH5α 
(Invitrogen) 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK
- mK
+), λ– 
  
DH10Bac 
(Invitrogen) 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara leu) 7697 galU galK λ– rpsL nupG/ 
pMON14272/pMON7124  
  
JM109(pLysS) 
(Yanisch-Perron et 
al, 1985) 
F´ traD36 proA+B+ lacIq Δ(lacZ)M15/Δ(lac-proAB) glnV44 e14- 
gyrA96 recA1 relA1 endA1 thi hsdR17 pLysS (CamR).  
  
MG1655 
(Blattner et al, 
1997) 
F-, lambda-, rph-1  
  
NR698 
(Ruiz et al, 2005) 
F- [araD139]B/r Δ(argF-lac)169* &lambda
- e14- flhD5301 
Δ(fruK-yeiR)725 (fruA25)‡ relA1 rpsL150(strR) rbsR22 
Δ(fimB-fimE)632(::IS1) deoC1 imp4213  
  
Rosetta 
(Novagen) 
F- ompT hsdSB(rB
- mB
-) gal dcm pRARE (CamR)  
  
Rosetta 2 
(Novagen) 
F- ompT hsdSB(rB
- mB
-) gal dcm pRARE2 (CamR) 
  
Top10 
(Invitrogen) 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG 
recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) 
endA1 λ-  
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ZnSO4, 0.00005% (w/v) biotin, 0.000025% (w/v) malachite green, 
0.00005% (w/v) CaCl. Supplement with Middlebrook ADC enrichment. 
Middlebrook ADC enrichment (10x) (Difco): 5% (w/v) bovine albumin 
fraction V, 2% (w/v) dextrose, 0.003% (w/v) catalase. 
Middlebrook 7H11 agar (Difco): 0.1% (w/v) enzymatic digest of casein, 
0.15% (w/v) Na2HPO4, 0.15% (w/v) KH2PO4, 0.05% (w/v) (NH4)2SO4, 
0.05% (w/v) monosodium glutamate, 0.04% (w/v) sodium citrate, 0.004% 
(w/v) ferric ammonium citrate, 0.005% (w/v) MgSO4, 0.0001% (w/v) 
CuSO4, 0.0001% (w/v) pyridoxine, 0.0001% (w/v) ZnSO4, 0.00005% (w/v) 
biotin, 0.000025% (w/v) malachite green, 1.35% (w/v) agar 
Plasmid DNA medium (PDM) (Danquaha & Fordea, 2007): 0.79% tryptone, 
0.44% w/v yeast extract, 0.05% w/v NH4Cl and 0.024% w/v MgSO4. After 
autoclaving add glucose to 1% w/v and 10x PDM phosphate buffer to 1x. 
PDM phosphate buffer (10x): 12.8 % w/v Na2HPO4.7H2O, 3% w/v KH2PO4. 
SOC medium: 2% w/v tryptone, 0.5% w/v yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgS04, 20 mM glucose. 
2.3.3 Preparation of chemically competent cells 
Competent cells were generated by a CaCl2 method. E. coli to be made 
competent were grown overnight in LB media. A 4 mL inoculum was then 
taken and added to 50 mL LB in a 250 mL conical flask. Cells were grown 
until the culture had entered early mid-log phase (~ 2 hrs) then centrifuged 
at 3453 x g for 4 minutes at 4°C (Sorvall Legend RT centrifuge, Heraeus 
rotor). The supernatant was then discarded and 50 mL of ice cold CaCl2 (50 
mM) was added. Cells were gently resuspended and left on ice for 30 min., 
after which they were centrifuged at 3453 x g for 3 minutes at 4°C. The 
cells were quickly returned to ice and the supernatant discarded. The pellet 
was then resuspended in 0.5 mL 50 mM CaCl2, 15% (v/v) glycerol. After a 
further 30 minutes on ice the cells were dispensed into 50 µL aliquots, snap-
frozen in liquid nitrogen and stored at -80°C. 
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2.3.4 Halo assays 
For E. coli work a 10 mL culture of E. coli MG1655 or NR698 was grown 
overnight at 37°C. Petri dishes containing LB agar were prepared aseptically 
and 100 µL of culture was spread across their surface. Filter disks soaked in 
compound were then applied to the surface and the bacteria allowed to 
grow at 37°C. The zone of clearing for each disk acted as an indicator of the 
compounds antimicrobial activity. 
For work on M. smegmatis a 50 mL culture was grown for 48 hrs in 
Middlebrooks 7H9 media at 37°C. Bacterial lawns were grown on 
Middlebrooks 7H11 agar for 48 hrs at 37°C. 
2.3.5 Slope assays 
A 10 mL culture of E. coli MG1655 or NR698 was grown overnight at 37°C. 
The culture was then diluted 1:1000 and streaked on Petri dishes containing 
LB agar. Colonies were allowed to develop by incubation of the plates at 
37°C overnight. Alternatively, 50 mL of M. smegmatis was grown for 48 hrs 
at 37°C, spread on Middlebrooks 7H11 agar and grown for 48 hrs at 37°C. 
The following day 50 mL of molten LB or Middlebrooks 7H11 agar was 
prepared and the desired concentration of test compound added. A 100 mm 
square Petri dish was propped at ~45o to horizontal and the agar poured in. 
After the agar had set the dish was returned to horizontal and another 50 
mL of molten agar (this time lacking compound) was added. This resulted in 
a gradient of compound concentration across the plate. Colonies from both 
strains were then streaked with a toothpick across the gradient and the 
plates incubated at 37°C overnight. 
2.3.6 Liquid-culture growth assays 
For E. coli work, a 10 mL culture of E. coli MG1655 or NR698 was grown 
overnight at 37°C. A 100 µL aliquot of the overnight culture was then added 
to 10 mL LB containing the desired concentration of compound. The culture 
was then allowed to grow at 37°C for 5 hours and its OD600 measured every 
hour. 
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For work on M. smegmatis a 50 mL culture was grown for 48 hrs in 
Middlebrooks 7H11 media at 37°C. A 100 µL of the overnight culture was 
then added to 10 mL Middlebrooks 7H11 containing the desired 
concentration of compound. The culture was then allowed to grow at 37°C 
for 9 hours and its OD600 measured every three hours. 
2.3.7 Colony counting assays 
A 50 mL culture of M. smegmatis was grown for 48 hrs in Middlebrooks 7H9 
media at 37°C. Cultures of 10 mL Middlebrooks 7H9 media containing the 
desired concentration of each compound were then inoculated with 100 µL 
and allowed to grow at 37°C overnight. After 16 hours, 20 µL samples were 
taken from the cultures and diluted 1 in 10, 000 with Middlebrooks 7H9 
media. Petri dishes containing Middlebrooks 7H11 agar were prepared and 
100 µL of each diluted culture was spread out. The plates were 
subsequently stored at 4°C. This was repeated every three hours for six 
hours, after which the plates were transferred to 37°C for 48 hrs. The 
numbers of colonies for each time point were counted manually. 
2.4 Arabidopsis Methods 
2.4.1 Arabidopsis lines used 
All experiments in this work were carried out on the Arabidopsis thaliana 
columbia (Col-0) line. 
2.4.2 Seed sterilization 
Seeds were surface sterilized with 5% bleach for 10 mins immediately prior 
to use. The seeds were then washed three times with sterile water under a 
laminar flow hood. 
2.4.3 Hypocotyl extension assays 
MS Salts medium (Murashige & Skoog, 1962) (micro and macro elements 
including vitamins, pH 5.8) was supplemented with 1 g/L sucrose and 
0.7g/L phytagel (Sigma) before autoclaving. After the medium cooled to 
~50°C it was divided into 50 mL aliquots and compounds to be tested (or 
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an equivalent amount of appropriate solvent for the controls) then added to 
the desired concentration under aseptic conditions. The media were then 
poured into separate 100 mm square Petri dishes and allowed to cool to 
room temperature in a laminar flow hood. Surface sterilized seeds were 
then planted in a grid pattern (32 seeds per dish) and the dishes sealed 
with surgical tape. 
 The plates were transferred to 4°C and left for 64 hrs in the dark to 
vernalise, after which they were transferred to a 22°C growth cabinet. After 
2 hrs of light exposure the plates were stacked vertically in the dark at 22°C 
to allow for hypocotyl extension along the agar’s surface. After 4-5 days the 
hypocotyls were observed using an optical microscope and their length 
measured. 
2.4.4 Flow cytometry experiments 
Flow cytometry experiments were carried out using a Partec PAS flow 
cytometer. Samples (either rosettes or hypocotyls) were finely chopped 
with a sharp razor blade in 1 mL nuclear extraction buffer (Partec) and 
passed through a 30 µM CellTric filter (Partec). A 1 mL solution of DAPI (4’, 
6-diamidino-2-phenylindole) staining buffer (CyStain UV Precise P, Partec) 
was then added. After approximately 30 seconds the sample was loaded 
into the cytometer. Samples were excited with a HBO mercury lamp (filters 
KG1, BG38, UG1) and their emission detected (FL-4, filter GG435) to an 
average of 20, 000 stained particle counts. 
2.4.5 Cryo- Scanning Electron Microscopy (SEM) 
on hypocotyls 
Five day old hypocotyls grown on media containing various concentrations 
of compound were frozen in nitrogen slush and loaded into a Philips XL30 
SEM with a cyro stage installed. Samples were sputter coated with platinum 
and transferred into the microscope chamber for image collection. 
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2.5 Plasmids and oligonucleotides 
2.5.1 Oligonucleotides 
The oligos used within this study were as follows (written 5' to 3'): 
TFO1: TCTCTCTCTCTCTCTC (5' modification: biotin) 
TFO1C: CCGACTCTCTCTCTCTCTCT 
TFO1W: TCGGAGAGAGAGAGAGAGAG 
2.5.2 Substrate plasmids 
The following plasmids were used as substrates in the topoisomerase assays 
carried out during the course of this work: 
pBR322* (Boros et al, 1984): A high-copy number plasmid containing a 
single point mutation to increase copy number. 
pNO1 (Maxwell et al, 2006): A modified version of pBR322* containing a 
triplex-forming insert. It was prepared by ligation of oligos TFO1W and 
TFO1C into the AvaI site of the plasmid. 
2.5.3 Small-scale preparation of plasmid DNA 
Plasmids preparations for cloning and transformation were prepared using a 
QIAprep Spin Miniprep kit (QIAGEN). 
2.5.4 Large-scale preparation of plasmid DNA 
Large-scale preparation of pNO1 for use in screening was carried out as in 
the established protocol (Jordan et al, 1999) with a few modifications. E. 
coli JM109 was transformed with the pNO1 plasmid. A 4 mL inoculum from 
a 10 mL overnight culture was added to 400 mL of PDM containing 
ampicillin and the cells grown at 37 °C, 300 rpm for 18 hours in a 2 L 
baffled flask.  
The cells were then pelleted by spinning at 6000 x g (Evolution RC 
centrifuge, S-3000 rotor, Sorvall) for 10 mins at 4 °C. The supernatant was 
discarded and the pellet kept on ice whilst being resuspended in 32 mL 
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chilled GTE (500 mM glucose, 250 mM Tris∙HCL pH7.5, 100 mM EDTA). A 
solution of 8 mL of GTE containing 20 mg/mL lysozyme was added and the 
cells incubated on ice for a 5 mins. A solution of 0.2 M NaOH and 2% SDS 
was freshly prepared and 80 mL added to the cell suspension. The 
suspension was carefully agitated by inversion and the cells allowed to lyse 
for a further 5 minutes on ice. The solution was neutralised by the addition 
of 45 mL of high salt solution (3 M KAc, 5% (v/v) formic acid) and carefully 
inverted several times. This was followed by a final incubation on ice for 5 
minutes. Waste precipitate was pelleted by centrifuging at 10,000 x g for 10 
mins at 4 °C (Evolution RC centrifuge, S-3000 rotor, Sorvall). The 
supernatant was transferred to a fresh tube and spun again to ensure 
complete removal of debris. 
The nucleic acids were then precipitated with propanol as described in 
section 2.5.6 and resuspended in 65 mL T10E1. For each mL of sample 1 g 
of caesium chloride was added and dissolved. The preparation was then 
transferred into 2x 35 mL ultracrimp tubes (Sorvall). Tubes were filled to 
the shoulder then 210 µL of 10 mg/mL ethidium bromide was added 
followed by the remainder of the preparation. The tubes were meticulously 
balanced, sealed and inverted several times. Care was taken to minimise 
exposure to light from this point. The gradient was formed by centrifugation 
at 350,000 x g for 16 hrs at 18 °C (WX ultra series centrifuge, TV-860 
rotor, Sorvall), with a low deceleration rate. 
After centrifugation, the tubes were secured with a clamp and pierced 
towards their top with a syringe needle. A wide bore syringe was used to 
carefully draw off the single visible band. The ethidium bromide was then 
removed by multiple extractions with aqueous butanol and the DNA 
precipitated as described in section 2.5.6. The concentration of the DNA was 
measured as in section 2.5.8 and its topological purity quantified by agarose 
gel electrophoresis (see section 2.7.1). The CsCl gradient steps were 
repeated until supercoiled pNO1 of sufficient purity was obtained. 
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2.5.5 Preparation of relaxed pNO1 
Relaxed pNO1 was prepared by incubating the supercoiled form with 
chicken erythrocyte topoisomerase I (~40-50 μg plasmid with 200 units 
topoisomerase I in 1x Chicken erythrocyte topoisomerase I relaxation 
buffer) for 1 hr at 37°C. The DNA was extracted with two phenol: 
chloroform:isoamyl alcohol (section 2.5.6) extractions and purified by 
ethanol precipitation. 
2.5.6 Phenol: chloroform:isoamyl alcohol 
extraction 
Where thorough removal of bound protein or intercalators from DNA was 
needed, extractions were performed with a mixture of 24:24:1 phenol: 
chloroform:isoamyl alcohol. An equal volume of phenol mixture to sample 
was added and the two phases mixed either by vortexing or vigorous 
pipetting. The samples were then spun at 15,700 x g for 5 minutes. The 
organic phase was then removed and an equal volume of chloroform added 
before the sample was once again vortexed and spun at 15,700 x g for 5 
minutes. The aqueous phase was then removed and retained. 
2.5.7 Precipitation of DNA 
Precipitation of DNA was carried out as detailed by Zeugin and Hartley 
(Zeugin & Hartley, 1985). The solution containing DNA was mixed with 10% 
volume 3 M KAc and either two volumes propan-2-ol or three volumes 
ethanol. The mixture was transferred to glass Corex tubes and incubated at 
room temperature for 15 mins before centrifugation at 16, 000 x g for 45 
minutes at 21°C to pellet the DNA (Evolution RC centrifuge, SS-34 rotor, 
Sorvall). The supernatant was drained and replaced with 80% ethanol. The 
solution was spun for a further 10 minute centrifugation at 16,000 x g, 
room temperature DNA (Evolution RC centrifuge, SS-34 rotor, Sorvall). The 
supernatant was discarded and the tubes spun briefly to draw residual liquid 
to the bottom which was then removed by pipetting. The DNA was carefully 
resuspended in the desired volume of T10E1 buffer. For smaller scale 
precipitations the above procedure was carried out using Eppendorf tubes 
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and centrifugation at 6000 x g for 10 min (5415D centrifuge, F45-24-11 
rotor, Eppendorf). 
2.5.8 Determination of DNA concentrations 
DNA concentration was determined either with a BioPhotometer (Eppendorf) 
or a Lambda 18 UV/Vis spectrometer (Perkin Elmer) with paired quartz 
cuvettes. The former was primarily used for cloning work whilst the latter 
was used to determine the concentrations of substrate plasmids. Samples 
were diluted 1 µL with 49 µL Milli-Q water and the absorbance at 260 nm 
was recorded. The concentration of DNA was determined by the Beer-
Lambert Law (Equation 2.1). 
Equation 2.1 The Beer-Lambert Law. A = absorbance; ε = extinction coefficient 
(dsDNA = 0.020 (μg/mL)-1 cm-1); l = path length (cm); c = concentration (μg/mL). 
2.5.9 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) was used for the cloning of DNA, with 
either Pfu (from Pyrococcus furiosus) or Taq (from Thermus aquaticus) DNA 
polymerases utilised (Pfu Ultra from Agilent Technologies, GoTaq from 
Promega). Reactions with GoTaq were typically carried out in 20 µL reaction 
volumes containing 10 µL GoTaq Master Mix (Promega), 50-500 ng DNA 
template and 100 pmol of oligonucleotide primers. All PCR reactions were 
carried out in a PTC-200 Thermo Cycler (MJ Research).  
Three types of PCR reaction were carried out: constant temperature 
(Table 2.4), touchdown (Korbie & Mattick, 2008) (Table 2.5) or colony. 
Colony PCR was identical to constant temperature PCR but instead of a DNA 
template a single colony of interest was picked and swirled in the reaction 
mix. The reaction was then heated for 5 min. at 94°C during the initial 
denaturing step rather than 3 min. Touchdown PCR was primarily used to 
obtain products which constant temperature PCR failed to produce. Initial 
rounds of primer annealing start above melting temperature of primers and 
decreases 1°C after each cycle. This helps eliminate non-specific annealing. 
Final rounds of primer annealing are carried out at a constant temperature. 
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of 55°C to amplify product. At this point specific product should be 
numerous enough to out-compete any non-specific interactions. 
2.5.10 Restriction digests and ligations 
Restriction digests were carried out with a wide range of restriction 
endonucleases from New England Biolabs. In general, the desired amount of 
substrate DNA was incubated with 1-200 units endonuclease and the 
appropriate reaction buffer (New England Biolabs) in a reaction volume of 
50 µL at 37°C for 1-2 hrs. Samples were then treated with 2x STEB and the 
product of the digestion gel purified (Section 2.5.11). 
 Ligations were carried out in 10 µL reaction volumes with 400 units 
T4 DNA ligase (New England Biolabs), 1 x ligation buffer (New England 
Biolabs), and 50-100 ng linear DNA (vector to insert ration 1:3). The 
reaction was allowed to proceed for at least 30 minutes at room 
temperature.  
2.5.11 Isolation of PCR products from agarose gels 
Linear products from PCR and restriction digests were purified by 
electrophoresis on a 1% (w/w) agarose gel. The required bands were 
excised and purified using a QIAquick Gel Extraction kit (QIAGEN) as per 
the supplied protocol.  
Temperature Time No. cycles Purpose 
94°C 3 min. 1 Initial denaturing 
94°C 45 sec 
30 
Denaturation 
50-70°C 
(~5°C below Tm of primers) 
45 sec Primer annealing 
72°C 1 min. per kb 
of product. 
DNA synthesis 
72°C 10 min. 1 Completes any 
partial products. 
10°C Forever 1  
Table 2.4 Constant temperature PCR. 
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2.5.12 DNA Sequencing 
DNA was sequenced using a BigDye v3.1 kit (Applied Bioscience) in a 10 µL 
reaction volume. Reactions contained BigDye 3.1 mix, 1x reaction buffer, 
50-100 ng DNA template and 20 µM sequencing primer. Reactions were 
carried out in a PTC-200 Thermo Cycler (MJ Research) with the program 
detailed below (Table 2.6). Once the reaction was completed the samples 
were sent to The Genome Analysis Centre (John Innes Centre) for 
Temperature Time No. cycles Purpose 
94°C 3 min. 1 Initial denaturing 
94°C 45 sec 
 
10 
Denaturation 
Initially 60-80°C 
(~2°C above Tm of primers) 
-1°C per cycle 
45 sec Primer annealing  
72°C 1 min. per kb 
of product. 
DNA synthesis 
94°C 45 sec Denaturation 
Initially 60-80°C 
(~2°C above Tm of primers) 
-1°C per cycle 
45 sec Primer annealing  
72°C 1 min. per kb 
of product. 
DNA synthesis 
94°C 45 sec 
15 
Denaturation 
55°C 
 
45 sec Primer annealing 
72°C 1 min. per kb 
of product. 
DNA synthesis 
72°C 10 min. 1 Completes any 
partial products. 
10°C Forever 1  
Table 2.5 Touchdown PCR program.  
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processing. Sequencing data was returned in the form of .txt and .abi 
chromatogram trace files.  
2.6 Protein preparation 
2.6.1 Insect cell culture conditions 
Spodoptera frugiperda Sf21 cells were grown in TC-100 media with L-
glutamate (PAA), 10% (v/v) fetal calf serum (FCS), penicillin, streptomycin 
and neomycin at 27°C. Cells were cultured in 75 cm2 culture flasks (PAA) 
until confluent then harvested by sloughing and subcultured into fresh 
flasks. After 30 passages the cells were discarded and fresh cultures were 
prepared from frozen stocks. The initial Sf21 cells were a kind gift from Dr 
Keith Saunders. 
2.6.2 Escherichia coli GyrA 
E. coli GyrA was expressed and purified as per published protocols (Maxwell 
& Howells, 1999). Escherichia coli JM109 (pLysS) was transformed with the 
expression plasmid pPH3 (Hallett et al, 1990). A 10 mL inoculum from a 
100 mL overnight grown culture was added to 1 L LB containing 
chloramphenicol and ampicillin. The cells were allowed to grow at 37°C until 
they reached an OD600 of around 0.4, whereupon expression was induced by 
the addition of IPTG to the final concentration of 0.2 mM. The culture was 
Temperature Time No. cycles Purpose 
95°C 1 min. 1 Initial denaturing 
95°C 30 sec 
30 
Denaturation 
45°C 15 sec Primer annealing 
60°C 4 min. DNA synthesis 
72°C 10 min. 1 Completes any 
partial products. 
10°C Forever 1  
Table 2.6 Program for BigDye 3.1 sequencing reactions. 
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incubated for a further 4 hours at 37°C before being spun at 6000 x g for 
10 min. (Evolution RC centrifuge, S-3000 rotor, Sorvall). The supernatant 
was discarded whilst the pellets were resuspended in 30 mL of Tris∙HCL pH 
7.5, 10% sucrose and EDTA-free protease inhibitors (Roche). The cells were 
then lysed by freeze-thawing. 
Upon thawing DTT, EDTA and KCl were added to 2 mM, 1 mM and 50 
mM respectively. The cells were then spun for 1 hr at 120, 000 x g (WX 
ultra series centrifuge, T-865 rotor, Sorvall) and the supernatant decanted. 
The supernatant was loaded onto a Hi-Load Q-Sepharose column (2.5 
mL/min., Pharmacia 16/10) and developed with a shallow gradient (250 
mL) 0-450 mM NaCl in TED (50 mM Tris∙HCL (pH 7.5), 1mM EDTA, 2 mM 
DTT). Fractions containing GyrA were identified via SDS-PAGE (section 
2.6.9) and pooled before dialyse overnight at 8°C into DNA gyrase dilution 
buffer. Protein concentration was determined by Bradford assay (section 
2.6.8) before the enzyme was snap-frozen in liquid nitrogen and stored at -
80°C. 
2.6.3 Escherichia coli GyrB 
E. coli GyrB was expressed and purified as per published protocols (Maxwell 
& Howells, 1999). Escherichia coli JM109 (pLysS) was transformed with the 
expression plasmid pAG111(Hallett et al, 1990). Cultures of 1 L were 
prepared and induced as with the expression of GyrA above.  
After freeze-thaw lysis DTT, EDTA and KCl were added to 2 mM, 1 
mM and 50 mM respectively. Cells were then spun for 1 hr at 34,000 rpm 
and the supernatant decanted. The lysate was then diluted 50:50 in TGED 
buffer (50mM Tris∙HCL pH 7.5, 10% glycerol (w/v), 1mM EDTA, 2mM DTT) 
+200 mM NaCl. Diluted lysate was applied to a 350 mL Heparin-Sepharose 
column (2.5 mL/min., Pharmacia 16/10). GyrB was eluted by stepping off 
with TGED +400 mM NaCl. Fractions containing GyrB were identified by 
SDS-PAGE (section 2.6.9), pooled and dialysed into TGED overnight at 8°C. 
The protein was then loaded onto a Mono-Q column (0.75 mL/min., 
Pharmacia) and developed with a shallow gradient of 0-400mM NaCl in TED. 
Fractions containing GyrB were identified by SDS-PAGE, pooled and dialysed 
into gyrase elution buffer overnight at 8°C. Protein concentration was 
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determined by Bradford assay (section 2.6.8) before the enzyme was snap-
frozen in liquid nitrogen and stored at -80°C. 
2.6.4 Methanosarcina mazei topoisomerase VI 
M. mazei topoisomerase VI was expressed and purified as per published 
protocols (Corbett et al, 2007). Codon Plus E. coli were transformed with a 
polycistronic duel expression vector for M. mazei top6A and top6B (Corbett 
et al, 2007). The proteins were overexpressed in autoinduction growth 
media containing kanamycin by incubating for 24 hrs at 37oC (the 
expression vector was kindly gifted by Prof. James M. Berger and Dr Kevin. 
Corbett; University of California Berkley). The cells were harvested by 
centrifugation at 9900 x g, 4oC for 10 min. (Evolution RC centrifuge, S-3000 
rotor, Sorvall), resuspended in Buffer A (20 mM HEPES pH 7.5, 10% (v/v) 
glycerol, 800 mM NaCl, 20 mM imidazole, 2 mM β-mercaptoethanol, EDTA-
free protease inhibitors) and lysed by freeze-thawing and French press.  
The lysate was centrifuged at 48, 000 x g, for 1 hr at 4oC (Evolution 
RC centrifuge, SS-34 rotor, Sorvall). The clarified lysate was then passed 
over a HisTrap™ FF Ni2+ affinity column (5 mL/min, GE Healthcare) and 
washed with Buffer B (20 mM HEPES pH 7.5, 10% (v/v) glycerol, 150 mM 
NaCl, 20 mM imidazole, 2mM β-mercaptoethanol, EDTA-free protease 
inhibitors). The protein was eluted with a 20-300 mM imidazole gradient (70 
mls, 5 mL/min.) and the protein containing fractions passed through a 
HisTrap™ SP Sepharose HP column (3 mL/min, GE Healthcare) in Buffer B 
to remove proteolyzed B-subunits. The flow-through was collected and 
waste protein bound to the column was stepped off with 800 mM NaCl. The 
flow-through was loaded onto a HisTrap™ Q HP (3 mL/min, GE Healthcare) 
column in Buffer B the protein eluted with a 150-800 mM NaCl gradient 
over 70 mls. The fractions were pooled and the amount of protein present 
was determined by a Bradford assay (section 2.6.8).  
The protein was then incubated overnight at 4°C with His-tagged 
Tobacco Etch Virus (TEV) protease using a ratio of 1:50 (wt/wt) TEV 
protease: M. Mazei topo VI. The protein was passed over a second Ni2+ 
affinity column to remove uncleaved protein, uncleaved tags, and His-
tagged TEV protease. The flow-through was collected and waste protein 
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stepped off with 0.5 M imidazole. The flow-through was passed through a 
S300 gel filtration column (0.5 mL/min., GE Healthcare) in Buffer C (20 mM 
HEPES pH 7.5, 10% (v/v) glycerol, 150 mM NaCl, 500 mM imidazole, 2 mM 
β-mercaptoethanol, EDTA-free protease inhibitors). The fractions containing 
protein were identified with SDS-PAGE, pooled and concentrated with 
centrifugal concentrators (10-30 kDa molecular weight cut offs) by 
centrifugation at 3250 x g at 4°C (Sorvall Legend RT centrifuge, Heraeus 
rotor). Fractions were pooled, concentrated by ultrafiltration, and aliquots 
were frozen in liquid nitrogen and stored at -80oC. Protein concentration 
was determined by Bradford assay (section 2.6.8) before the enzyme was 
snap-frozen in liquid nitrogen and stored at -80°C. 
2.6.5 Plasmodium falciparum hypothetical 
topoisomerase VI 
Expression trials were carried out with the hypothetical Plasmodium 
falciparum topoisomerase VI genes PF10_0412 (PfTopo6A1), PFL0825c 
(PfTopo6A2) and MAL13P1.328 (PfTopo6B) identified by Aracind et al 
(Aravind et al, 2003). PfTopo6A1 and PfTopo6A2 were cloned into the 
pET28-a (Novagen) expression vector and trials conducted with E. coli 
strains BL21 (pLysS), Codon Plus, Rosetta and Rosetta 2.  
 Expression trials were carried out in a baculovirus-insect cell 
expression system (Spodoptera frugiperda Sf21 cells) as per the Bac-to-
Bac™ Expression System Manuel (Invitrogen). PfTopo6A1, PfTopo6A2 and 
PfTopo6B were cloned into the pFastBac-Duel baculovirus expression vector 
then transformed into E. coli strain DH10Bac containing a bMON14272 
baculovirus shuttle vector (bacmid) and a transposition helper plasmid 
(pMON7124). After transformation Tn7 transposition occurs, transferring the 
gene of interest into the bacmid. The transformation mix is then plated on 
LB agar plates containing kanamycin, tetracycline, gentamycin and 200 
µg/mL X-gal (bromo-chloro-indolyl-galactopyranoside). The plates were 
incubated at 37°C for 48 hrs and recombinant colonies chosen by blue-
white selection. Selected colonies were picked and transferred to 1 mL PDM 
media containing tetracycline and gentamicin.  
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The cells were allowed to grow overnight at 37°C then centrifuged 
6000g for 10 min (5415D centrifuge, F45-24-11 rotor, Eppendorf). The 
supernatant was discarded and the cell pellet resuspended gently in 0.3 mL 
of 15 mM Tris·HCl pH 8.0, 10 mM EDTA, 100 g/mL RNAse. A solution of 
0.3 mL 0.2M NaOH, 1% SDS was then added and samples gently mixed. 
After 5 mins. at room temperature 0.3 mL of 3 M KAc (pH 5.5) was added 
and the samples transferred to ice for 10 mins. The samples were then 
centrifuged at 6000 x g for 10 min (5415D centrifuge, F45-24-11 rotor, 
Eppendorf). The supernatant was transferred to a fresh tube and 0.8 mL 
propan-2-ol was added. After a further 10 min. on ice the samples were 
centrifuged at 6000 x g for 45 min. at room temperature (5415D centrifuge, 
F45-24-11 rotor, Eppendorf). The supernatant was then discarded, the 
samples spun briefly once more and residual propan-2-ol removed by 
pipetting. The DNA was then carefully resuspended in 40 µL T10E1 buffer. 
Approximately 1x 106 SF21 insect cells in Complete TC-100 media 
with L-glutamate (PAA) (+10% (v/v) FCS, penicillin, streptomycin and 
neomycin) were placed in 35 mm cell culture dishes and allowed to attach. 
After approximately 1 hr the media was drained and 2.5 mL Plating Medium 
(TC-100 media with L-glutamate + 1.5% (v/v) FCS) was added. Solutions 
of 100 µL 8% (v/v) Cellfectin II (Invitrogen) in TC-100 medium with L-
glutamate and 100 µL 1% (v/v) bacmid in TC-100 medium with L-glutamate 
were prepared, mixed and left at room temperature for 25 min. The mixture 
was then applied dropwise to the cell cultures and left for 5 hrs. The 
medium was then removed and replaced with Complete TC-100 media and 
the cells left to grow at 27°C until they displayed signs of late-stage 
infection (i.e. detachment from the plate surface after ~ 3 days). P1 viral 
particles were harvested by removing and retaining the media. Viral 
particles were stored in the dark at 4°C.  
To amplify the viral titre 2x 106 SF21 insect cells in Complete TC-100 
with L-glutamate media were placed in 35 mm cell culture dishes. After 
approximately 1 hr 220 µL P1 virus was added and the cells allowed to grow 
at 27°C until they displayed signs of late-stage infection. P2 virus was 
harvested by removing and retaining the media. Expression trials were then 
conducted using P2 viral stocks. 
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2.6.6 Chicken erythrocyte topoisomerase I 
Chicken erythrocyte topoisomerase I was kindly provided as a gift by Mrs. 
Alison J. Howells of Inspiralis Ltd, Norwich Research Park, Norwich. 
2.6.7 Wheat germ topoisomerase I 
Wheat germ topoisomerase I was purchased from Inspiralis Ltd. 
2.6.8 Protein concentration determination 
Protein concentrations were determined by Bradford assay (Bradford, 
1976). Bradford reagent was prepared by the addition of 100 mg Coomassie 
Brilliant blue G to 50 mL of 95% (v/v) ethanol plus 100 mL of 85% (v/v) 
phosphoric acid and made up to one litre with Milli-Q water. To determine 
protein concentration, 5 µL of protein solution was diluted to 100 µL in a 
suitable dilution buffer and mixed with 900 µL Bradford reagent in a 1 cm 
path length cuvette. Samples were left to react for 5 min. at room 
temperature, before they were mixed by inversion and their absorbance at 
595 nm was measured by a BioPhotometer (Eppendorf). The samples were 
compared to a blank solution consisting of 100 µL dilution buffer mixed with 
900 µL Bradford reagent. The concentration of the samples was obtained by 
comparison of their absorbance to a calibration curve of BSA standards. 
2.6.9 SDS-PAGE 
Protein analysis was carried out by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) using a Bio Rad Miniprotein-III setup (Bio 
Rad). Samples were boiled for 5 minutes in 1x SAB (125 mM Tris∙HCL, 4% 
(w/v) SDS, 20% (w/v) glycerol, 10% (v/v) β-mercaptoethanol, 0.002% 
(w/v) bromophenol blue). Samples were run on 12.5% discontinuous 
polyacrylamide gels with a 4% stacking gel for 15 min. at 120 V the 1 hr at 
200 V. Gels were stained with a Coomassie stain (15% (v/v) acetic acid, 
10% (v/v) methanol and 0.1% (w/v) Coomassie stain). Gels were destained 
in Milli-Q water and photographed using a Syngene GeneGenius Bio-
Imaging Gel Doc system (Synoptics).  
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2.7 DNA topoisomerase assays 
2.7.1 Agarose gel electrophoresis assay 
The DNA gyrase supercoiling reactions were conducted under the following 
conditions in a reaction volume of 30 µL: 500 ng of relaxed or negatively 
supercoiled pNO1, 1x reaction buffer (either DNA gyrase supercoiling or 
topoisomerase VI relaxation buffer) and up to 5% (v/v) DMSO. Reactions 
were incubated with 1 unit of DNA gyrase and the desired concentration of 
drug at 37°C for 30 min. then stopped with 30 µL volume 
chloroform:isoamyl alcohol (24:1) and 30 µL 2x STEB (+2% (w/v) sodium 
dodecyl sulphate for M. mazei topoisomerase VI reactions). The reactions 
were vortexed and centrifuged at 6000 x g for 10 min (5415D centrifuge, 
F45-24-11 rotor, Eppendorf). The upper phase was analyzed by 
electrophoresis on a 1% agarose gel in TAE buffer for 2-3 hrs at 80 V. The 
gel was then stained by soaking in 2 µg/mL ethidium bromide for 10 min. 
and visualized under UV light with a Syngene GeneGenius Bio-Imaging Gel 
Doc system (Synoptics). One unit of enzyme is defined as the amount of 
topoisomerase required to supercoil or relax 500 ng of substrate in 30 min. 
at 37°C under standard assay conditions. 
2.7.2 Cleavage-complex stab stabilization assay 
Assays to detect the stabilization of cleavage complexes were identical to 
the protocol for topoisomerase activity detection detailed above except as 
follows. Cleavage experiments with DNA gyrase were carried out in DNA 
gyrase relaxation buffer instead of DNA gyrase supercoiling buffer. 
Reactions were stopped with 3 µL 10% SDS and incubated with 3 µL 1 
mg/mL proteinase K solution at 37°C for 1 hr. The reactions were then 
treated with chloroform:isoamyl alcohol (24:1) and 2x STEB before analysis 
by gel electrophoresis, as detailed above. For cleavage complex protection 
assays with suramin, the standard DNA relaxation supercoiling was modified 
to contain 4 mM CaCl rather than MgCl. 
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2.7.3 ATPase assay 
To determine the effect on ATPase activity of various compounds the 
required amount of topoisomerase was prepared in clear, colorless 96-well 
Microtitre plates (Pro-bind™, Becton Dickinson) in a 100 µL reaction 
containing 1x reaction buffer lacking ATP (DNA gyrase supercoiling or 
topoisomerase VI relaxation), 800 µM phosphoenolpyruvate (PEP), 400 µM 
NADH, 1% (vol/vol) PK/LDH (pyruvate kinase-lactate dehydrogenase 
mixture in 50% (w/v) glycerol,100 mM KCL, 10 mM HEPES (pH 7.0) and 
compound as desired and 1 mM ATP (initially withheld). The mixture was 
allowed to sit for 5 min. then initiated by the addition of ATP. A control was 
always included in which the addition of ATP was replaced with Milli-Q 
water. The absorbance at 340 nm was then measured over the course of an 
hour by a Spectra Max Plus absorbance reader (Molecular Devices).  
 Data was processed by omitting the first 10-15 minutes of collection 
and normalizing the first retained time point (i.e. the 10 or 15 minute data 
point). This was done to exclude artifacts observed with this time frame and 
for ease of comparison of rates. The slope of the control lacking ATP was 
then subtracted from that of the other reactions to exclude the effect of 
contaminants. 
2.7.4 Native gel-shift assay 
Samples of topoisomerase and drug were prepared under the following 
conditions in a final volume of 10 μL: 1 nM 140 bp linear fragment of DNA 
derived from pBR322 (Pierrat & Maxwell, 2005) with 1x gel shift binding 
buffer. Samples were incubated for 30 mins at room temperature before 
being run on a 5% (29:1) Protogel acrylamide (National Diagnostics) gel in 
TBM buffer at 150 V for 45 min. The DNA was stained by soaking in 2 
mg/mL ethidium bromide for 10 min. and visualized under UV light. 
2.7.5 Microtitre plate-based assay 
Note: due to the fluorometric nature of the assay it was vital to ensure all 
solutions were free of particles, which may result in light scattering and 
increased noise. To eliminate this possibility all solutions should be filtered 
before use.  
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Wells in a black 96-well Microtitre plate (Pierce) were washed with 3 
x 200 μL of Wash Buffer. The wells were then loaded with 100 μL 500 nM 
TFO1 oligo (diluted from stock in Wash Buffer) and immobilization was 
allowed to proceed for 2 min. The oligo solution was removed and the wells 
washed with 3 x 200 μL volumes of Wash Buffer. Assays were performed in 
the wells in a 30 μL reaction volume containing: 1-2 units topoisomerase; 1 
μg relaxed or negatively supercoiled pNO1 and 1x reaction buffer (DNA 
gyrase supercoiling buffer or topoisomerase VI relaxation buffer).  
The reactions were incubated at 37°C for 30 min. and stopped with 
the addition of 100 μL TF buffer or 75 mM calcium acetate (pH 4.7). The 
plate was incubated at room temperature for 30 min. to allow triplex 
formation to occur. Supercoiled DNA became immobilized on the plate while 
relaxed DNA remained in solution. 
Unbound relaxed and linear plasmid was removed by washing the 
wells thoroughly with 3 x 200 μL volumes of TF buffer. After the final wash 
the wells were drained and bound DNA stained with 200 μL 1 x SYBR Gold 
(Sigma) diluted in T10E1 buffer. The plate was incubated for a further 20 
min. at room temperature. After incubation, the contents of the wells were 
mixed and their fluorescence readings at excitation wavelength 470 nm and 
emission wavelength 520 nm detected in a SpectraMax Gemini fluorometer 
(Molecular Devices). 
2.8 Screening of a compound library for 
topoisomerase inhibitors 
2.8.1 Library used 
Both screens were conducted on the Genplus library from Microsource Ltd., 
a collection of 960 compounds in twelve 96-well Microtitre plates. The 
library consists of 80% U.S.A., European, and Japanese approved drugs, 
with the remaining 20% compounds being experimental entities selected for 
their unique biological character. Daughter plates were prepared with a 
compound concentration of approximately 250 µM. 
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2.8.2 Screening protocol 
Twelve plates were screened in duplicate over three days manually using a 
multichannel pipette. Wells in a black 96-well Microtitre plate (Pierce) plate 
were washed with 3 x 200 μL of Wash Buffer. The wells were then loaded 
with 100 μL 500 nM TFO1 oligo (diluted from stock in Wash Buffer) and 
immobilization was allowed to proceed for 2 min. The oligo solution was 
removed and the wells washed with 3 x 200 μL volumes of Wash Buffer. A 
solution of 1 μg pNO1 (relaxed for DNA gyrase or negatively supercoiled for 
topoisomerase VI) in 27 μL reaction buffer (either DNA gyrase supercoiling 
buffer or topoisomerase VI relaxation buffer) was then dispensed into each 
well followed by 3 µL library compound in 100% DMSO giving a final 
concentration of approximately 25 µM compound. The reactions were then 
initiated with by the addition of two units of topoisomerase in 30 μL reaction 
buffer. Each plate contained 16 control reactions: eight positive for enzyme 
activity which contained 3 μL 100% DMSO instead of a library compound 
and eight negative for enzyme activity, which lacked both enzyme and 
library compounds. 
The plates were then incubated at 37°C for 30 min. before the 
reactions were stopped by the addition of 100 μL 75 mM calcium acetate 
(pH 4.7) and incubated at room temperature for further 30 min. The wells 
were then washed with 3 x 200 μL 75 mM calcium acetate (pH 4.7). DNA 
retained in the wells was stained with 200 μL 1x SYBR Gold (Sigma) in 
T10E1 buffer and the plates were incubated for 20 min. at room 
temperature before quantification by fluorometry at excitation wavelength 
470 nm and an emission wavelength of 520 nm, detected in a SpectraMax 
Gemini fluorometer (Molecular Devices). 
2.8.3 Data processing, hit selection and hit 
validation 
Once the data had been collected from the screen the fluorescence signals 
for the duplicates were averaged and converted into percentage inhibition 
using the positive and negative controls. The standard deviation of the 
controls was calculated and converted into percentage inhibition. From 
these values the 95% confidence interval for the screen was calculated, 
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which was used as an indicator of significance. Compounds giving 
percentage inhibitions above and around this value were selected for further 
studies. The Z' factor for the assay was calculated (Equation 2.2) to 
determine the quality of the data, with a good Z' value being defined as 
greater than 0.5 and a Z' value being defined as 1 (Zhang et al, 1999). Hits 
obtained from the screen were verified using the agarose gel 
electrophoresis assay detailed above. Fresh stocks of compounds were 
purchased (Sigma) for verification, rather than solutions taken from the 
library to ensure that the inhibition seen is not due to any cross-
contamination or degradation which may have occurred during library 
storage. 
     
                                         
                                    
  
Equation 2.2 Equation to calculate the Z' of an assay. Positive control refers to 
positive control for enzyme activity whilst negative control refers to a sample 
containing substrate but lacking enzyme. 
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Chapter 3 
3 Exploration of Topoisomerase Assays 
3.1 Introduction 
Topoisomerase supercoiling or relaxation activity has been traditionally 
detected by agarose gel electrophoresis (Section 2.7.1.). This technique 
produces a remarkably information rich picture of the topological changes 
DNA undergoes when processed by topoisomerases. Unfortunately, it is 
slow (with combined assay and gel running times of 3-4 hours), qualitative 
(non-quantative) and requires a high degree of manual handling. The 
microtitre plate-based assay (Section 2.7.5.) on the other hand is quicker, 
has the possibility to be automated and produces quantitative results.  
 As such it was decided that the technical limitations of the agarose 
gel assay and their possible mitigation would be explored. The key factor in 
undesirably long running times involved in agarose gel electrophoresis is 
the generation of heat during the assay if high voltages are used, which can 
reduce the integrity of both the gel and the sample. Brody and Kern 
demonstrate (Brody & Kern, 2004) that the inclusion of Tris and sodium 
ions (in the form of Na2EDTA) results in a positive feedback loop in which 
the conductivity of the media and the heat generated increases over time 
even though the voltage is kept constant. The solution they proposed was 
the elimination of EDTA (which was thought to be superfluous) from the 
running buffer and switching from Tris to a lower conductivity medium 
(Brody et al, 2004). They showed that running buffers designed under these 
principles could be run at higher voltages and for much shorter times 
without compromising resolution. Since all of these studies were carried out 
on linear DNA fragments it remained to be found whether these buffers 
could also be used for the separation of different topoisomers by 
electrophoresis. These studies were focused on a 5 mM lithium acetate 
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running buffer, since this was thought to be the best at resolving high-
molecular weight DNA fragments (Brody et al, 2004).  
 The use of the triplex-formation principles from the Microtitre plate 
assay to purify supercoiled DNA away from other topoisomers was also 
investigated. The current method of choice to topologically purify plasmid 
DNA is the caesium chloride gradient (section 2.5.4), a process requiring 
lengthy centrifugation times and large quantities of ethidium bromide. The 
purification of supercoiled DNA by triplex-affinity column chromatography 
has already been attempted (Schluep & Cooney, 1998; Schluep & Cooney, 
1999), but attained only modest yields. By changing the triplex forming 
buffer and, as suggested by Schluep and Cooney, using Continuous Affinity 
Recycle Extraction (CARE) it was hoped that yields would be improved to an 
acceptable level. Since triplex formation is greatly influenced by the buffer’s 
pH (Singleton & Dervan, 1992), the valency of cation present (Hampel et al, 
1991; Rougee et al, 1992) and the buffer’s ionic strength (Rougee et al, 
1992; Singleton & Dervan, 1993) this study focused on these three factors. 
Additionally the effects of using various different alkaline earth and 
transition metal ions as triplex stabilizers were also tested. 
As an extension of this work, the performance of the most promising 
triplex forming buffers from the column work was tested in the assay 
relative to the standard TF buffer. The majority of the work below focuses 
on calcium and magnesium acetate based buffers due to promising results 
from the column work and preliminary tests.  
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3.2 Results 
3.2.1 Lithium Acetate as a running buffer. 
To investigate if 5 mM lithium acetate (LiOAc) would be a superior running 
buffer of agarose gel electrophoresis stocks of 20 ng/µL relaxed or 
supercoiled pNO1 were prepared in T10E1 buffer. This concentration was 
chosen since it was roughly equivalent to that used in a topoisomerase 
reaction. A 10x stock solution of 50 mM LiOAc (~pH 6.5) was also prepared 
for the making and running of agarose gels. Samples were prepared by 
mixing 30 µL DNA stock with either 30 µL 2x STEB (for TAE gels) or 30 µL 
LiOAc loading buffer (10 mM lithium acetate, 40% sucrose, 0.5 mg/mL 
bromophenol blue). The samples were then loaded on to 1% agarose gels 
prepared with either TAE or 5 mM LiOAc and run for the desired amount of 
time. 
Under standard running conditions (80 V, 6.5 V/cm, 3 hrs.) it was 
observed that both relaxed and supercoiled plasmid run with a LiOAc 
running buffer progressed much slower through the gel than when it was 
run with the TAE buffer (Figure 3.1 A. and B.), moving ~3 cm rather than 
~7 cm through the gel. Additionally, the degree of separation between 
topoisomers was reduced in the LiOAc running buffer compared to the TAE. 
This was puzzling since the separation of different sized fragments of linear 
DNA was not reported to be affected in a similar way (Brody et al, 2004). 
Since the only major difference between the two buffers, apart from the 
conductive ions, was the presence or absence of EDTA it was decided to see 
if adding back the EDTA to the LiOAc buffer would improve its ability to 
separate topoisomers. To avoid the inclusion of sodium ions EDTA free acid 
(pH 8.0 with LiOH) was used to prepare a 10x stock of Lithium Acetate 
EDTA (LAE) running buffer (5 mM lithium acetate, 2 mM EDTA). Inclusion of 
EDTA in the running buffer restored the resolution, allowing for easy 
separation of topoisomers under standard running conditions (Figure 3.1. 
C.)  
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Next the ability of LAE buffer to resolve topoisomers at higher 
voltages for shorter times was examined (Figure 3.2). Since TAE gels 
melted at the voltages used in these experiments comparison between 
buffers was impossible. To investigate the effects of these voltages on the 
resolution of linear DNA a 1 kb DNA ladder was run in addition to the 
relaxed and supercoiled pNO1. Although there was no difference in the 
resolution of linear fragments from each other as voltage was increased, 
resolution between topoisomers decreased. Relaxed topoisomers were seen 
to become more condensed and migrate faster through the gel as voltage 
was increased, whilst supercoiled topoisomers seemed to migrate more 
slowly. This meant that the maximum voltage samples could be run and still 
retain a decent degree of resolution was 160 V (13 V/cm), decreasing the 
running time by half (1.5 hrs.).  
                           
Figure 3.1 Running relaxed and SC pNO1 in lithium acetate buffer. Gels run for 3 
hrs. at 80 V (6.5 V/cm) in 1% agarose gels either in TAE running buffer, 5 mM 
lithium acetate running buffer or 10 mM lithium acetate, 2 mM EDTA (free acid) 
running buffer (LAE). 
                       
Figure 3.2 Running LAE gels at high voltages. 1 kb marker (M), relaxed pNO1 and 
SC pNO1 run on 1% agarose gels in LAE buffer at: 80 V (6.5 V/cm) for 3 hrs.; 160 V 
(13 V/cm) for 1.5 hrs. or 240 V (19.5 V/cm) for 45 min. 
 
80V 
LAE TAE LiOAc 
Rel Rel Rel SC SC SC 
160V 240V 
Rel Rel Rel SC SC SC M M M 
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3.2.2 Resolution of a second band from supercoiled 
plasmid with LAE. 
When working with the LAE running buffer, it was observed that supercoiled 
topoisomers when run at low voltages (20 V, 1.625 V/cm) for long periods 
of time (16 hrs.) seemed to partially resolve into two bands (Figure 3.3 A.). 
Better resolution of this second band, which is not normally observed under 
these conditions with TAE, was attempted by running SC pNO1 for 24 hrs. 
at 15 V (1.219 V/cm). These conditions clearly resolved a second band from 
the classic supercoiled topoisomer band (Figure 3.3 B.). This second band 
appeared fainter than the standard SC band, and ran slightly faster than the 
main band. This additional band could represent denatured plasmid or a 
more exotic topoisomer such as Form V DNA (two single-stranded DNA 
molecules coupled by supercoiling) (Stettler et al, 1979). Unfortunately, 
lack of time meant that the exact nature of the secondary band was unable 
to be determined.  
                      
Figure 3.3 SC plasmid run for long periods on an LAE gel. 1 kb marker (M), relaxed 
pNO1 and SC pNO1 run on 1% agarose gels in LAE buffer at 20 V (1.625 V/cm) for 
16 hrs.. SC pNO1 run on 1% agarose gels in LAE buffer at 15 V (1.219 V/cm) for 24 
hrs.  
 
20V, 16hr 
M Rel SC SC 
15V, 24hr 
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3.2.3 Triplex affinity purification of supercoiled 
plasmid 
To test for initial conditions for triplex affinity purification (Figure 3.4) 100 
µL bed-volume spin columns were prepared by incubating 100 µL 
streptavidin coated 4% agarose beads (Sigma) with 100 nM TFO1 oligo in 
T10E1 buffer. After leaving the oligo to bind for 1 minute the columns were 
centrifuged at 2300 x g for 30 s (5415D centrifuge, F45-24-11 rotor, 
Eppendorf) to remove the fluid. The columns were then equilibrated with 1 
mL of the appropriate triplex forming buffer (Table 3.2), spun them dry and 
added 2.5 µg of topologically impure pNO1 (containing a range of DNA 
species) in 100 µL triplex forming buffer. All experiments were carried out 
with twin spin columns, one using standard TF buffer and the other with the 
experimental triplex forming buffer, in order to gauge relative effectiveness. 
After 30 min the columns were spun again and retained the flow-through for 
analysis. The columns were washed with 100 µL triplex forming buffer and 
eluted four times with µL T10E100 buffer (10 mM Tris·HCl (pH 8.0), 100 mM 
EDTA) by centrifugation under the conditions listed above. Samples were 
mixed with 2x STEB and analysed by gel electrophoresis (Figure 3.5). Band 
intensity was quantified by Syngene and processed to get the buffers 
purification and binding potential relative to the standard buffer (Table 3.1).   
 
Figure 3.4 Triplex-affinity column chromatography of DNA. A. Streptavidin coated 
agarose beads incubated with biotin labeled TFO in a column. Excess oligo washed 
off. B. Mixture containing nicked, supercoiled and linear pNO1 plasmid added to 
column in a low pH, high salt buffer. Supercoiled plasmid forms triplexes with the 
TFO and is captured in the column, whilst linear and nicked forms are washed 
away. C. Supercoiled plasmid eluted in a high pH buffer. 
A. B. C.
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 Since pH is integral to the formation of DNA triplexes a range of 
buffers above and below the pH of the standard TF buffer were tested 
(Buffers 1-3). The expected result was that lowering the pH would result in 
greater triplex formation and therefore increased DNA binding. However, 
lowering the pH seemed to preferentially promote triplex formation by OC 
plasmid, resulting in decreased SC yield and purity. Addition of the 
polyvalent cation spermine (Buffers 4-5) had little effect on binding but 
reduced purity at 10 mM, whilst replacement of magnesium with spermine 
or spermidine (Buffers 6-7) reduced purity and, in the case of spermine, 
binding. Decreasing the concentration of MgCl2 to 5 mM had no effect on 
purity, but drastically reduced binding (Buffer 8). However, the replacement 
of the traditional buffer with 75 mM MgOAc (pH 4.7, Buffer 9) increased 
binding without changing the purity. Strangely, when the concentration of 
MgOAc was increased to 150 mM (Buffer 10) a reduction in binding was 
observed compared to 75 mM. A variety of divalent metal acetates were 
tested in the place of MgOAc, including alkaline earth metals and transition 
metals, in the place of or supplementary to MgOAc (Buffers 11-14). The 
effects of utilizing zinc or silver acetate in the buffer were investigated since 
they had previously been shown to promote triplex formation in novel ways
 
Figure 3.5 Triplex-affinity purification with TF or buffer 9. Composition of buffer 9 
found in Table 3.2. The following samples were loaded on the gels: Sample before 
purification; Flow-Through; Wash with either TF or buffer 9; and four Elutions with 
T10E100. 
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Initial material Flow-through Wash Elution 1 Elution 2 Elution 3 Elution 4 
 
    TF Buffer 9 TF Buffer 9 TF Buffer 9 TF Buffer 9 TF Buffer 9 TF Buffer 9 TF Buffer 9 
 Fraction 
of sample 
(%) 
Dimer 3 2 4 3 0 0 0 0 0 0 0 0 0 0 
 
OC 44 45 60 67 38 56 16 20 17 20 12 17 9 11 
 
L 1 1 1 1 0 0 0 0 0 0 0 0 0 0 
 
SC 52 51 35 28 62 44 84 80 83 80 88 83 91 89 
                 
                 
 
    TF Buffer 9 
            
 
 Total Yield (%) 58 77 
            
 
 Final Purity (%) 85 83 
            
Relative Yield (%)  100 133 
           
Relative Purity (%)  100 97 
          Table 3.1 Example of band quantification and data processing for TF and buffer 9. Intensities of bands were quantified for samples 
from each step of the purification (Syngene).  The percentage of the total sample intensity attributed to each DNA species was 
calculated (fraction of sample). The percentages of the recovered SC present in the elution samples, rather than in the flow-through 
or wash samples, were calculated to act as a guide for the yield of both buffers (total yield). The overall purity was calculated by 
combining the data from the four elutions (final purity). These values were then used calculate the efficiency of Buffer 9, in terms of 
SC purification and binding, relative to the values for the standard TF.  As such, a relative purity or binding of 100% indicates 
identical efficiency to the TF buffer, with higher and lower scores indicating greater or less efficiency respectively. 
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(Bernues et al, 1989; Tanaka et al, 2002). The majority of these lowered 
both purity and binding, with the exception of CaOAc (Buffer 12), which 
produced results comparable to MgOAc. A summary of the buffers 
performances can be found below (Table 3.3). 
Buffer Composition 
1 TF (pH 3.6) 
2 TF (pH 4.25) 
3 TF (pH 5.25) 
4 TF (pH 4.7), 1 mM spermine 
5 TF (pH 4.7), 10 mM spermine 
6 50 mM NaOAc (pH 4.7), 10 mM spermine 
7 50 mM NaOAc (pH 4.7), 10 mM spermidine 
8 50 mM NaOAc (pH 4.7), 5 mM MgCl2, 
9 75 mM MgOAc (pH 4.7) 
10 150 mM MgOAc (pH 4.7) 
11 75 mM MgOAc (pH 4.7), 50 µM AgOAc 
12 75 mM CaOAc (pH 4.7) 
13 75 mM ZnOAc (pH 4.7) 
14 75 mM BaOAc (pH 4.7) 
Table 3.2 Compositions of triplex forming buffers tested. TF refers to the standard 
Triplex forming buffer (Table 2.1) with indicated modifications. 
 
Buffer 
Relative SC purity 
(%) 
Relative SC Yield 
(%) 
TF 100 100 
1 80 85 
2 92 111 
3 99 110 
4 111 104 
5 81 116 
6 63 74 
7 63 116 
8 100 62 
9 97 133 
10 101 110 
11 87 77 
12 92 129 
13 89 38 
14 98 68 
Table 3.3 Efficiencies of different buffers in triplex-affinity purification of SC 
plasmid. The purity and yield of SC was determined by quantitative software 
(Syngene) and calculated relative to the performance of standard TF buffer (Table 
2.1). 
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 Having established that 75 mM MgOAc (Buffer 9) was the best of the 
buffers tested a scaled up purification was attempted by preparing a 1 mL 
bed volume gravity column and attempting to purify 1 mg of plasmid 
(~80% purity). DNA was prepared as per section 2.5.4. but halted before 
the caesium chloride gradient. The sample was then overdigested with 
RNAse and diluted the sample into 5 mL of 75 mM MgOAc (giving 1 mg at a 
concentration of 0.2 mg/mL). The sample was loaded 1 mL at a time and 
collected the flow-through and eluting with 1 mL T10E100 before adding the 
next millilitre. To remove the large quantities of EDTA present the fractions 
were ethanol precipitated before being quantified by Syngene (as described 
above) and determining their concentration by Uv/Vis spectrometry. By 
combining these two methods the yield for the purification of supercoiled 
plasmid was calculated to be 65% with 95% purity. 
 Since a large proportion of the DNA was still present in the initial 
flowthrough, Continuous Affinity Recycle Extraction (CARE) was investigated 
as a method to improve upon the yield. The above experiment was 
repeated and the initial flowthrough after sample loading was retained. 
After the bound DNA was eluted the column was re-equilibrated with Buffer 
9. The previously retained flowthrough was then applied to the column. 
Bound DNA was then eluted, ethanol precipitated and analysed as above. 
The yield of this setup was calculated to be 68% (97% purity). 
Unfortunately due to time constraints this work could not be pursued any 
further.  
3.2.4 Performance of buffers 9 and 12 in the 
microtitre plate-based assay 
Since buffers 9 and 12 (Table 3.2) seemed to promote triplex formation 
more effectively than the classic TF buffer in the triplex-affinity columns 
experiments were carried out to see how they compared in the microtitre 
plate-based assay (Section 2.7.5.). Samples were prepared by mixing 30 µL 
of Milli-Q water containing 0.5 µg of either relaxed or supercoiled pNO1 with 
100 µL of the appropriate triplex forming buffer. Samples were incubated in 
microtitre plate wells prepared with TFO1 for 30 min at 18°C and then 
washed with the appropriate triplex-forming buffer, stained and analysed as 
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detailed in Section 2.7.5 (Figure 3.6). Each buffer was tested in triplicate 
their relative signal variation and Z' factor could be determined (Section 
2.8.3.). From these data the Z' factor was calculated to be 0.92 for TF 
buffer, 0.88 for Buffer 9 and 0.92 for Buffer 12. 
3.3 Discussion 
3.3.1 Lithium Acetate EDTA as an electrophoresis 
running buffer 
Although lithium acetate running buffers have been previously used to 
resolve linear fragments of DNA based on their size in gel electrophoresis, 
separation of closed circular topoisomers had not been attempted. The 
experiments above have shown that lithium acetate can act as a running 
buffer for the resolution of relaxed and supercoiled plasmid but only when 
supplemented with EDTA. In the absence of EDTA both relaxed and 
supercoiled plasmids migrate much slower, with reduced resolution between 
topoisomers. Since it is unlikely that the EDTA is interacting directly with 
the plasmid one explanation for this observation would be that trace 
amounts of contaminating divalent metal ions are binding to the DNA. Since 
0
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Figure 3.6 Buffers 9 and 12 as triplex forming buffers in the Microtitre plate assay.  
30 µL Milli-Q water containing 0.5 µg of relaxed or supercoiled pNO1 was mixed 
with either TF buffer (Table 2.1), Buffer 9 (75 mM MgOAc, pH 4.7) or buffer 12 (75 
mM CaOAc, pH4.7). Reactions were carried out in triplicate. Error bars represent 
the standard deviations of the three repeats. 
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the binding of such small amounts would not result in a change in overall 
charge it is possible that the reduced migration is due to conformational 
changes in the plasmid. Two explanations for this phenomenon would be 
the binding of divalent ions subtly altering the rigidity of the DNA or the ions 
are binding in clusters at the intersections where two double strands cross 
(where there would be a high density of negative charge) and disrupting 
conformation by repulsion.  
 Although lithium acetate EDTA (LAE) seemed a good buffer for 
running gels under standard conditions, often producing crisper bands and 
generating less heat than TAE, increasing the voltage in order to reduce 
running times proved untenable. Whereas the migration of linear DNA 
increases proportional to the increase in voltage, high voltages reduced the 
resolution of closed-circular DNA topoisomers. At 240 V, three times the 
standard voltage, an increase in the mobility of relaxed and open-circle 
plasmid was observed, as well as clustering of the relaxed topoisomers. 
Supercoiled plasmid, on the other hand, decreased in mobility. This effect 
had been observed previously with TAE at much lower voltages than the 
ones tested here (Johnson & Grossman, 1977), although the exact reason 
for this phenomenon remains mysterious. From these findings it can be 
concluded that the fastest an agarose gel can be run and still achieve 
decent resolution of topoisomers is 160 V for 1.5 hrs. 
 Additionally it was observed that by using LAE as the running buffer 
and running the gel for long time periods (16-24 hrs.) at low voltage (20-15 
V) the band corresponding to the supercoiled topoisomers could be resolved 
as two discrete bands. This resolution could be the result of either the 
binding of lithium ions to the DNA resulting in a change in charge or 
conformation for some supercoiled topoisomers but not others, or could be 
a result of the lower conductivity of the buffer allowing more charge to pass 
directly through the sample rather than short-circuiting through the buffer. 
As to what these two bands represent, they might signify topoisomers with 
different degrees of supercoiling beginning to be resolved or the resolution 
of some other kind of topoisomer from the supercoiled band, such as 
denatured or Form V DNA (two single-stranded DNA molecules coupled by 
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supercoiling) (Stettler et al, 1979). Unfortunately there was insufficient time 
to follow this up any further. 
3.3.2 Triplex-affinity purification of supercoiled 
plasmids 
For triplex affinity purification of supercoiled plasmids two buffers have been 
identified (Buffers 9 and 12) which produced superior yields to the standard 
TF without decreasing purity. These buffers were comprised of 75 mM 
magnesium or calcium acetate (pH 4.7). The increase in binding due to the 
elimination of sodium is likely to be due to the fact that monovalent ions act 
antagonistically to the more efficient triplex stabilizing divalent ions 
(Singleton & Dervan, 1993). The other alkaline earth metal tested, 
Beryllium (Buffer 14), and zinc (Buffer 13) performed poorly as triplex 
stabilizers under the conditions tested. This may be due either to their 
physical properties or their coordination. Decreasing the pH increased the 
binding of OC plasmid (Buffer 1) which resulted in a decrease in purity. 
Increasing the pH to 5.25 (Buffer 3) seemed to marginally improve the 
purity without changing the yield. These observations suggest that the 
triplex formation of open circular DNA is much more sensitive to pH than 
supercoiled plasmid. Using a sodium acetate buffer containing either 
spermine (Buffer 6) or spermidine (Buffer 7), which were predicted to 
promote triplex formation (Singleton & Dervan, 1993), resulted in a lower 
purity and, the case of spermine, a lower yield which is possibly due to 
competition with sodium ions. Addition of silver acetate (Buffer 11) reduced 
both purity and yield, implying it disrupted triplex formation. This is likely a 
competition effect between the silver and magnesium ions. 
 The purification of 1 mg of SC plasmid using Buffer 9 produced a high 
degree of purification and a modest yield of 64%. This is comparable to 
previously published data (Schluep & Cooney, 1999), which focused on 
improving the matrix rather than the buffer. It is possible that by using the 
matrix devised by Schluep and Cooney and Buffer 9 even higher yields 
could be reached. The use of Continuous Affinity Recycle Extraction (CARE) 
only marginally improved the yield, although due to the labour intensive 
nature of the procedure the flow-through was only recycled once (more 
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cycles, and probably high yields, could be achieved if the process was 
automated). However, it was surprising that the increase in yield was so low 
(~3%), which implies the level of binding for the second cycle was much 
lower than the first. It is unlikely that the binding capacity of the column 
shifted since it was thoroughly washed and re-equilibrated between cycles. 
It may be the case that only certain supercoiled topoisomers are binding 
efficiently to the column, as it has been previously observed that triplex 
formation is proportional to the level of supercoiling of the DNA (Maxwell et 
al, 2006). In fact, our results with the lithium acetate EDTA agarose gels 
demonstrate that the supercoiled topoisomers are not homogenous since it 
is possible to separate the band into two species. 
 Testing Buffers 9 and 12 as triplex-forming buffers in the Microtitre 
plate assay revealed that Buffer 12 performs marginally better than the 
classic TF buffer. Since it had a simpler composition to the classic TF buffer 
it was used in all further experiments in this study. 
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     Chapter 4 
4 Escherichia coli DNA Gyrase Screen 
4.1 Introduction 
DNA topoisomerases are essential enzymes which have been found in all 
known cells to date (Bates & Maxwell, 2005). They are responsible for 
controlling the topological state of DNA within the cell, and the catalysis of a 
wide range of reactions: knotting/unknotting, catenation/decatenation and 
supercoiling/relaxation of DNA (Schoeffler & Berger, 2008). The crucial 
nature of their role has led them being successfully exploited as targets for 
a range of antimicrobial and anti-cancer drugs as well as potential targets 
for herbicidal, anti-viral and anti-protozoal agents. The bacterial 
topoisomerase DNA gyrase, for example, is the target for the quinolone 
class of drug (Gellert et al, 1977; Sugino et al, 1977) which includes some 
of the most successful antimicrobials currently in clinical use (Saravolatz & 
Leggett, 2003; Thadepalli et al, 1988; Wispelwey & Schafer, 2010). 
Unfortunately the development of therapeutic drugs which target 
topoisomerases have been limited by the low-throughput and labour-
intensive nature of traditional assays for their activity.  
To address this issue a novel assay (Maxwell et al, 2006) has been 
developed based on DNA triplex formation and exploiting the preferential 
formation of DNA triplexes in supercoiled over relaxed DNA (Hanvey et al, 
1988; Sakamoto et al, 1996). During the assay a biotinylated, single-
stranded triplex-forming oligo is annealed to the surface of a streptavidin 
coated microtitre plate well, to which the reaction mix containing the 
enzyme and substrate plasmid is added. After the reaction is completed a 
low pH, high salt buffer is added to promote triplex formation. As a result 
supercoiled plasmid is bound to the plate, whilst relaxed plasmid can be 
washed away. Addition of a fluorescent dye allows quantification of the 
retained DNA and consequently the activity of the enzyme. 
 Chapter 4 
 
  90 
 
Although this technique has been trialed on a small scale successfully 
(Anderle et al, 2008) it had yet to be assessed in a high-throughput format. 
As such, the main focus of this project was validating the assay as a high-
throughput screen and exploring any hits uncovered. Initially a pilot screen 
of 960 compounds against the well characterised Escherichia coli DNA 
gyrase would be conducted. The library chosen for screening was the 
Genplus library from Microsource (http://www.msdiscovery.com/ 
spectrum.html; last accessed 06/06/11) 80% of which is comprised of 
U.S.A., European and Japanese drug standard body approved drugs with 
the remaining 20% being natural products with novel structures. It was 
hoped that by screening compounds already known to be biologically active 
that our hit rate would be increased and reduce the time required for clinical 
trials of any hits which were viable novel antibiotics (Chong & Sullivan, 
2007).  
4.2 Results 
4.2.1 Initial screening 
After some preliminary attempts, the standard Microtitre plate-based assay 
was modified to make it more amenable to a high-throughput format. To 
improve consistency the reaction volume was increased from 30 µL to 60 
µL, which made sample handling easier. All buffers and solutions used in the 
screen were filtered to prevent scattering by contaminating particles during 
the staining step. Finally, the triplex forming and staining steps were carried 
out at 18°C to minimise variation due to ambient temperature changes. The 
library was screened at a relatively low concentration and after a few trials 
decided on 25 µM. The screen was conducted in duplicate over four days 
(see Section 2.8.2. for details of the protocol used). An arbitrary hit 
threshold of 25% inhibition was set, and any compound exceeding this limit 
were investigated (Figure 4.1, Figure 4.2). Twenty one compounds were 
identified as inhibitors by the screen, whilst two compounds seemed to give 
a increase in DNA gyrase activity: quinacrine and merbromin (35 and 37% 
activation respectively). 
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Figure 4.1 Results of E. coli gyrase screen. A. Percentage inhibition for a duplicated screen of the Genplus library against E. coli DNA 
gyrase. Each bar represents the average value for a single compound screened in duplicate. The dotted line indicates the arbitrary hit 
threshold of 25% inhibition. See the Appendix for the data for individual plates. 
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Figure 4.2 Percentage inhibition for Genplus plate 8 against E. coli DNA gyrase with hits labelled. Percentage inhibition was 
calculated from the ‘no enzyme’ and ‘no drug’ controls. Error bars for the no enzyme and no drug controls were calculated from the 
standard deviation of sixteen repeats.  
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4.2.2 Intrinsic fluorescence of the library 
To identify compounds with intrinsic fluorescence, which could interfere with 
the assay if they persisted in the wells, fluorescence readings (Ex: 470 nm, 
Em: 520 nm) were taken during the screen prior to incubation of the plates 
at 37°C (Figure 4.3). Four compounds were identified which fluoresced 
under the conditions of the screen: quinacrine, calcein, merbromin and 
riboflavin.  
4.2.3 Elimination of false positives 
The majority of the 21 compounds picked up in the screen (Table 4.1) were 
already characterised DNA gyrase inhibitors, including a large number of the 
highly successful fluoroquinolone class. This was not particularly surprising 
since DNA gyrase is a well-exploited antimicrobial target and the library 
screened was largely made up of commercial drugs. In fact, the screen’s 
ability to detect these already known inhibitors was heartening. Since they 
were already characterised, they were excluded from further study. 
 
Figure 4.3 Intrinsic fluorescence of Genplus library. Fluorescence readings taken in 
the presence of DNA gyrase and pNO1. Each bar represents a single compound. A. 
Quinacrine B. Calcein C. Merbromin D. Riboflavin. 
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The effects of the remaining hits on DNA gyrase activity at 100 µM 
were tested using the agarose gel assay (Figure 4.4) to determine if they 
were genuine inhibitors or whether they had been detected due to 
interference with other aspects of the microtitre plate-based assay (e.g. 
triplex formation). To exclude the effects of any contaminants or 
degradation products present in the library, fresh stocks of each hit were 
purchased from the appropriate supplier (Sigma, Microsource). Acrisorcin, 
one of the hits to be tested, was actually a mixture of 9-aminoacridine and 
hexylresorcinol. As such the two compounds were tested separately. Out of 
the hits tested 9-aminoacridine, a component of acrisorcin, seemed to 
actually stimulate gyrase activity in the gel assay whilst mitoxanthrone and 
suramin displayed inhibition (see Section 4.2.6 below). The remaining nine 
False positives 
Inhibition 
(%) Known inhibitors 
Inhibition 
(%) Novel inhibitors 
Inhibition 
(%) 
Harmalol  85 Gatifloxacin 96 Mitoxanthrone  93 
Biotin 52 Moxifloxacin 91 Suramin 70 
Quinalizarin 42 Novobiocin 91 
  Acrisorcin 38 Levofloxacin 88 
  Quercetin 35 Perfloxacine Mesylate 85 
  Digitoxin 30 Lomefloxacin 82 
  Roxarsone 30 Norfloxacin 74 
  Niacin 28 Ofloxacin 66 
  p-chlorophenylalanine 27 Acriflavinium  66 
  
  
Ciprofloxacin 59 
  
  
Surafloxacin  46 
  
Table 4.1 Summary of compounds selected by the E. coli gyrase screen. Percentage 
inhibition of compound in screen given. 
          
Figure 4.4 Example of validation assay for putative E. coli gyrase screen hits. 
Similar experiments were carried out for all potentially novel hits. Relaxed DNA 
incubated with 0.5 units of DNA gyrase to produce partial supercoiling. Samples 
incubated with or without 100 µM compound. Ciprofloxacin was used as a positive 
control for inhibition. 1. Harmalol. 2. p-chlorophenylalanine. 3. Roxarsone. 4. 
Niacin. 5. 9-aminoacridine. 6. Hexylresorcinol. 
Rel Gyr. Cipro. 1 2 3 4 5 6 
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compounds tested did not seem to affect DNA gyrase activity in the gel-
based assay. 
This made me curious as to why these compounds had been picked 
out by the screen to begin with. It was especially interesting that harmalol, 
which gave a high percentage inhibition in the screen, seemed entirely 
inactive in the gel assay. To test whether the compounds had interfered 
with either the triplex-formation or staining steps of the microtitre-plate 
based assay, the compounds were incubated with supercoiled plasmid in the 
absence of gyrase under standard assay conditions (Figure 4.5). A decrease 
in signal compared to the control indicated the compound was either 
disrupting triplex formation or interfering with the staining. Of the 
compounds tested, it appeared that both 9-aminoacridine and 
hexylresorcinol reduced the signal. This explained why Acrisorcin (a mixture 
of the two) was picked up by the screen even though 9-aminoacridine 
activates DNA gyrase. The remaining compounds had no effect. 
 
Figure 4.5 Example of testing the ability of false positives to interfere with the 
assay. Similar experiments were carried out for all false positives. Supercoiled 
pNO1 in 1x gyrase assay buffer incubated with 100 µM of the indicated compound. 
The total concentration of DMSO present in all samples was 5%. Error bars 
represent the standard deviation of three repeats. 
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Since harmalol had given such a strong response in the screen but 
neither displayed inhibition in the gel assay nor appeared to be interfering 
with the microtitre plate-based assay it was possible that the sample in the 
library had become contaminated in some way. To test this the freshly 
bought stock to the library sample were compared in both the gel assay and 
in the microtitre plate-based assay (Figure 4.6). It was found that neither 
inhibited DNA gyrase in the gel assay, but the sample from the library 
strongly reduced the signal of supercoiled plasmid in the microtitre plate-
based assay. It was likely therefore that the library sample had either 
become contaminated or degraded during storage, and the strong inhibition 
 
 
 
Figure 4.6 Comparing harmalol library stock to fresh preparation. A. Testing for 
interference with the microtitre plate-based assay. 0.75 µg supercoiled pNO1 
incubated with 100 µM harmalol from the library or freshly prepared. B. Comparing 
effects on DNA gyrase activity in the gel assay. 0.5 µg relaxed pNO1 incubated with 
0.75 units DNA gyrase in the presence or absence of compound. 1. Harmalol from 
library stock. 2. Harmalol from fresh preparation. 
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seen in the screen was entirely due to this contaminant interfering with the 
assay. Some smearing of the supercoiled band was observed with the 
library stock in the gel assay, suggesting the contaminant is an intercalator 
and was not fully removed by the extraction process. 
4.2.4 Statistical evaluation of screen 
The mean fluorescent signal for the 192 negative (relaxed plasmid, no 
enzyme) and 192 positive (relaxed plasmid with DNA gyrase and no drug) 
controls was calculated to be 80 and 370 RFU respectively, with standard 
deviations of 6 and 29 RFU (Table 4.2). The signal-to-background ratio was 
calculated to be 5 whilst the signal-to-noise ratio was 10. From the control 
data the average Z' value for the screen was calculated to be 0.64 (See 
Equation 2.2). This value indicated that there was a good degree of 
separation between the positive and negative controls, implying that data 
quality for the screen was good. The distribution of the Z' value for each 
plate around the mean (Figure 4.7) was close, with no single plate giving a 
value below 0.5. This assured me that this average value was a good 
representation of the screens overall quality. Thirteen compounds detected 
by the screen were validated as hits, giving a hit rate of 1.35%. Of these 
two were novel inhibitors of DNA gyrase, giving a novel hit rate of 0.21%. 
Checking the list of compounds present in the library revealed that four 
known DNA gyrase inhibitors were missed by the screen: nalidixic acid, 
cinoxacin, oxolinic acid and enoxacin. 
 
Table 4.2 Table of control data and Z' values per plate for the E. coli gyrase screen. 
Averages and standard deviations are derived from 16 repeats. Standard deviations 
were also converted to percentage inhibition. 
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4.2.5 Quinacrine and 9-aminoacridine as activators 
of DNA gyrase 
As shown above (Figure 4.4), 9-aminoacridine appears to act as an 
activator of DNA gyrase. Two compounds from the screen appeared to be 
also activating the enzyme: quinacrine and merbromin. It had also been 
observed that these two compounds fluoresced at the wavelengths used in 
the assay (Figure 4.3). It was therefore interesting to see if these 
compounds were genuine activators or if the apparent increase in activity 
was due to them persisting in the wells after the final wash steps. To 
investigate this 100 µM of each of the compounds was incubated under 
standard assay conditions either with no plasmid present, relaxed pNO1 or 
supercoiled pNO1 (Figure 4.8). Merbromin gave me a high signal even when 
no plasmid was present, suggesting it persisted in the wells after the wash 
steps. This made sense since merbromin is a protein dye which reacts with 
thiol groups (Wilken et al, 2010). The increase in signal and apparent 
activation was therefore likely due to the compound covalently binding to 
the streptavidin coats of the wells. Merbromin also appeared to inhibit DNA 
gyrase in the gel assay, but due to its general reactivity with proteins this 
 
Figure 4.7 Histogram of Z' values for the E. coli gyrase screen, with the average Z' 
value for the twelve plates indicated by the dotted line. 
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inhibition was discounted as being non-specific. Quinacrine, on the other 
hand, did not seem to persist within the well and in fact reduced signal 
when incubated with supercoiled plasmid. This suggested that the activation 
observed was genuine rather than due to the intrinsic fluorescence of the 
compound. 
 To investigate further the activation of DNA gyrase by quinacrine, a 
titration of gyrase in the presence of either 10 or 20 µM quinacrine was 
performed (Figure 4.9). Activation of DNA gyrase was observed with both 
concentrations, resulting in a doubling of the supercoiling activity of the 
enzyme. However, this increase in activity was identical for both the 
concentrations tested. This suggests that which was observed here is the 
limit of quinacrine’s ability to promote supercoiling by DNA gyrase. 
 In order to address the cause of this activation, relaxed and 
supercoiled pNO1 were run on on a 1% agarose gel in the presence or 
absence of 2 µM quinacrine in the gel and running buffer (Figure 4.10). 
Supercoiled plasmid was unaffected by the presence of the drug, whilst 
 
Figure 4.8 Testing the effects of merbromin and quinacrine on the microtitre plate-
based assay. 100 µM of each compound incubated under standard assay conditions 
either in the absence of plasmid, with relaxed pNO1 or supercoiled pNO1. Error 
bars are the standard deviation of three repeats. 
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relaxed plasmid ran as a single band slightly ahead of the supercoiled DNA. 
This suggested that activation of DNA gyrase by quinacrine may be a result 
of the drug intercalating with relaxed DNA and causing it to adopt a form 
which was a better substrate for the enzyme (e.g. positively supercoiled 
plasmid). 
4.2.6 Mitoxanthrone and suramin as novel DNA 
gyrase inhibitors 
Out of the thirteen hits identified by the screen two were novel gyrase 
inhibitors: mitoxanthrone and suramin. Both these compounds have been 
previously shown to have activity against eukaryotic topoisomerase II (topo 
II) (Bojanowski et al, 1992; Smith et al, 1990), but they had not been 
previously tested against DNA gyrase. As such, the IC50s of these 
compounds against E. coli DNA gyrase were determined to be 12 µM for 
mitoxanthrone and 80 µM for suramin in the gel assay (Figure 4.11 A and 
B).  
Mitoxanthrone is from the anthraquinone class of drugs and is 
currently used as an antineoplastic agent (Schrappe, 2010). It is thought to 
inhibit topo II by stabilisation of the DNA cleavage intermediate, leading to 
generation of double-stranded breaks in DNA (Smith et al, 1990). To 
determine if this mode of action is the same for its inhibition of gyrase, an 
agarose gel assay was conducted under conditions which reveal formation 
 
 
 
Figure 4.9 DNA gyrase activation in the presence of quinacrine. DNA gyrase titrated 
from 0.25 units to two units under standard assay conditions. Reactions contained 
either 0, 10 or 20 µM quinacrine. Samples lacking quinacrine had an equivalent 
amount of DMSO added. 
Rel. 
[Gyrase] [Gyrase] [Gyrase] 
20 µM quinacrine 10 µM quinacrine 
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of the cleavage intermediate (Figure 4.11 C; Section 2.7.2). It was 
observed that mitoxanthrone induced DNA cleavage strongly at 10 µM in 
the presence of 10 units of DNA gyrase, comparable to the known cleavage 
intermediate stabiliser ciprofloxacin, showing that mitoxanthrone stabilises 
the cleavage complex of gyrase as well as topoisomerase II. This is likely 
due to the drug intercalating at the DNA break generated in the cleavage 
complex in both enzymes. It also appears that at 100 µM the drug’s ability 
to stabilize the cleavage complex is reduced. This is probably because 
mitoxanthrone is an intercalator and at this concentration it is distorting the 
DNA in such a way which prevents the enzyme binding. 
Suramin is an antiprotozoal drug that has also entered clinical trials 
for the treatment of several forms of cancer (Stein, 1993). Although it has 
been shown to protect against cleavage of DNA by topo II induced by 
cleavage-intermediate stabilising agents (Bojanowski et al, 1992), its exact 
mode of inhibition was yet to be determined (Swift et al, 2008). As such the 
ability of suramin to protect DNA from gyrase-induced cleavage was tested 
(Figure 4.11 D; Section 2.7.2). To eliminate the possibility of drug—drug 
 
Figure 4.10 Effect of 2 µM quinacrine on the migration of relaxed and supercoiled 
pNO1. 1% agarose gels in TAE with or without 2 µM quinacrine in the gel and 
running buffer run for 3 hr at 80 V. Samples for the gel containing quinacrine were 
prepared in the presence of 2 µM quinacrine. A 1kb DNA ladder (M) was also 
included. The samples were prepared in duplicate. 
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interactions Ca2+ was used to induce cleavage by DNA gyrase (Reece & 
Maxwell, 1989). Suramin was able to completely protect DNA from cleavage 
by gyrase in the presence of 4 mM calcium chloride at 80 µM, indicating that 
its mode of action is similar to that found with topo II and is independent of 
drug—drug interactions.  
To determine if the drug was protecting from cleavage by preventing 
binding of the protein to DNA, rather than preventing cleavage directly, a 
native gel shift assay of the binding of DNA gyrase to a 147 bp fragment of 
DNA in the presence or absence of 100 µM suramin was carried out (Figure 
4.12; Section 2.7.4). In the absence of suramin the conversion of free DNA 
to a slower migrating form was observed as enzyme was titrated in, 
whereas the presence of 100 µM suramin abolishes this shift. This suggests 
that the drug is preventing the binding of the enzyme to DNA rather than 
 
Figure 4.11 In vitro characterisation of mitoxanthrone and suramin. A. Determining 
the IC50 of mitoxanthrone. 1. Relaxed pNO1. 2. With 1 unit of DNA gyrase. 3. With 
100 µM ciprofloxacin. 4-14. With 2 to 22 µM mitoxanthrone in 2 µM increments. B. 
Determining the IC50 of suramin. 1. Relaxed pNO1. 2. With 1 unit of DNA gyrase. 3. 
With 100 µM ciprofloxacin. 4-10. With 10 to 400 µM suramin in doubling 
increments. C. Cleavage complex stabilization assay with mitoxanthrone and 
suramin. 1. Supercoiled pNO1. 2. With DNA gyrase under relaxation conditions. 3-4. 
With 10 and 100 µM ciprofloxacin. 5-6. With 10 and 100 µM mitoxanthrone. 7-8. 
With 10 and 100 µM suramin. D. Cleavage protection by suramin. Reactions carried 
out in the presence of 4 mM CaCl to promote DNA gyrase mediated cleavage. 1. 
Relaxed pNO1. 2. With DNA gyrase. 3-6. 80-640 µM suramin in doubling 
increments. 7. With 0.8 µM novobiocin. Novobiocin is a strong (nM) ATPase 
inhibitor of DNA gyrase, and does not protect against cleavage. 
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preventing cleavage directly, similar to the antibiotic simocyclinone D8 
(Flatman et al, 2005). 
4.2.7 Effect on growth of Gram-negative and Gram-
positive bacteria. 
Having characterised the mechanisms of both mitoxanthrone and suramin 
their antimicrobial activities were explored. For these studies the effect of 
the drugs on the growth of both Gram-negative bacteria (in the form of the 
wild-type E. coli strain MG1655 (Blattner et al, 1997)) and Gram-positive 
bacteria (in the form of wild-type M. smegmatis strain mc2155) was 
investigated. Additionally the growth of the membrane permeable E. coli 
strain NR698 in the presence of the drugs was investigated (Ruiz et al, 
2005). E. coli NR698 carries an in frame deletion for the imp gene 
(imp4213), the product of which is responsible for lipopolysaccharide 
assembly in the outer membrane (Ruiz et al, 2006). This mutation causes 
the outer membrane of the bacteria to become leaky, making it more 
sensitive to antimicrobials. It was hoped that using this mutant would help 
me discount entry into the cell as a cause of resistance if the bacteria 
turned out to be unaffected by the drugs. 
 
Figure 4.12 Gel shift analysis of the binding DNA gyrase to DNA in the presence of 
suramin. 1. 25 nM 147 bp DNA fragment. 2. 200 nM DNA gyrase (no 147 bp). 3-5. 
50, 100 and 200 nM DNA gyrase with 25 nM 147 bp. 6-8. 50, 100 and 200 nM DNA 
gyrase with 25 nM 147 bp and 100 µM suramin. 
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 Initially the effect of the drugs on bacteria grown on solid agar was 
studied. Experiments were conducted using slope assays (Section 2.3.5), in 
which a single colony is streaked across an agar plate containing a gradient 
of compound (Figure 4.13 A). Since no antimicrobial activity was observed 
for the compounds at the concentrations tested, halo assays were used 
(Section 2.3.4) in which paper disks soaked in 2 mM compound are placed 
on a bacterial lawn (Figure 4.13 B). Antimicrobial activity is measured by 
the zone of clearing generated around the disk. Unfortunately no effect was 
observed with either compound. 
 
Figure 4.13 The effects of mitoxanthrone and suramin on bacterial growth on solid 
media. A. Slope assays for E. coli MG1655, NR698 and M. smegmatis mc2155. 
Control plates have only had DMSO added to them. All other plates have a gradient 
of increasing compound from left to right. The E. coli strains were streaked in 
duplicate, whereas the M. smegmatis plates contained four repeats. Ciprofloxacin 
gradient: 0-0.2 µM for E. coli, 0-30 µM for M. smegmatis. Mitoxanthrone gradient: 0-
24 µM for E. coli, 0-100 µM for M. smegmatis. Suramin gradient: 0-160 µM for E. coli, 
0-1 mM for M. smegmatis. B. Halo assays for E. coli MG1655, NR698 and M. 
smegmatis mc2155. All disks soaked with 2 mM compound. 1. Ciprofloxacin. 2. 
Mitoxanthrone. 3. Suramin. 4. 100% DMSO. 
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 One concerning question was whether this lack of antibacterial 
activity was genuine or whether the compounds were having difficulty 
diffusing through the agar. To address this problem, growth curve assays in 
liquid media were carried out (Section 2.3.6) in the presence or absence of 
the compounds (Figure 4.14).  
 
Figure 4.14 Bacterial growth in liquid media. A. E. coli MG1655 or NR698 after 1, 2, 
3, 4 or 5 hr growth the presence of the indicated concentration of compound. B. M. 
smegmatis mc2155 after 3, 6, 9 or 24 hr growth the presence of the indicated 
concentration of compound. 
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Neither mitoxanthrone nor suramin had any effect on the growth of E. 
coli MG1655 or NR698, both in terms in the final OD reached and in the 
doubling times of the bacteria. However, 65 µM mitoxanthrone  reduced the 
growth of M. smegmatis. The presence of mitoxanthrone often disrupted 
 
Figure 4.15 Colony counting of M. smegmatis mc2155 in the presence of 
mitoxanthrone or suramin. A. Liquid cultures after 22 hr growth in the presence of 
65 µM mitoxanthrone or 800 µM suramin. Similar cultures were prepared for 13 µM 
mitoxanthrone and 80 µM suramin. B. Aliquot of liquid cultures after 22 hr growth, 
plated onto Middlebrooks 7H11 agar free of test compounds and grown for a 
further 48 hr. Similar plates were prepared after 16 and 19 hr liquid culture 
growth. C. Colony counts for all compound concentrations and time points. 
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OD600 readings, possibly due to it having poor solubility in the media or 
due to its bright pigmentation.  
To get a more accurate idea of the effect of mitoxanthrone on M. 
smegmatis growth colony counting assays were carried out (Section 2.3.7) 
on both mitoxanthrone and suramin (Figure 4.15). In these experiments M. 
smegmatis was grown in liquid media with or without test compound. An 
aliquot was taken after various time points (16, 19 and 22 hr), diluted 1 in 
10,000 and plated onto Middlebrooks 7H11 agar plates which did not 
contain the test compounds. After 48 hr growth the colonies on each plate 
were counted manually. Bacteria grown in the presence of suramin grew 
similarly to the control at all time points. M. smegmatis grown in the 
presence of 65 µM mitoxanthrone produced fewer colonies than the control, 
indicating that the drug was inhibiting their growth at this concentration. 
The bacteria grown in 13 µM mitoxanthrone produced fewer colonies at each 
time point compared to the control, but since the differences were marginal 
it’s difficult to say if this is due to genuine antimicrobial activity or to 
variation in the assay. 
 This raised the question why mitoxanthrone was inhibiting M. 
smegmatis growth in the liquid media and not on solid agar. To try and 
clarify if it was due to the drug diffusing poorly through the solid media, a 
single M. smegmatis colony was streaked onto a Middlebrooks 7H11 agar 
plate containing 100 µM mitoxanthrone (Figure 4.16). In this setup the drug 
would be evenly dispersed across the plate, rather than having to diffuse as 
 
Figure 4.16 M. smegmatis streaked on Middlebrooks 7H11 agar containing 100 µM 
mitoxanthrone. Plates incubated at 37°C for 48 hr. 
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in the slope assays. Mitoxanthrone still did not affect bacterial growth, 
suggesting that the lack of inhibition on the plates wasn’t due to diffusion. 
Alternatively, it could be due to the difference in bacterial growth states 
between the liquid and solid media setups. 
4.3 Discussion 
4.3.1 Performance of the screen 
The work above has shown that the microtitre plate-based assay can be 
used in a high-throughput format to identify known and novel inhibitors of 
DNA gyrase, with an average Z' factor of 0.64. No single plate had a Z' 
factor below 0.5, indicating that there was good separation of positive and 
negative controls on all plates. There was no obvious pattern to the 
readings for the compounds on any of the plates. However it was observed 
that for some plates the majority of compounds showed either mild 
inhibition or activation. This was likely due to day-to-day or run-to-run 
variations of the screening process. With a hit threshold of 25% inhibition, 
21 compounds were selected for further investigation. Thirteen of these 
were confirmed as hits. Four known DNA gyrase inhibitors were missed by 
the screen. They were likely missed due to variations within the assay or 
degradation of the compounds during storage. 
Out of the 13 hits discovered by the screen only two were novel 
gyrase inhibitors, both of which were already known topoisomerase II 
inhibitors. This was likely a result of the library selection, since both DNA 
gyrase and human topoisomerase II are well exploited drug targets with 
similar modes of action. This causes a number of problems when using a 
library of existing drugs to screen for novel and therapeutically relevant 
inhibitors of these enzymes. Firstly, any DNA gyrase inhibitors you find may 
also be cytotoxic chemotherapy drugs which target human topoisomerase 
II. Such compounds are toxic to humans and produce numerous unpleasant 
side effects. Although it may be possible to re-engineer these compounds to 
mitigate the side effects, doing so would negate one of the points of 
selecting a library in this way, since their physiochemical properties would 
have to be re-characterised. Secondly, when looking for human 
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topoisomerase II inhibitors for cancer therapy you will find hits which have 
activity against DNA gyrase. If these drugs shared common binding sites to 
currently used antibiotics you would run the risk of inadvertently breeding 
antibiotic resistant bacteria. Thirdly, many of your hits will already be 
known to affect the target you were screening against. As such, a tailored 
library of known drugs excluding already known inhibitors would be 
essential for a larger-scale screen. 
Nine of the compounds selected by the screen turned out to be false 
positives. Out of these only one, harmalol, was shown to interfere with the 
assay. The library stocks for this compound must have become degraded or 
contaminated in some way, since fresh stocks didn’t show any interference. 
The remaining false positives were probably selected because the hit 
threshold was set too low (See Chapter 6 for further discussion). 
4.3.2 9-aminoacridine and quinacrine as DNA gyrase 
activators 
Two activators of DNA gyrase were identified through the screen: 9-
aminoacridine and quinacrine. Both of these compounds are intercalators, 
and have been shown that quinacrine is capable of causing relaxed plasmid 
to run as a single band with a faster mobility than negatively supercoiled 
plasmid. One explanation for the identity of this band is that it is positively 
supercoiled plasmid. This could explain the enhancement in DNA gyrase 
activity brought about by the drug, since positively supercoiled plasmid is a 
superior substrate for DNA gyrase compared to relaxed DNA (Bates et al, 
1996). Although the migration of DNA in the presence of 9-aminoacridine 
was not tested it is likely that it operates by a similar mode of action. 
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4.3.3 Mitoxanthrone and suramin as novel DNA 
gyrase inhibitors 
Two of the hits from the screen were novel DNA gyrase inhibitors: 
mitoxanthrone and suramin (Figure 4.17). However, neither of these 
compounds are novel topoisomerase inhibitors both having been previously 
shown to inhibit topoisomerase II. (Bojanowski et al, 1992; Smith et al, 
1990). The IC50s were determined to be 12 µM and 80 µM, respectively, in 
the agarose gel assay. 
 Mitoxanthrone has been shown to inhibit topoisomerase II by 
stabilising the cleavage complex (Smith et al, 1990). As shown above this 
mode of action holds true for its inhibition of DNA gyrase. This makes it 
similar to ciprofloxacin in terms of its inhibitory potential and mechanism. 
 Suramin, on the other hand, had been shown to protect against drug 
mediated DNA cleavage by topoisomerase II (Bojanowski et al, 1992). 
However, it was not clear from this if this protective activity was due to 
direct inhibition of cleavage, due to the blocking of DNA binding or a drug—
drug interaction. With DNA gyrase was shown that suramin can protect from 
calcium mediate cleavage of DNA. This eliminated the possibility of drug—
drug interactions being involved in the process. It has also been shown by 
native gel shift experiments that suramin prevents the binding of the DNA 
gyrase to DNA. These facts imply that suramin chiefly inhibits DNA gyrase, 
and protects against gyrase-mediated cleavage, by preventing binding of 
 
Figure 4.17 Structures of novel DNA gyrase inhibitors from screen. A. 
Mitoxanthrone. B. Suramin. 
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the enzyme to DNA. An interesting possibility is that the sulfonic acid 
groups on suramin could allow it to mimic the 5'-phosphate group of a 
nicked DNA backbone and compete for binding with DNA directly at the 
active site. 
4.3.4 Mitoxanthrone as an antimicrobial compound 
Although suramin displayed no antimicrobial activity with any of the 
bacterial strains tested, it has been shown that mitoxanthrone is capable of 
inhibiting the growth of M. smegmatis in liquid cultures at 65 µM. However, 
no inhibition of growth was seen with either wild-type E. coli MG1655 or the 
membrane permeable strain NR698. This was true for bacteria grown on 
both liquid and solid media, suggesting that either the drugs still cannot 
gain entry to the bacteria, despite the mutation present in NR698, or that E. 
coli is naturally resistant to them (e.g. via an efflux pump or degradation 
pathway). 
 The reason why mitoxanthrone can inhibit bacterial growth only in 
liquid cultures may be because the bacteria exist in a very different growth 
state whilst they are growing on solid media. It has been shown that 
bacteria growing in biofilms can be more resistant to antimicrobial agents 
than free-floating planktonic cells (Mah & O'Toole, 2001). Reasons why this 
might be are numerous including: the colony preventing diffusion of drug; 
slower growth rate of the bacteria on the solid media and the induction of 
biofilm-specific stress responses and phenotypes. 
 Although mitoxanthrone may also inhibit growth of pathogenically 
relevant Mycobacterium, such as Mycobacterium tuberculosis, its prospects 
as a commercial antibiotic are fairly limited. It is currently administered via 
injection as a treatment for some forms of cancer and multiple sclerosis 
(Hartung et al, 2002; Schrappe, 2010). This mode of delivery is undesirable 
for antibiotics since it requires administration by trained medical personnel 
and sterile needles. It would also reduce patient compliance due to the 
discomfort caused by the injections, with the result being higher rates of 
people abandoning the treatment before the course was completed. This 
would in turn lead to faster development of resistance. These factors are of 
particular importance for the developing world where tuberculosis is a major 
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epidemic. Several potentially lethal side effects have been identified for 
mitoxanthrone, including increased chance of leukaemia and heart failure 
(Le Page et al, 2011), further decreasing its appeal. It is conceivable, 
however, that the structure of mitoxanthrone could be used as a scaffold for 
synthesis of compounds with more favourable characteristics and lower 
cytotoxcitiy. 
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     Chapter 5 
5 Methanosarcina mazei topoisomerase 
VI screen 
5.1 Introduction 
In the previous chapter it has been shown that the microtitre plate-based 
assay could be used to screen for new inhibitors of the well characterised E. 
coli gyrase. Having carried out this proof-of-principle screen, it was decided 
to progress to a less well studied enzyme: topoisomerase VI (topo VI). Topo 
VI is member of the type IIB class of topoisomerases and has been 
discovered in archaea and plants (Bergerat et al, 1997; Corbett & Berger, 
2003). However few inhibitors have been described in the literature for this 
enzyme, including the HSP90 inhibitor radicicol (Gadelle et al, 2006). The 
IC50 of this compound with the Sulfolobus shibatae topo VI has been shown 
to be 250 µM, making it a poor inhibitor. This lack of inhibitors and the 
relatively small amount of study conducted with the enzyme made topo VI 
an interesting candidate for the screen: any novel inhibitors found would 
have the potential to give us greater insight into how the enzyme functions. 
In plants topo VI has been shown to be essential for 
endoreduplication (the process by which plants create multiple copies of 
their genome without fission) and cell expansion (Corbett & Berger, 2003; 
Yin et al, 2002), meaning that inhibitors targeting the enzyme have 
potential as dwarfing agents or herbicides. Unfortunately, the Arabidopsis 
topo VI has yet to be expressed in a soluble form. Topo VI from the archaea 
Methanosarcina mazei is easy to express and has been crystallised by one 
of our collaborators (Corbett et al, 2007). In addition, the majority of the 
biochemical studies on topo VI have been conducted with the S. shibatae 
enzyme meaning that M. mazei topo VI has not been extensively 
characterised. It was therefore decided to screen against the M. mazei 
version of the enzyme in the hopes that any inhibitors discovered would 
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help probe the mechanism of the enzyme. Any hits could be tested against 
the Arabidopsis enzyme in vivo with an assay using a hypocotyl extension 
assay. 
Additionally, genes for topo VI have been identified in the genome of 
the malaria parasite Plasmodium falciparum (Aravind et al, 2003). These 
include two genes with homology for the topo VI A subunit (PF10_0412, 
abbreviated to PfTopo6A1; PFL0825c, abbreviated to PfTopo6A2) whilst one 
gene had homology for the topo VI B subunit (MAL13P1.328, abbreviated to 
PfTopo6B). The presence of a topo VI makes sense in terms of the biology 
of the parasite since it undergoes a process called schizogony as part of its 
life cycle, which bears similarities to endoreduplication in plants. During the 
process of schizogony the parasite replicates its genome several times 
without cell division before budding daughter cells (Gantt et al, 1998; Sturm 
& Heussler, 2007). This convinced us that it would be worthwhile 
attempting to express and purify these hypothetical proteins to test for topo 
VI activity. The hits from the M. mazei topo VI screen could then be tested 
against the P. falciparum enzyme. If successfully validated, this enzyme 
may be a novel target for anti-malarial drugs. 
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5.2 Results 
5.2.1 Characterisation of M. mazei topo VI 
Since M. mazei topo VI was relatively unstudied this study began with 
biochemical characterisation of the enzyme. Initially enzyme was titrated in 
the presence of the published assay buffer (Corbett et al, 2007) in both the 
agarose gel based and microtitre plate-based assays (Figure 5.1). Reactions 
were incubated at 37°C for 30 min. In the gel-based assay almost complete 
relaxation of 0.5 µg supercoiled pNO1 was observed with between 23 and 
 
Figure 5.1 Activity of M. mazei topo VI. A. Titration M. mazei topoisomerase in the 
agarose gel-based assay: 23, 46, 92, 184 or 368 nM enzyme. B. Titration M. mazei 
topoisomerase in the microtitre plate-based assay. 
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46 nM topo VI. However, strangely, not all the supercoiled plasmid 
appeared to be relaxed by the enzyme. Increasing the concentration of 
enzyme did not result in relaxation of the lingering SC DNA, and lead to the 
formation of a series of defined bands. The banding pattern produced at 
high concentrations was distinct from the patterning seen for partial 
relaxation at 23 nM. Faster migrating species emerged as the concentration 
of enzyme increased. In the plate assay the majority of the fluorescence 
signal attributable to supercoiled DNA was lost with the addition of 24 nM 
topo VI. Increasing the concentration to 46 nM caused a further, but minor, 
decrease in signal. Raising the concentration above 46 nM had hardly any 
effect with the exception of 368 nM topo VI, which exhibited a very slight 
increase in signal. 
 To further investigate the formation of the unusual banding pattern 
formed by topo VI at high concentrations a titration of the enzyme in the 
presence of relaxed DNA was performed (Figure 5.2 A). It was observed 
that topo VI was capable of forming the strange banding pattern with 
relaxed as well as supercoiled DNA, implying that it was a not due to auto-
 
Figure 5.2 Titration of M. mazei topo VI with relaxed or SC pNO1. A. 60, 120, 240, 
480 or 960 nM topo VI with relaxed or SC pNO1. B. Reactions stopped with 1% SDS 
and incubated with 0.1 mg/ml proteinase K for a further 1 hr at 37°C. C. Samples 
from A run on a gel containing 0.5 µg/mL chloroquine. D. Samples from A run on a 
gel containing 1 µg/mL chloroquine. 
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inhibition of the enzyme at the higher concentrations. Since it was possible 
the patterning could be due to enzyme remaining stuck to the DNA whilst it 
was on the gel the experiment was repeated with a more stringent protein 
removal protocol (Figure 5.2 B). After the standard topo VI reaction the 
samples were stopped with 1% SDS and digested with 0.1 mg/mL 
proteinase K for 1 hr at 37°C. The remaining protein was then removed via 
phenol/chloroform extraction. The unknown bands remained unaffected 
compared to the standard extraction protocol, implying that the banding 
pattern was not due to protein remaining bound to the DNA. To try and 
discern the topological state of the unexplained bands the samples were re-
run on gels containing either 0.5 or 1 µg/mL chloroquine (Figure 5.2 C and 
D). Chloroquine is a weak DNA intercalator whose binding causes the writhe 
of DNA to become more positively supercoiled. As such, relaxed DNA 
treated with chloroquine begins to migrate faster whilst negatively 
supercoiled DNA begins to shift up the gel. Samples treated with up to 120 
nM topo VI displayed behaviour typical of relaxed DNA. However samples 
with 240 nM or more topo VI were less affected by the chloroquine. This 
suggested that the band emerging at these concentrations may be 
something other than supercoiled or relaxed DNA. 
 In order to further explore the identity of these bands it was decided 
to see if they could be relaxed by wheat germ topoisomerase I (topo I) 
(Figure 5.3). Since the topo VI reaction is Mg2+ dependent whilst the topo I 
reactions is not, it was possible to selectively stop the topo VI with EDTA 
after it had completed its reaction. Topo I could then be added and its affect 
on the unusual bands observed. In the absence of topo VI or EDTA, topo I 
was capable of fully relaxing supercoiled DNA. The inclusion of EDTA at the 
beginning of the reaction decreased its activity slightly. Topo VI, on the 
other hand, was completely stopped by the presence of EDTA from the start 
of the reaction. In the absence of ATP topo VI was not capable of forming 
the unusual bands, suggesting they were not general degradation due to a 
contaminant. However, a linear band was observed which is likely 
attributable to a contaminant in this batch of enzyme. Some relaxation 
activity was seen with topo VI in the presence of ATP and absence of MgCl2 
and EDTA, which was probably due to trace amounts of Mg2+ from other 
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sources. These controls made us confident that topo VI could be selectively 
stopped with EDTA but leave topo I active, and the appearance of the 
strange bands was both ATP- and Mg2+-dependent. The samples incubated 
with EDTA, topo I and topo VI from the beginning showed the standard 
relaxation pattern for topo I. However samples in which topo VI was allowed 
to react for 30 min before the addition of EDTA and topo I showed the 
strange banding pattern. This showed that topo I was unable to process the 
DNA topoisomers generated by topo VI, which implies they are something 
other than relaxed or supercoiled DNA. 
  
 
Figure 5.3 Processing of unusual products of topo VI by wheat germ topoisomerase 
I. All reactions were carried out in 1x topo VI assay buffer lacking ATP or MgCl2. 
Various components were added to the assays either at the beginning of the 
experiment (+) or after 30 min (30). These components included: wheat germ topo 
I (4 U), M. mazei topo VI (940 nM), ATP (1 mM), MgCl2 (10 mM), EDTA (17 mM), SC 
pNO1 (0.5 µg) or linear pNO1 (0.5 µg). Reactions lacking topo VI were incubated 
for 1.5 hours at 37°C whilst reactions with topo VI were incubated for 2 hours at 
37°C. This was done to keep topo I incubation times identical in all reactions. 
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It was of interest whether these bands were the end product of the 
topo VI reaction or whether they were purely a concentration-dependent 
effect. As such time course reactions with topo VI were carried out at 5, 10, 
20 or 80 nM (Figure 5.4). The unusual banding was observed after 15 min 
with 20 or 80 nM, with the reaction having reached completion after 30 min. 
In contrast, the strange bands were never observed with 5 or 10 nM topo VI 
even after 160 minutes. The reactions containing 20 nM topo VI appeared 
to reach completion after 10 minutes, considerably faster than the samples 
with 80 nM.  
One possibility was that the enzyme was somehow introducing knots 
into the plasmids. Generating single-strand nicks in supercoiled or relaxed 
topoisomers results in conversion to open circular DNA (due to release of 
tension from the molecule). Knotted DNA, on the other hand, would be 
unaffected by the presence of single-strand nicks since its structure arises 
from the crossing over of double-stranded DNA (Bates & Maxwell, 2005). 
DNA processed by topo VI at high concentrations was treated with the 
nicking endonuclease Nb.BstI (Figure 5.5). pNO1 was predicted to have a 
 
Figure 5.4 Time course reactions for M. mazei topo VI. Reactions with 5, 10, 20 or 
80 nM topo VI were stopped at the indicated time points. 
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single nicking sequence for Nb.BstI, meaning supercoiled or relaxed pNO1 
treated with this enzyme should be entirely converted to open circular DNA 
with a single nick present. It was observed that this was the case with 
supercoiled pNO1 in the presence or absence of topo VI with no ATP. Some 
linear DNA formation was observed when topo VI was included in the 
reaction (with or without ATP), but this was likely due to a contaminant 
being present with the enzyme. However, addition of Nb.BstI after the 
reaction with topo VI has been allowed to complete did not result in the 
conversion of the unusual bands to the open circular form. This implied that 
these bands were not relaxed or supercoiled topoisomers, and suggested 
that they might be either knotted or linear DNA of different sizes. 
  
 
Figure 5.5 Processing of unusual topo VI products by nicking endonuclease 
Nb.BtsI. All reactions carried out in 1x topo VI assay buffer lacking ATP. Various 
components were added to the assays either at the beginning of the experiment 
(+) or after 30 min (30). These components included: M. mazei topo VI (940 nM), 
Nb.BtsI (10 U), ATP (1 mM), SC pNO1 (0.5 µg) or linear pNO1 (0.5 µg). Reactions 
were incubated for a total of 2 hr at 37°C. 
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To determine the topology of these bands our collaborators August 
Johansson and Dr Neil Thompson (University of Leeds) conducted atomic 
force microscopy on samples of supercoiled, wheat germ topo I relaxed, M. 
mazei topo VI (50 nM) relaxed and M. mazei topo VI (960 nM) relaxed 
pNO1 (Figure 5.6). These reactions were prepared in the same way as in 
the reactions above and their characteristics verified by agarose gel 
electrophoresis. After the reactions had been completed the samples were 
treated with 1% SDS and digested with proteinase K for 1 hr at 55°C. They 
were then subjected to phenol-chloroform extraction and ethanol 
precipitated. The samples were sent as dried pellets to our collaborators for 
 
Figure 5.6 AFM images of M. mazei topo VI reaction products. Samples of substrate 
supercoiled pNO1 and the resulting products after relaxation by either 4 U wheat 
germ topo I, 50 nM M. mazei topo VI or 960 nM M. mazei topo VI. Images kindly 
provided by August Johansson and Dr Neil Thompson. 
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analysis. All samples were prepared on mica using Mg2+ as the binding 
cation, so all the molecules should be in their 2D surface relaxed form (i.e. 
binding method to the surface should not introduce further strain energy 
into circular DNA). 
The supercoiled control did not display the expected frequency of 
cross-overs, being only between one to three, whilst some molecules 
appeared to be open-circles. This may have been due to writhe being 
converted to twist by surface interactions or the sample becoming damaged 
in transportation. The samples treated with wheat germ topo I or 50 nM M. 
mazei topo VI appear more relaxed than the supercoiled samples although 
some cross-overs remain, which was expected for relaxed DNA. The sample 
treated with 960 nM M. mazei topo VI appeared more like the supercoiled 
DNA, but possessed structures not seen in the other samples including 
plectonemes and DNA condensation. Additionally, many molecules appear 
to be decorated with protein molecules that have not been removed during 
sample preparation. This was surprising due to the thoroughness of the 
protein extraction. It has been observed in this study that the enzyme binds 
to DNA in the absence of ATP (see native gel shift experiments below) and 
that the formation of the strange banding pattern the gel is ATP-dependent. 
Therefore the decoration observed in the AFM and the strange banding seen 
the gel assays may indicate topo VI-DNA cleavage complexes. 
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5.2.2 Inhibition of M. mazei topo VI by radicicol 
The only published inhibitor of topo VI is the HSP90 inhibitor radicicol, which 
has been shown to target the ATPase activity of the enzyme (Corbett & 
Berger, 2006). Since the majority of studies on topo VI have been on the 
enzyme from S. shibatae it remained to be tested radicicol also inhibited the 
M. mazei enzyme in a similar way. The compound was titrated from 0 to 
400 µM into reactions containing 0.5 units M. mazei topo VI for analysis in 
the agarose gel assay (Figure 5.7). The reported IC50 for radicicol with S. 
shibatae topo VI is 250 µM. The M. mazei enzyme appeared less sensitive to 
the inhibitor, with an IC50 of around 400 µM. 
 Having established that M. mazei topo VI was sensitive to radicicol 
experiments were conducted to confirm the drug targeted the ATPase 
activity of the enzyme. Preliminary ATPase assays (see Section 2.7.3) were 
performed with the E. coli GyrB subunit which was known to work well in 
the assay. Titrating in novobiocin, a well characterised ATPase inhibitor for 
DNA gyrase, resulted in a reduction in the enzyme’s rate of ATP hydrolysis 
at nanomolar concentrations (Figure 5.8). Radicicol, on the other hand, only 
showed modest inhibition at 500 µM. At concentrations below 500 µM 
radicicol appeared to stimulate the ATPase activity of GyrB in a dose-
responsive manner. This could either be a genuine activation of the 
 
Figure 5.7 Titration of radicicol with M. mazei topo VI in the agarose gel assay.  
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enzyme, or the drug interfering with linked assay in some manner. 
Reactions with GyrB and 500 µM radicicol but lacking ATP did not display 
any change in absorbance compared to similar reactions lacking radicicol. 
This showed that the compound did not affect absorbance just by being 
present.  
 Next the effect of radicicol on the ATPase activity of M. mazei topo VI 
was investigated. To establish the best concentration of enzyme to use in 
future studies a titration of topo VI from 80 to 580 nM  was performed 
 
Figure 5.8 Titrations of novobiocin and radicicol with E. coli GyrB in the ATPase 
assay. A. Sample raw data. Novobiocin titrated from 0 to 1 µM. B. Sample processed 
data. The first 15 min were excluded due to artefacts and the remaining data were 
normalised to the 15 minute data point. The slope of the control lacking ATP was 
subtracted from all data sets to eliminate any background changes in absorbance. 
The rates of ATP hydrolysis could be calculated from the gradient of the slopes. C. 
Summary of percentage inhibition for novobiocin and radicicol at the indicated 
concentrations. The percentage inhibition was calculated relative to the rate of ATP 
hydrolysis in the absence of compound. 
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(Figure 5.9 A). Although the enzyme displayed ATPase activity at all 
concentrations tested the 580 nM concentration produced the clearest 
results. As such, both novobiocin and radicicol were titrated into reactions 
containing 580 nM topo VI (Figure 5.9 B). Novobiocin had no effect on 
ATPase activity at 2 µM, whereas this concentration of drug had almost 
entirely stopped the ATPase activity of E. coli GyrB. However, radicicol 
inhibited the ATPase activity of the enzyme in a dose-responsive manner. 
From these data the IC50 of radicicol in this assay was estimated to be 
approximately 350 µM. This value was similar to that which had been 
observed in the agarose gel assay. From this it can be concluded that M. 
mazei topo VI is sensitive to radicicol (although less so that S. shibatae topo 
VI) and that radicicol inhibits the ATPase activity of the enzyme. 
5.2.3 Screening against M. mazei topo VI 
Since the previous protocol had worked well for the DNA gyrase screen it 
was duplicated exactly for the M. mazei topo VI screen (Section 4.2.1). The 
screen was conducted in duplicate over four days (Figure 5.10 and Figure 
5.11; see Section 2.8.2. for details of the protocol used). The arbitrary hit 
threshold of 25% inhibition from the previous screen was kept since the 
number of false positives generated was manageable. The nine compounds 
which exceeded this threshold were selected for further study. 
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Figure 5.9 Titrations of novobiocin and radicicol with M. mazei topo VI in the 
ATPase assay. A. Rates of ATP hydrolysis for M. mazei topo VI at 72.5, 145, 290 or 
580 nM. B. Summary of percentage inhibition for novobiocin and radicicol at the 
indicated concentrations with 580 nM M. mazei topo VI. 
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Figure 5.10 Results of M. mazei topo VI screen. A. Percentage inhibition for a duplicated screen of the Genplus library against M. 
mazei topo VI. Each bar represents the average value for a single compound screened in duplicate. The dotted line indicates the 
arbitrary hit threshold of 25% inhibition. See the Appendix for the data for individual plates. 
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Figure 5.11 Percentage inhibition for Genplus plate 6 against M. mazei topo VI with hits labelled. Percentage inhibition was 
calculated from the „no enzyme‟ and „no drug‟ controls. Error bars for the no enzyme and no drug controls were calculated from the 
standard deviation of sixteen repeats.  
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5.2.4 Elimination of false positives 
Out of the potential hits selected by the screen (Table 5.1) only m-
amsacrine had been previously reported as an inhibitor of topo VI (Bergerat 
et al, 1994), and only against the S. shibatae enzyme. All nine hits were 
tested in the agarose gel-based assay (Figure 5.12). All the compounds 
tested, except for pristimerin, inhibited M. mazei topo VI in the gel assay. 
However, two of the compounds turned out to be non-specific inhibitors: 
cetylpyridinium and merbromin. Cetylpyridinium is a cationic detergent 
which has been used to precipitate both DNA and proteins (Geck & Nasz, 
1983; Grote & Fromme, 1984), whilst merbromin is a fluorescent protein 
stain which reacts with thiol groups (Wilken et al, 2010). This contrasted to 
the DNA gyrase screen, where merbromin masqueraded as an activator by 
binding to the streptavidin coat of the plate and fluorescing. This arose from 
the fact that topo VI is a relaxing enzyme, meaning enzyme activity is 
donated by a decrease in fluorescence signal. Therefore a fluorescent drug, 
like merbromin, persisting in the wells would appear to be an inhibitor 
rather than an activator. The remaining six compounds were declared hits. 
 Two of the six compounds identified as hits were already known to be 
type IIA topoisomerase inhibitors: amsacrine and suramin. Since the latter 
had already been identified in the E. coli gyrase screen. Amsacrine is an 
antineoplastic drug which has been shown to target human topo II (Finlay 
et al, 1999; Horstmann et al, 2005). Hexylresorcinol and 9-aminoacridine 
are the two active ingredients of acrisorcin (Akrinol), a topic antifungal 
(Nierman, 1961). In addition, hexylresorcinol has been used as an oral 
antiseptic (Kraal et al, 1979) and is an active ingredient in Strepsil Extra 
False positives 
Inhibition 
(%) Novel inhibitors 
Inhibition 
(%) 
Cetylpyridinium 59 Hexylresorcinol  67 
Merbromin  40 Acrisorcin 49 
Pristimerin* 26 Suramin 44 
    Quinacrine 34 
    Amsacrine 30 
    Purpurin* 26 
Table 5.1 Summary of compounds selected by the M. mazei topo VI screen. 
Percentage inhibition of compound in screen given. 
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throat lozenges. Purpurin (1,2,4-trihydroxyanthraquinone) is a red dye and 
a member of the anthraquinone family, which includes mitoxanthrone (one 
of the hits from the E. coli gyrase screen). Quinacrine is an anti-malarial 
drug (Chauhan & Srivastava, 2001) whose target is not yet known, but has 
been shown to be a human topoisomerase II inhibitor (Preet et al, 2011)  
In the previous chapter it was shown that both quinacrine and 9-
aminoacridine were intercalators that interfered with the E. coli DNA gyrase 
screen. Intercalators decrease the twist of DNA when they bind, which is 
relieved as positive writhe. Relaxing enzymes, such as topo I and topo VI, 
can remove these positive supercoils. When the intercalator is extracted 
from the DNA the positive writhe it induces is also removed and the DNA 
ends up being negatively supercoiled rather than relaxed. This process is 
used in the production of negatively supercoiled DNA of specific superhelical 
densities (Courey, 1999). As such, intercalators may appear as inhibitors of 
topoisomerase relaxation activity when in fact they have no effect on the 
activity of the enzymes. 
Since quinacrine was of potential medical interest it was desirable to 
investigate if it was a genuine topo VI inhibitor as well as an intercalator. 
Reactions with both wheat germ topo I and M. mazei topo VI with various 
concentrations of quinacrine were carried out. These reactions were then 
run on gels with or without 1 µg/mL chloroquine to determine the relative 
supercoiling states of the DNA (Figure 5.13). Supercoiled DNA incubated 
 
Figure 5.12 Validation for putative M. mazei topo VI screen hits. Supercoiled DNA 
was incubated with 0.5 units of M. mazei topo VI to produce partial relaxation. 
Samples incubated with or without 100 µM compound. 1. Hexylresorcinol. 2. 
Cetylpyridinium. 3. Suramin. 4. Merbromin. 5. Quinacrine. 6. Amsacrine. 7. 
Purpurin. 8. Pristimerin.  
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with wheat germ topo I and 10 µM displayed apparent inhibition of enzyme 
activity. However, running these samples on the chloroquine gel revealed 
that reactions containing 100 or 1000 µM quinacrine were more tightly 
supercoiled than DNA which had not been treated with enzyme. This 
indicates that with topo I the intercalation of quinacrine is causing the 
enzyme to introduce negative supercoils into the DNA. In contrast, similar 
reactions treated with M. mazei topo VI did not display any difference in 
mobility to the control DNA. This suggested that quinacrine is a genuine 
inhibitor of M. mazei topo VI. Similar experiments were carried out with 9-
aminoacridine which produced identical results, suggesting that it too is a 
genuine inhibitor. 
  
 
Figure 5.13 Titrations of quinacrine with wheat germ topo I or M. mazei topo VI. 
Samples run on agarose gels with or without 1 µg/mL chloroquine present in the 
gel and running buffer. 
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5.2.5 Statistical evaluation of screen 
The mean fluorescent signals for the 192 negative (supercoiled plasmid, no 
enzyme) and 192 positive (relaxed plasmid with topo VI and no drug) 
controls were calculated to be 667 and 160 RFU respectively, with standard 
deviations of 33 and 18 RFU (Table 5.2). The signal-to-background ratio 
was calculated to be 4 whilst the signal-to-noise ratio was 15. From the 
control data the average Z' value for the screen was calculated to be 0.69 
(See Equation 2.2). This value indicates that there was a good degree of 
separation between the positive and negative controls, implying that data 
quality for the screen was good. The distribution of the Z' value for each 
plate around the mean (Figure 5.1) was broader than with the E. coli DNA 
gyrase screen, with plates 8 and 12 giving a Z' below 0.5 but above 0.4. 
This meant that the separation of the positive and negative controls was 
generally good, but slightly worse for these two plates. Six compounds 
detected by the screen were validated as hits, giving a hit rate of 0.63%. 
 
Table 5.2 Table of control data and Z' values per plate for the M. mazei topo VI 
screen. Averages and standard deviations are derived from 16 repeats. Standard 
deviations were also converted to percentage inhibition. 
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5.2.6 Characterisation of novel topo VI inhibitors in 
vitro 
Having identified six novel inhibitors of M. mazei topo VI this study 
progressed to explore their mechanism of action in the agarose gel assay. 
The IC50s of the compounds were determine by titrating the various 
compounds into reactions containing 1 unit topo VI (Figure 5.15, Table 5.3). 
The most potent hit was 9-aminoacridine, with an IC50 of 6 µM, whilst the 
least potent inhibitor was hexylresorcinol, with an IC50 of 40 µM. The IC50 of 
suramin was estimated to be 30 µM with M. mazei topo VI whereas it’d 
previously been shown it had an IC50 of 80 µM with E. coli DNA gyrase. 
 To test if any of the hits inhibited M. mazei topo VI by preventing the 
binding of the enzyme to DNA native gel shift assays were carried out with 
M. mazei topo VI in the presence of the screen hits (Figure 5.16). The topo 
VI-DNA complex did not seem to enter very far into the gel, which was 
probably due to the fact that the buffer used was designed for use with DNA 
gyrase. 
 
Figure 5.14 Histogram of Z' values for the M. mazei topo VI screen, with the 
average Z' value for the twelve plates indicated by the dotted line. 
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Figure 5.15 Determination of IC50s for M. mazei topo VI hits. Reactions carried out 
with 1 U topo VI. 
Compound IC50 (µM) 
9-aminoacridine 6 
Quinacrine 8 
Purpurin 25 
Amsacrine 30 
Suramin 30 
Hexylresorcinol 40 
Table 5.3 Approximate IC50s for M. mazei topo VI hits. Determined by visual 
inspection of agarose gel assay results. 
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However since it was possible to differentiate between bound and 
unbound DNA this was not considered a problem. Out of the six compounds 
both suramin and purpurin appeared to prevent the binding of topo VI to 
DNA. Since this study had previously determined that suramin had a similar 
mechanism of action with E. coli DNA gyrase it was likely this result was 
genuine, and suramin was excluded from further mechanistic tests. For the 
sample containing purpurin two faint bands part way into the gel were 
observed. This could indicate that the drug is actually causing the subunits 
of the enzyme to dissociate rather than preventing the binding of DNA 
directly. As such, these bands could signify DNA bound to topo VIA subunit 
monomers or dimers. 
 Next the hits were tested in the ATPase assay to see if they had any 
effect on the enzyme’s rate of ATP hydrolysis (Figure 5.17). Controls were 
included in which the enzyme and hit were incubated in the absence of ATP 
to account for any non-specific effects of the drug. These controls were 
used as baselines for the remaining reactions. Out of the compounds tested 
purpurin and quinacrine displayed inhibition. However, a precipitant was 
 
Figure 5.16 Native gel shift assays for the binding of M. mazei topo VI to a 147 bp 
DNA fragment in the presence of screen hits. 105 nM 147 bp and 150 nM topo VI 
used (1 pmol: 5 pmol). 1. 120 µM 9-aminoacridine. 2. 600 µM Amsacrine. 3. 800 µM 
hexylresorcinol. 4. 500 µM purpurin. 5. 160 µM quinacrine. 6. 600 µM suramin. 
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seen to form in the wells containing purpurin and no topo VI. This 
suggested that it was reacting with something in the ATPase assay mix, and 
as such its inhibition of ATPase activity is probably an artefact. Quinacrine, 
on the other hand, appeared to genuinely inhibit ATPase activity of the 
enzyme with an IC50 of ~400 µM. Hexylresorcinol appeared to increase the 
ATPase activity of the enzyme, an effect which was reproducible in several 
repeats.  
  
 
Figure 5.17 Inhibition of the ATPase activity of M. mazei topo VI by screen hits. The 
percentage inhibition was calculated relative to the rate of ATP hydrolysis of a 
control lacking drug. Radicicol was used as a positive control for inhibition. All 
compounds were tested at 500 µM with 580 nM topo VI. From left to right: 
radicicol, 9-aminoacridine, amsacrine, hexylresorcinol and purpurin. 
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Since the ATPase activity is a linked assay with pyruvate kinase it 
was desirable to investigate if hexylresorcinol and quinacrine were affecting 
the pyruvate kinase rather than topo VI. To assay pyruvate kinase activity 
reactions similar to the topo VI ATPase assays were prepared, but lacking 
topo VI. The absorbance at 340 nm was measured in the plate reader for 30 
minutes then initiated the reaction with 10 µL of various concentrations of 
ADP (Figure 5.20 A). The absorbance was measured for a further 30 
minutes. Pyruvate kinase activity was indicated by a sharp drop in 
absorbance upon ADP addition. A blank control was included into which 10 
µL of water was added instead of ADP. Data was processed similarly to the 
ATPase assays (zeroing of the slope to the background and conversion of 
absorbance into relative units). Additionally the change in absorbance for 
the blank control (which represented the change due to dilution) was 
subtracted from all samples and the data was normalised to the time point 
immediately prior to ADP addition. This was done to make the decrease in 
signal due to pyruvate kinase ability easier to compare. Since 800 µM ADP 
produced a very clear decrease this concentration was used to test the 
effects of 500 µM hexylresorcinol or quinacrine on pyruvate kinase activity 
(Figure 5.18 B). The inclusion of quinacrine in the reaction resulted in a less 
pronounced decrease in signal, indicating that the compound was inhibiting 
the pyruvate kinase activity. This suggested that the apparent inhibition of 
topo VI ATPase activity was actually due to its inhibition of pyruvate kinase. 
Hexylresorcinol, on the other hand, had no effect on pyruvate kinase 
activity. 
To exclude the possibility of hexylresorcinol hydrolysing ATP on its 
own control reactions were carried out which contained the standard 
reaction mix, ATP, and 500 µM hexylresorcinol but with no enzyme (Figure 
5.19). Since these controls revealed that the drug was not able to hydrolyse 
ATP by itself it appears that hexylresorcinol is a genuine activator of M. 
mazei topo VI ATPase activity. It may be that hexylresorcinol somehow 
uncouples the ATPase activity of the enzyme from its ability to perform 
strand passage, increasing the rate of hydrolysis whilst reducing the overall 
activity of the enzyme.  
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Figure 5.18 Pyruvate kinase assays with hexylresorcinol and quinacrine. A. 
Titration of ADP from 12.5 µM to 800 µM with pyruvate kinase. B. Percentage 
inhibition values for 500 µM hexylresorcinol or quinacrine in the presence of 800 µM 
ADP and pyruvate kinase. 
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 Finally the ability of the hits to stabilize the cleavage complex of M. 
mazei topo VI was tested. Since stabilization of the cleavage complex had 
not yet been described with this enzyme, it was necessary to carry out 
some preliminary tests. Since both the non-hydrolysable ATP analogue 
ADPNP and CaCl2 had been previously shown to stabilize the cleavage 
complexes of S. shibatae topo VI (Buhler et al, 2001) their effect on the M. 
mazei enzyme in the cleavage assay was tested (Section 2.7.2.; Figure 
5.20). Some background cleavage was seen in the absences of ATP at 240 
nM topo VI. This was likely due to the presence of some contaminant in the 
enzyme preparation. Replacing ATP with ADPNP resulted in the formation of 
a small amount of linear DNA at all concentrations tested and an increase in 
the amount of nicked DNA. A similar result was seen when MgCl2 was 
replaced by CaCl2 in the reaction buffer. However some relaxation activity 
was observed at 240 and 480 nM topo VI in the presence of CaCl2. This was 
likely due to trace amounts of magnesium being present in the enzyme 
preparation. These results contrast with the findings for the S. shibatae 
enzyme, which displayed a higher level of cleavage with both ADPNP and 
 
Figure 5.19 Activation of M. mazei topo VI ATPase activity by hexylresorcinol. 
Percentage activity is relative to the sample containing 580 nM topo VI, ATP and no 
drug. 
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CaCl2 than M. mazei topo VI. To try and improve the formation of linear 
DNA the reaction was stopped with an increased amount of SDS (2%), 170 
µM NaOH (pH 11 final), 600 µM guanidinium hydrochloride or 800 µM urea. 
None of these conditions increased ADPNP-induced cleavage of DNA by M. 
mazei topo VI. 
 As such the ability of the screen hits to stabilize the cleavage complex 
was tested by using the standard conditions for the cleavage assay (Figure 
5.21). An enzyme concentration of 50 nM was chosen since background 
cleavage would be negligible at this level. Reactions containing enzyme 
were incubated with 0, 1, 10, 100 or 1000 µM compound to test for 
cleavage-complex stabilization. To test if the compounds had any intrinsic 
DNA cleavage activity control reactions were included containing pNO1 and 
the highest concentration of each drug tested with no enzyme. To establish 
the level of background cleavage a control was included containing topo VI 
in the standard reaction buffer but lacking ATP. As a positive control for 
cleavage a reaction was included containing topo VI and 1 mM ADPNP. No 
increase was observed in DNA cleavage above the background with any of 
the compounds, which suggests that none of the compounds tested stabilize 
the cleavage complex. However, the level of cleavage observed in the 
 
Figure 5.20 Testing cleavage conditions with M. mazei topo VI. A. Titrations of topo 
VI in standard relaxation buffer with or without 1 mM ATP or ADPNP. B. Titrations 
of topo VI in standard relaxation buffer with or without 10 mM MgCl2 or CaCl2. 
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positive control containing ADPNP was very low when compared to similar 
experiments with E. coli DNA gyrase (Figure 4.11). This low level of 
cleavage in the positive control and the presence of some background 
cleavage in the absence of ATP made it difficult to definitively conclude 
much from these experiments. These results were reproducible and were 
observed with two independent batches of enzyme. Since the AFM data had 
shown that topo VI remained bound to the DNA despite proteinase K 
digestion, this may indicate that the enzyme-DNA complex is both resistant 
to proteinase digestion and very stable. 
5.2.7 Cross-reactivity of M. mazei topo VI and E. coli 
DNA gyrase hits 
Since some compounds, such as suramin, were hits in both the E. coli DNA 
gyrase and M. mazei topo VI screens it was decided to cross-test the hits 
from the two screens. By doing this it was hoped that some compounds 
 
Figure 5.21 Cleavage complex stabilization assays with M. mazei topo VI hits. 
Reactions carried out in topo VI relaxation buffer with or without 1 mM ATP or 
ADPNP. Controls with: 1000 µM amsacrine, quinacrine, 9-aminoacridine, 
hexylresorcinol or purpurin; SC pNO1 and no enzyme included to check for intrinsic 
cleavage activity of drugs. 
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which had been a false negative in one screen but a hit in the other, and to 
get an idea of the selectivity of the inhibitors. This study has already shown 
that suramin was a common inhibitor of both E. coli gyrase and M. mazei 
topo VI, and whilst quinacrine and 9-aminoacridine inhibited topo VI activity 
they acted as stimulators of DNA gyrase. The remaining two topo VI hits, 
hexylresorcinol and purpurin, did not display any ability to inhibit 0.5 U of 
DNA gyrase in the agarose gel assay at 100 µM. 
 Testing the DNA gyrase screen hit mitoxanthrone against M. mazei 
topo VI in the gel assay revealed that it was also a potent inhibitor of topo 
VI with an IC50 of 1.5 µM, meaning it was a false negative in the topo VI 
 
Figure 5.22 Mitoxanthrone as an inhibitor of M. mazei topo VI. A. Titration of 
mitoxanthrone in the gel assay with 1 unit topo VI. B. Testing the effect of 
mitoxanthrone on the binding of supercoiled pNO1 in the microtitre plate assay. 
Supercoiled plasmid was incubated in the absence or presence of 100 µM 
mitoxanthrone. The error bars are the standard deviation of three repeats. 
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screen (Figure 5.22). Previously this study has shown that its IC50 against E. 
coli gyrase was 12 µM, meaning mitoxanthrone was approximately four 
times more potent against topo VI. This raised the question of why it had 
not been picked up as a hit in the topo VI screen. Since mitoxanthrone was 
known to be an intercalator it was suspected it was able to interfere with 
DNA triplex formation. To test this hypothesis 100 µM mitoxanthrone was 
incubated with supercoiled pNO1 under standard microtitre plate-assay 
conditions. The presence of the drug caused a substantial decrease in 
signal, suggesting it was preventing the formation of DNA triplexes. Since 
topo VI relaxation activity is indicated by a decrease in signal in the assay 
the drop in signal due to the interference of mitoxanthrone could mask the 
drugs inhibitory potential. This would explain why mitoxanthrone was 
missed in the topo VI screen. As such, it was included as a hit in all further 
experiments. 
5.2.8 Inhibition of S. shibatae topo VI by the M. 
mazei topo VI hits. 
Since it had proved difficult to achieve clear results for cleavage complex 
stabilization of M. mazei topo VI by the screen hits it was decided to test 
them against the Sulfolobus shibatae enzyme. Cleavage complex 
stabilization with S. shibatae topo VI by ADPNP and CaCl2 has been 
demonstrated previously.. The S. shibatae topo VI for these experiments 
was kindly provided by Danielle Gadelle (University of Paris XI, Orsay). 
 Initial experiments focused on testing for inhibition of S. shibatae 
topo VI by the screen hits at 10 or 100 µM compound (Figure 5.23 A). 
Neither hexylresorcinol nor suramin showed any inhibitory activity against 
the enzyme at 100 µM. Amsacrine showed partial inhibition at 100 µM, 
suggesting its IC50 was around this concentration. 9-aminoacridine, purpurin 
and quinacrine all displayed strong inhibition at 100 µM but no inhibition at 
10 µM, suggesting their IC50s lay between these concentrations. 
Mitoxanthrone, on the other hand, showed complete inhibition at 10 µM. 
 The compounds which were inhibitors of S. shibatae topo VI were 
then tested in the cleavage assay at concentrations which were predicted to 
give complete inhibition (Figure 5.23 B). ADPNP was used as a positive 
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control for cleavage complex stabilization and showed a good level of 
cleavage. However no induction of cleavage by any of the screen hits was 
observed. 
 To test if any of the inhibitors operated by preventing the cleavage of 
DNA by S. shibatae topo VI, cleavage assays were carried out in the 
presence of ADPNP with or without the compounds (Figure 5.24). A 
reduction in intensity of the linear band would indicate the drug was able to 
prevent ADPNP-induced cleavage of the DNA by topo VI. All five compounds 
displayed a marked ability to reduce the amount of cleavage, suggesting 
either they were preventing the binding of ADPNP or stopping the enzyme 
cleaving DNA. This was expected for purpurin, which was shown in earlier 
experiments to prevent the binding of M. mazei topo VI to DNA but was 
surprising for the other compounds, none of which had shown any ability to 
affect DNA binding. It may be that these compounds are capable of 
preventing cleavage of DNA by topo VI directly. 
 
Figure 5.23 Testing M. mazei topo VI hits against S. shibatae topo VI. A. 9-
aminoacridine, amsacrine, hexylresorcinol, purpurin, mitoxanthrone, suramin and 
quinacrine tested for inhibition of S. shibatae topo VI relaxation activity. B. Testing 
for cleavage complex stabilization by S. shibatae topo VI inhibitors. A positive 
control for cleavage complex formation was included which contained 1 mM ADPNP 
instead of ATP. The compounds were tested at the following concentrations: 50 µM 
9-aminoacridine, 500 µM amsacrine, 20 µM mitoxanthrone, 200 µM purpurin and 
200 µM quinacrine. 
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5.2.9 Testing against Arabidopsis topo VI in vivo 
Despite years of trying Arabidopsis topo VI has not been expressed in a 
soluble form by our lab nor has its soluble expression been reported in the 
literature. However, knock-out mutants for topo VI in Arabidopsis have 
been shown to have a very clear “dwarf” phenotype. This arises from the 
fact topo VI is involved in the process of endoreduplication in plants, which 
is in turn linked to cell expansion. As such plants lacking topo VI are 
generally smaller than wild-type plants and have reduced cell size and 
ploidy (chromosome count). It is therefore possible to assay for compounds 
that inhibit Arabidopsis topo VI in vivo by looking for the induction of these 
characteristics. 
 As such, the ability of the hits from the M. mazei topo VI screen to 
inhibit the growth of Arabidopsis columbia seedlings in a hypocotyl 
extension assay was tested (Section 2.4.3). Arabidopsis seeds were sowed 
onto square Petri dishes containing MS agar with or without 100 µM hit 
compound and grew the plants vertically in the dark for 5 days. During this 
time the plant hypocotyls extend along the surface of the agar. It was then 
possible to measure the length of each seedling using a light microscope 
and calculate an average length for plants grown in the presence of each 
 
Figure 5.24 Cleavage protection assay for screen hits with S. shibatae topo VI. 0.5 
units of S. shibatae topo VI was incubated with 1 mM ADPNP in the absence or 
presence of: 50 µM 9-aminoacridine, 500 µM m-amsacrine, 20 µM mitoxanthrone, 
200 µM purpurin or 200 µM quinacrine. 
 Chapter 5 
 
  146 
 
compound. Out of the six hits tested (mitoxanthrone was not included in 
these experiments since it had not been shown it was a topo VI inhibitor at 
this point) only hexylresorcinol displayed any effect on plant growth, 
completely preventing seed germination at 100 µM.  
To explore this further the ability of hexylresorcinol to inhibit plant 
growth was tested at a range of concentrations. For each concentration the 
average plant length and the percentage of seeds which had germinated 
was calculated (Table 5.4, Figure 5.25). It was observed that the number of 
seeds germinated remained constant up to 50 µM hexylresorcinol, whilst the 
average length of the seedlings dropped rapidly. At 80 µM germination was 
reduced, whilst no seeds germinated at 100 µM. 
 
 
Table 5.4 Table of compiled data from Arabidopsis hypocotyl assays with 
hexylresorcinol. All seedlings were grown for 5 days in the dark. A seedling was 
classified as having germinated if the petioles or roots had emerged from the seed 
casing after this time. 
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 Although seedlings germinated at 50 µM the plants were too small to 
discern any differences in morphology. As such further studies were focused 
on plants grown on 40 µM hexylresorcinol. A closer examination of the 
Arabidopsis seedlings grown in the presence of this concentration of drug 
reveal a range of responses to the compound (Figure 5.26). Although the 
average hypocotyl length was considerably reduced a few plants appeared 
to be unaffected by the drug, reaching similar hypocotyl lengths as plants 
grown in the absence of compound. Out of the shorter plants some 
 
Figure 5.25 Inhibition of Arabidopsis hypocotyl extension by hexylresorcinol. All 
plants were grown for 5 days in the dark. A. Percentage germination of seedlings 
grown on 20, 30, 40 50, 80 or 100 µM hexylresorcinol. B. Average length of 
seedlings grown on 20, 30, 40 50, 80 or 100 µM hexylresorcinol. Error bars 
represent the standard deviation of the samples. 
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appeared to have normal morphology (apart from their reduced size) whilst 
others were very short with fatter hypocotyls, the latter of which matched 
the description of topo VI knock-out mutants. These plants were therefore 
designated as having “dwarf” morphology. 
 Plants grown on 40 µM hexylresorcinol were allowed to mature into a 
rosette (Figure 5.27). Plants were grown on MS salts agar with or without 
40 µM hexylresorcinol in a 22°C growth cabinet under a 16 hr day for 3 
weeks. Although the majority of the seeds germinated, only seven of the 32 
plants were able to develop into a rosette. All seven of these plants 
appeared pale, yellowish and slightly transparent compared to control 
plants grown without drug. Some of the plants (plants 1 and 6) displayed 
 
Figure 5.26 Sample Arabidopsis seedlings from hypocotyl assay grown on 40 µM 
hexylresorcinol. The plants were grown for 5 days in the dark in the absence or 
presence of 40 µM hexylresorcinol. Some plants grown on hexylresorcinol grew 
shorter than the control but displayed normal morphology (centre), whilst others 
exhibited “dwarf” morphology (right). The photo of “dwarf” plant taken with 
smaller scale to the other two plants. 
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normal morphology and were close to the control in size. One plant (plant 
3) displayed normal morphology, but was greatly reduced in size suggesting 
its growth was slowed. The remaining plants (plants 2, 4, 5 and 7), which 
had displayed the “dwarf” morphology whilst they were hypocotyls, were 
very small with shortened leaf stems. Some of these plants (such as plants 
5 and 7) had a trace of red pigmentation. 
  
 
Figure 5.27 Light-grown Arabidopsis grown on 40 µM hexylresorcinol. The plants 
were grown horizontally for 3 weeks under a 16 hr day. A control plate which did 
not contain the compound was also included. Photos at a higher magnification were 
taken of plants displaying different morphologies. Plants 2, 5 and 7 displayed the 
“dwarf” morphology, whilst plants 1 and 6 were similar to the control in 
appearance. Plants 3 and 4 appeared intermediate in morphology. All 
hexylresorcinol-grown plants appeared somewhat transparent compared to the 
control plants. 
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 To see if the effects of hexylresorcinol were reversible, plants which 
had been grown on 40 µM hexylresorcinol for three weeks were taken and 
transplanted them to a fresh MS salts agar plate with no drug. The plants 
were then grown for a further two weeks (Figure 5.28). Plants which had 
 
Figure 5.28 Recovery of hexylresorcinol fed Arabidopsis plants. The plants were 
grown for 3 weeks on 40 µM hexylresorcinol under a 16 hr day. They were then 
transferred to a fresh agar plate lacking hexylresorcinol and grown for a further 2 
weeks in order to recover. Higher magnification photos of the three plants which 
recovered provided (from above and the side). Plant 1 exhibited “dwarf” 
morphology prior to recovery. Plant 2 displayed normal morphology, reduced size 
and slight transparency prior to recovery. Plant 3 displayed normal morphology, 
normal size and slight transparency prior to recovery. 
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failed to develop into rosettes on the hexylresorcinol containing agar were 
still unable to mature, suggesting that these plants had died. All the plants 
which were able to form rosettes lost the paleness and transparency 
observed whilst they were growing on hexylresorcinol containing media. 
Plants which had exhibited normal morphology and either normal size (plant 
3) or reduced size (plant 2) displayed notable recovery with both plants 
growing to roughly the same size. This suggests that hexylresorcinol had 
been slowing the growth of plant 2 rather than altering its morphology. 
Patches of necrotic tissue was also observed on some of their leaves, which 
in extreme cases caused entire leaves to become white and shrivelled. This 
is likely due to the plants sequestering the drug in those leaves in order to 
purge the compound from its system. The plant which had displayed the 
“dwarf” morphology whilst grown on the media containing hexylresorcinol 
remained considerably smaller than the other plants (roughly half the size) 
although it possessed a similar number of leaves which suggested it was at 
the same stage of development to them. It also did not appear to have any 
necrotic tissue like the other two plants. This may indicate that the “dwarf” 
plant was susceptible to the hexylresorcinol since it was unable to 
effectively sequester the compound at this concentration. 
 To see if the reduction of size in the “dwarf” plants was due to a 
reduction in cell size, rather than a reduction in the number of cells, Cyro- 
Scanning Electron Microscopy (SEM) was conducted on Arabidopsis 
hypocotyls grown for 5 days in the dark (section 2.4.5). It was observed 
that the hypocotyls of control seedlings grown without hexylresorcinol were 
comprised of cells ~300 µm in length (Figure 5.29A). Seedlings which 
possessed normal morphology when grown on 40 µM hexylresorcinol had 
cell lengths very similar to the control (Figure 5.29B). In contrast, seedlings 
which displayed the “dwarf” morphology had drastically reduced cell sizes of 
~50 µm (Figure 5.29 C). These results suggested that the “dwarf” plants 
reduced size was due to a reduction in cell size rather than number, an 
observation consistent with the hypothesis hexylresorcinol targets topo VI in 
the plants. 
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Figure 5.29 SEM images of Arabidopsis seedling hypocotyls grown on 
hexylresorcinol. Single cell highlighted in blue for each image. A. Control seedling 
which was not grown with the compound. B. Seedling grown on 40 µM 
hexylresorcinol that did not display the “dwarf” morphology. C. Seedling grown on 
40 µM hexylresorcinol that did display the “dwarf” morphology.  
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 To examine if there was any difference in ploidy between seedlings 
grown on hexylresorcinol and those which were not flow cytometry was 
conducted on 3 week-old plants grown at 22°C under a 16 hr day on MS 
salts media with or without 30, 40 or 50 µM hexylresorcinol (Section 2.4.4, 
Figure 5.30). For 40 µM seedlings displaying the “dwarf” morphology were 
tested separately to those which did not. Ploidy counts were taken for two 
plants of each concentration or morphology. The counts attributable to each 
ploidy peak were converted into a percentage of the overall counts obtained 
in order to ease comparison between samples. Finally, the values for the 
two duplicates were averaged. Very similar peak distributions were 
 
Figure 5.30 Flow cytometry of Arabidopsis plants grown on hexylresorcinol. The 
plants were grown horizontally for 3 weeks under a 16 hr day. Readings were 
taken in duplicate. Plants grown on 40 µM hexylresorcinol displaying the “dwarf” 
morphology were tested separately from those displaying normal morphology at 
that concentration.  
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observed for plants grown on 0, 30 and 50 µM hexylresorcinol, as well as 
plants grown on 40 µM which did not display the “dwarf” morphology. 
However, those grown at 40 µM which did display the “dwarf” morphology 
showed a skewed distribution with a decrease in the number of counts 
attributable to the 4n and 8n peaks, and a increase in counts attributable to 
the 2n peak. This reduction in ploidy for these plants suggests that they 
also have a reduction in their levels of endoreduplication. This provides 
further circumstantial evidence that hexylresorcinol is targeting topo VI in 
the Arabidopsis plant. 
5.2.10 Expression trials with P. falciparum topo VI 
Previous studies have identified that the malaria causing protozoa 
Plasmodium falciparum possesses genes homologous to both topo VI 
subunits in its genome (Aravind et al, 2003). Two homologues of the A 
subunit were identified whilst only one was found for the B subunit: PfT6A1 
(PF10_0412), PfT6A2 (PFL0825c) and PfT6B (MAL13P1.328). P. falciparum 
undergoes a process called schizogony as part of its life cycle, which has 
similarities to endoreduplication in plants. As such it made sense that P. 
falciparum would have a topo VI. A cursory examination using BLAST and 
online genomics databases (Table 5.5) revealed that two other protozoa 
which underwent schizogony also possessed homologues to the B subunit 
whereas Toxoplasma gondii, which does not undergo schizogony, did not. In 
addition quinacrine, one of the hits from the M. mazei topo VI screen, is an 
anti-malarial drug with an as of yet unknown mode of action. 
 
Table 5.5 BLAST search results for the putative P. falciparum topo VI B subunit in various 
protozoa. Homologues were found in the two parasites which underwent schizogony. The 
databases were last visited on 09/08/11. 
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 As such expression of the hypothetical P. falciparum topo VI subunits 
was attempted with the view to test the hits from the M. mazei screen 
against it. All three genes were commercially synthesised in a form codon 
optimized for E. coli expression (Geneart) and cloned into the pEt-28a (+) 
expression vector (Figure 5.31). pEt-28a (+) was chosen because it codes 
for an N-terminal His-tag which would ease purification. After a 
conversation with our collaborators Prof. Patrick Forterre and Daniele 
Gadelle (University of Paris XI, Orsey), who had independently drawn the 
same conclusions as ourselves, we decided that we should focus our efforts 
on expressing the A subunits. As such expression of PfT6A1 and A2 in 
various E. coli strains (BL21, Rosetta, Rosetta 2 and Codon Plus) was 
attempted with induction at an OD600 of 0.6. Since no expression was 
observed, a method for the expression of plasmodium proteins in E. coli 
from the literature was attempted where induction is carried out at an OD600 
of 2 (Flick et al, 2004). Using this method strong expression was achieved, 
but the protein appeared to be entirely insoluble (Figure 5.32). Growing the 
 
Figure 5.31 Cloning strategy for expression of P. falciparum topo VI A1 in E. coli. An 
identical strategy was followed for PfT6A2. A. PfT6A1 in pMA-T vector, as provided 
by Geneart. B. PfT6A1 excised by double digest with NdeI and XhoI. C. PfT6A1 
ligated into pET-28a(+). 
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bacteria in Auto Induction Media (AIM) produced identical results. Although 
there appeared to be a faint band present at the correct molecular weight 
for the soluble extract this was confirmed by MALDI mass spectrometry (Dr 
Mike Naldrett and Dr Gerhard Saalbach, JIC Proteomics Facility, Norwich) to 
not be the correct protein. 
 Since achieved soluble expression had not been achieved with the E. 
coli system expression of PfT6A1, A2 and B in a baculovirus-insect cell 
system was attempted (Section 2.6.5). Meanwhile, our collaborators in Paris 
would continue attempting expression in E. coli. PCR was used to add 
restriction sites (EcoRI and SphI for PfT6A1/2, or BamHI and SpeI for 
PfT6B) to the ends of the genes which were compatible with one of the two 
cloning nests in the pFastBac-Duel baculovirus expression vector (Figure 
5.34 A). The initial cloning strategy adopted also contained a step in which 
the initial PCR fragment was blunt ligated into the Zero Blunt TOPO 
expression vector (Invitrogen) to allow for proliferation of the fragment and 
to ease later cloning. However, since the vector contained cutting sites for 
the restriction enzymes a confusing combination of fragments was 
produced. As such the strategy was re-designed to omit the Zero Blunt 
TOPO vector step, with the initial PCR fragment being directly ligated into 
pFastBac-Duel (Figure 5.33). The presence of the correct fragment in the 
 
Figure 5.32 Expression of P. falciparum topo VI A1 and A2 in E. coli. Expression in 
the Codon Plus E. coli strain either carried out in LB media (induced at an OD600 of 
2) or in Auto Induction Media (overnight). Marker (M), Non-induced (N), Whole-
cell (W), Soluble (S) or Insoluble (I) samples run on acrylamide gels. Both PfT6A1 
and A2 have a molecular weight of 40 kDA. 
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vector was confirmed by double digesting with the relevant restriction 
enzymes (Figure 5.34 B). 
The plasmids were then transformed into E. coli strain DH10Bac 
containing a bMON14272 baculovirus shuttle vector (bacmid) and a 
transposition helper plasmid (pMON7124). After transformation Tn7 
transposition occurs, transferring the gene of interest into the bacmid. Since 
the bacmid contained pUC/M13 forward and reverse primers either side of 
the transposition site the presence of the genes in the bacmid by PCR was 
confirmed with different combinations of pUC/M13 and gene-specific 
primers (Figure 5.35). These reactions resulted with fragments of the 
expected sizes, with the exception of the combination of the PfT6B reverse 
primer and the pUC/M13 forward primer. Sequencing (The Genome Analysis 
Centre, Norwich) of the genes in the pMFastBac-Duel vector revealed that a  
 
Figure 5.33 Cloning strategy for baculovirus expression of P. falciparum topo VI A1. 
Similar strategies were carried out for PfT6A2 and PfT6B, with EcoRI and SphI 
being replaced by BamHI and SpeI for PfT6B. A. The synthesised genes were 
provided by Geneart in the pMA-T vector. B. Appropriate restriction sites were 
added to the genes via PCR and linear fragments gel purified. C. The genes were 
ligated into a modified version of the bacmid transfer vector pFASTBAC-Duel 
containing a EcoRI restriction site in the P10 cloning nest. PfT6A1 and PfT6A2 were 
put under the control of the P10 promoter (Pp10) whereas Pft6B was ligated into 
the site controlled by the polyhedral promoter (Pph). 
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Figure 5.34 Cloning of P. falciparum genes for baculovirus expression. A. PCR 
products from pMA-T vectors containing the genes of interest. The primers were 
designed to add EcoRI and SphI cut sites to the 5' and 3' ends respectively of 
PfT6A1 and A2. The primers for PfT6B were designed to add BamHI and SpeI sites 
to the genes 5' and 3' ends. B. Double restriction digest of pMFastBac-Duel vectors 
containing the genes of interest with the appropriate restriction enzymes. 
 
Figure 5.35 PCR analysis of bacmids containing P. falciparum topo VI genes. A. PCR 
reactions with bacmids and various primers. A 1 kb ladder (M) was included in all 
gels. The PCR reactions were carried out a constant annealing temperature of 55°C 
with a combination of either pUC/M13 forward (M13-F) or pUC/M13 reverse (M13-
R) primer with the relevant forward (F) or reverse (R) primer for the gene to be 
analysed. B. Cartoon of the genes in the bacmid with the expected sizes for 
products with various primer pairs. Both PfT6A1 and A2 are approximately 1 kb in 
length, whilst PfT6B is ~1.7 kb. 
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point deletion had resulted in an 86 amino acid truncation on the C-
terminus of PfT6B, which explained why the PCR using the PfT6B reverse 
primer failed. Strangely, the reaction using the PfT6B forward and reverse 
primers produced a fragment of approximately the correct size.  
Regardless, expression trials proceeded with all three genes and used 
the bacmids to transfect surface grown SF21 insect cells. After 72 hr the P1 
virus which had been released into the media was collected and used it to 
infect fresh cells with a multiplicity of infection (MOI) of approximately 0.5. 
The viral titre was estimated as per the guidelines from Invitrogen. After 
another 72 hr the virus released in the media was again harvested to obtain 
the P2 viral stocks. These stocks were then used in expression trials. The 
initial expression trials were carried out at a MOI of approximately 3, again 
estimated from the Invitrogen guidelines (Figure 5.36). The cells were 
harvested after 48, 72 or 96 hrs and analysed by acrylamide gel 
electrophoresis. No expression was observed with any of the genes at any 
of the time points tested. This process was repeated with a second 
preparation of bacmids, but expression was still not observed. Since time 
was running short, the remaining trials were focused primarily on the most 
likely candidate of the two A subunits: PfT6A1. One of the troubleshooting 
suggestions from Invitrogen was that if the viral titre of the P1 virus used to 
generate the P2 virus was too high deleterious mutations could accumulate 
 
Figure 5.36 Initial time course baculovirus expression of P. falciparum topo VI 
genes. Non-infected (N) and cells infected with transgenic P2 virus containing the 
PfT6A1 (A1), PfT6A2 (A2) or PfT6B (B) genes harvested after the indicated time 
point. The multiplicity of infection was approximately 3, as calculated from 
Invitrogen estimates. 
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and prevent expression. As such P2 viral stocks were prepared from P1 
virus diluted 1:10, 1:100 or 1:1000 and used them to infect fresh cells 
(Figure 5.37). Since it was not possible to estimate the viral titre 1x 106 
cells were infected with 200 µL of virus. The cells were then harvested after 
34, 72 or 96 hr. In addition some cells were infected using thePfT6B P2 
virus from a previous expression for comparison. No expression of PfT6A1 
was observed, but surprisingly expression of a band the right size for PfT6B 
was seen. Unfortunately the PfT6B produced was likely in a truncated form, 
(as previously indicated by sequencing and PCR analysis) and there was no 
time to pursue this work further. 
  
 
Figure 5.37 Expression of PfT6A1 and PfT6B in the baculovirus system. Either 1 or 
10 µL of each sample was loaded onto the gel. The PfT6A1 P2 virus used was 
generated with either a 1:10, 1:100 or 1:1000 dilution of the P1 viral stock. The 
cells were harvested at the time point indicated. 
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5.2.11 Activities of anti-malarial compounds 
against M. mazei topo VI 
Since quinacrine was one of the hits from the M. mazei topo VI screen, and 
is an anti-malarial (Chauhan & Srivastava, 2001) of unknown mechanism it 
was decided to test other related anti-malarial compounds against the 
enzymes which were available in our lab. Reactions containing 0.5 units M. 
mazei topo VI with 100 µM chloroquine, mefloquine, primaquine, quinacrine 
or quinolone were prepared. Out of these compounds only quinacrine 
produced inhibition, although there may have been a very low level of 
inhibition from chloroquine. As such we were interested in investigating 
compounds related to quinacrine. Dr Mark Thompson (University of 
Sheffield) has previously generated a range of thiazole compounds derived 
from quinacrine (Thompson et al, 2011) which showed varying potency 
against the malaria parasite (Figure 5.39). Dr Thompson provided a 
selection of these compounds as well as a collection of β-carboline 
compounds designed for anti-malarial activity (paper under review at the 
time of writing; structures not disclosed). Unfortunately none of the 
compounds tested had any effect on the activity of 1 unit of M. mazei topo 
VI (Figure 5.40). 
 
Figure 5.38 M. mazei topo VI with various anti-malarial compounds. All compounds 
tested at 100 µM. 
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β-Carboline compounds   
 
1. MT-IC16 
2. MT-IC41 
3. MT-IC43 
4. MT-IC46 
5. MT-IC47 
6. MT-IC48 
7. MT-IC49 
8. MT-IC52 
  
 
 
Figure 5.39 Structures of experimental anti-malarial compounds. All compounds 
were purified to >95% by HPLC, except 13. whose purity was unable to be 
determined due to an unusual interaction with the column. The structures in this 
image were kindly provided by Dr Mark Thompson. 
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5.3 Discussion 
5.3.1 M. mazei topo VI ATPase activity and DNA 
cleavage 
In this work the biochemical properties of M. mazei topo VI have been 
explored, as well as confirming some expected ones based on the work 
previously carried out on S. shibatae topo VI. Several basic facts about the 
enzyme have be validated, including the necessity of ATP and Mg2+ for the 
relaxation activity of the enzyme. It has also been demonstratedthat  M. 
mazei topo VI could be inhibited by radicicol, but with a two-fold greater 
IC50 than that reported for S. shibatae topo VI. With an IC50 value of around 
400 µM, radicicol is a very poor inhibitor of M. mazei topo VI. Furthermore 
radicicol has been demonstrated to inhibit the ATPase activity of the 
enzyme with an IC50 close to that in the gel assay, indicating this was its 
likely mode of action. In contrast the DNA gyrase ATPase inhibitor 
novobiocin had no effect on the activity of the enzyme, similar to that which 
has been observed with the S. shibatae enzyme. 
Stabilization of the cleavage complex by M. mazei topo VI with 
ADPNP or Ca2+ proved difficult. A very slight increase in linear DNA over the 
background could be observed which was likely attributable to contaminants 
in the enzyme preparation, but this was less than that which DNA gyrase or 
S. shibatae topo VI produced under similar conditions. It is possible that M. 
 
Figure 5.40 Testing putative anti-malarial compounds against M. mazei topo VI. 
Various β-carboline and thiazole derivatives were tested for their ability to inhibit 
topo VI at 100 µM. The numbering of compounds is as in Figure 5.39. 
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mazei topo VI does not bind ADPNP very well, which would account for the 
low level of cleavage in that control. Trying different ATP analogues may 
yield better results. However, a lack of compatibility with ADPNP does not 
explain the low amount of cleavage seen with Ca2+. 
The AFM images revealed that M. mazei topo VI appeared to remain 
on the DNA even after SDS-proteinase K digest and phenol-chloroform 
extraction. This may indicate that M. mazei topo VI is resistant to 
proteinase K digestion, and that the interactions holding the enzyme-DNA 
cleavage complex are strong enough to remain associated despite exposure 
to SDS and phenol. This would make sense in light of the fact that, unlike 
type IIA topoisomerases, the A subunit of topo VI lacks a C-terminal exit 
gate. It has been suggested that the primary function of this C-terminal 
gate is to hold the complex together during DNA-gate opening in order to 
prevent disassociation and the formation of double-strand breaks (Bates et 
al, 2011; Stuchinskaya et al, 2009). The lack of this additional interface in 
topo VI may be compensated for by an increase in the strength of subunit 
association. This is supported by the fact that both topo VI enzymes to date 
can only be produced in a soluble, active form when the two subunits are 
co-expressed. Furthermore the subunits remain bound together on a His-
trap column even when exposed to elution buffers containing 2 M NaCl, 
10% PEG or nothing but water. This implies that the interactions within the 
topo VI complex are very strong. It was possible to observe ADPNP-induced 
cleavage of DNA by S. shibatae topo VI, but the thermophilic nature of the 
enzyme makes drawing comparisons difficult. It could be that only the M. 
mazei orthologue of the enzyme is resistant to proteinase K digestion. It 
may be possible to reveal the cleavage complex of M. mazei topo VI by 
using a more aggressive proteinase.  
5.3.2 Unusual topoisomers produced by M. mazei 
topo VI 
Perhaps the most unusual observation made about the biochemistry of M. 
mazei topo VI was the formation of unexplained bands at high 
concentrations of the enzyme. This banding pattern was distinct from that 
of partial activity, with certain bands becoming more prominent than others, 
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suggesting that the enzyme was not self-inhibiting at these high 
concentrations. Furthermore, the formation of this pattern was observed 
with both relaxed and supercoiled DNA which eliminates the potential of 
auto-inhibition. By carrying out time-course reactions it was observed that 
the strange banding never appeared below a certain concentration of 
enzyme despite extended reaction times. This suggested that the DNA 
topoisomers these bands represent are not the standard end product for the 
topo VI reaction, and may require some distortion of the DNA brought about 
by the presence of multiple enzymes on a single DNA molecule to be 
produced. They were not abolished by carrying out an SDS/proteinase K 
digest which appeared to show that they were not due to enzyme remaining 
bound to the DNA whilst it was being run on the gel. 
Although some cleavage activity attributable to contamination was 
observed in the absence of ATP the formation of this banding pattern was 
largely ATP-dependent, indicating it was an activity of the enzyme rather 
than a contaminant. The bands shifted slightly when run on an agarose gel 
containing chloroquine, which suggested that they were still closed-circular 
and not linear DNA fragments. In addition the bands could not be converted 
back to the standard relaxed form by wheat germ topo I and were not 
converted to a single open circle band by the nicking endonuclease Nb.BstI. 
These data show that these bands cannot be explained as negatively or 
positively supercoiled DNA. It is possible that they might represent the 
formation of DNA knots, which would not be resolvable by either topo I or 
Nb.BstI. How the enzyme would introduce knots under these conditions is 
unclear, although it may be that a large number of enzyme molecules 
present on a single plasmid may cause the DNA to distort in such a way to 
permit knotting. 
However the AFM images of DNA treated with high concentrations of 
M. mazei topo VI do not appear to support this hypothesis, since no knotted 
structures were definitively observed. Rather, the DNA appeared condensed 
and with a plectonemic appearance. Some molecules appeared highly 
decorated with enzyme molecules, suggesting that the protein was resistant 
to proteinase digestion. This was interesting, since the bands did not appear 
when enzyme was incubated with DNA in the absence of ATP and native gel 
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shift assays have shown that the enzyme does bind DNA in the absence of 
ATP. Since their formation is ATP dependent, they could represent cleavage 
complexes of the topo VI with DNA trapped by the SDS treatment. This 
makes sense in light of our failure to stabilize the M. mazei topo VI cleavage 
complex with ADPNP or the inhibitors from the screen.  
5.3.3 Performance of the screen 
The quality of data for the screen against M. mazei topo VI remained high, 
with an average Z' value of 0.69. This figure was close to that which was 
previous calculated for the DNA gyrase screen. However, looking at the Z' 
factor for individual plates revealed there was a broader distribution for the 
M. mazei screen with two reaction plates having Z' less than 0.5 (plates 9 
and 12, with Z' = 0.44 and 0.46 respectively). This indicates that the data 
for these two plates were of marginally poorer quality than the rest of the 
screen, although still of an acceptable standard. There were no obvious 
patterns to the data; however it was observed again that most compounds 
showed some inhibition or activation activity. On some plates (such as 2, 4, 
8 and 11) the majority of the compounds showed a low level of inhibition 
whilst other plates (such as 10 and 12) showed a low level of activation. 
The remaining plates did not have a bias either way. These variations were 
likely the result of day-to-day or run-to-run variations of the screening 
process. Nine compounds gave percentage inhibitions values above the 
25% threshold, with six being confirmed as hits. Of these only m-amsacrine 
had been previously reported as an inhibitor of S. shibatae topo VI 
(Bergerat et al, 1994), giving a novel hit rate of 0.52%. 
5.3.4 Novel inhibitors of M. mazei topo VI 
Out of the nine compounds selected by the screen six were validated as hits 
in the gel assay. None of these compounds had been previously shown to 
inhibit M. mazei topo VI and only m-amsacrine had been shown to inhibit S. 
shibatae topo VI (Bergerat et al, 1994).The hits from the screen came 
predominately from two classes of compound: the acridines and 
anthraquinones (Figure 5.41). Members of both these classes have been 
described as topoisomerase inhibitors (including amsacrine and 
mitoxanthrone). 
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Two of the hits, quinacrine and 9-aminoacridine, were also 
intercalators. DNA relaxation in the presence of intercalators causes 
negative supercoils to be introduced rather than removed. To prove that 
these compounds were genuine inhibitors, relaxation reactions were carried 
out with either M. mazei topo VI or wheat germ topo I (a type I 
topoisomerase with a different mechanism), and various concentrations of 
the two drugs. The relaxation activity of both enzymes appeared to be 
reduced by the drugs. However, when the samples were run on agarose 
 
Figure 5.41 Structures of M. mazei topo VI screen hits. 
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gels containing the weak intercalator chloroquine it was revealed that the 
samples containing topo I and either quinacrine or 9-aminoacridine had 
become more tightly supercoiled than the substrate DNA. In contrast the 
samples which contained M. mazei topo VI and either drug did not display 
this tightening, which indicated that the enzyme was genuinely being 
inhibited. A clearer experiment would have been to repeat the experiment 
but with relaxed DNA as a substrate. With this setup wheat germ topo I 
would start supercoiling the DNA when a certain concentration of drug was 
reached (around 100 µM from our data) whereas M. mazei topo VI would 
not. 
 Having verified that the all six hits were genuine experiments were 
carried out to determine their IC50s. The two most potent inhibitors were 9-
aminoacridine and quinacrine with IC50 values around 10 µM. The weakest 
was hexylresorcinol with an IC50 of 40 µM, which still was a respectable 
value. Interestingly, quinacrine was an anti-malarial of unknown 
mechanism, as discussed below, and that hexylresorcinol was an oral 
antiseptic. Although there are currently no known pathogenic archaea one 
study has found the number methanogenic archaea, similar to M. mazei, in 
the mouths of people suffering from chronic periodontitis is increased (Lepp 
et al, 2004). Since hexylresorcinol is used to treat this type of infection, it 
would be interesting to see its effect on the growth of methanogenic 
archaea in vitro and in vivo. 
5.3.5 Cross-reactivity of M. mazei topo VI and E. coli 
gyrase screen hits 
The compound suramin was a hit in both the E. coli gyrase and the M. 
mazei topo VI screen. Its IC50 was determined to be approximately two-fold 
more potent with M. mazei topo VI. However, it is difficult to interpret 
whether this difference in potency is due to the difference in activity of the 
two enzymes as well the different definition of what concentration of 
enzyme constitutes one unit of activity.  
 Interestingly none of the other hits from the M. mazei topo VI screen 
inhibited E. coli gyrase at the concentrations tested, which suggests a level 
of specificity of these compounds for topo VI. This may arise from them 
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binding to novel binding sites on the topo VI enzyme which are either not 
present or very weak in the gyrase enzyme. This would only be confirmable 
by structural techniques such as X-ray crystallography which were beyond 
the scope of this project. Since the M. mazei topo VI enzyme has already 
been crystallised (Corbett et al, 2007), it would be relatively simple (with 
the appropriate investment of time) for this to be followed up. 
 On the other hand mitoxanthrone, the second of the novel E. coli 
DNA gyrase hits, was also an inhibitor of M. mazei topo VI. This identified it 
as a “false negative” for the screen, and was due to the compound’s ability 
to interfere with DNA triplex formation by intercalation. Mitoxanthrone was 
substantially more potent against M. mazei topo VI than DNA gyrase with 
an IC50 approximately ten-fold lower. This means that mitoxanthrone is able 
to inhibit topo II (Smith et al, 1990), DNA gyrase and topo VI making it a 
prolific inhibitor of topoisomerases. It is likely that it intercalates at the DNA 
break generated in the G-segment during the reaction, since this step is 
common to the reactions of all three enzymes. However, it is also a strong 
intercalator and there was no time to check if its apparent inhibition against 
topo VI was an artefact of this property (such as was carried out with 
quinacrine and 9-aminoacridine). The validity of mitoxanthrone as a topo VI 
inhibitor would need to be confirmed in this regard before any major 
conclusions should be drawn from these results. 
5.3.6 Mechanism of action for screen hits 
The hits were run through a range of assays to determine their modes of 
action. Suramin was show to prevent the binding of topo VI to DNA making 
its mode of action identical for both topo VI and DNA gyrase as well as likely 
the same for topo II (Bojanowski et al, 1992).  
Purpurin also displayed the ability to prevent the binding of DNA to 
topo VI, but instead of a straight abolition of binding the formation of two 
bands was observed with molecular weights intermediate those 
corresponding to bound and unbound. It may be that these bands 
correspond to DNA bound to A subunit monomers or dimers, which would 
mean that purpurin inhibits the enzyme by disrupting protein—protein 
interactions rather than preventing DNA binding directly. In this scenario it 
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would make sense if the binding site for the compound was located at the 
interface between the A and B subunits. The question arises how specific 
purpurin is as an inhibitor, since it may just interfere with protein—protein 
interactions generally. However, its inability to inhibit E. coli DNA gyrase 
does show that it possesses some level of specificity for M. mazei topo VI. 
This specificity may be linked to the incredibly high strength of the 
interaction between the A and B subunits of M. mazei topo VI. Since it has 
been observed that the subunits are very difficult to separate during column 
chromatography it would be interesting to see if the inclusion of a low 
concentration of purpurin in the elution buffer would allow for separation of 
the two subunits. 
Testing the remaining hits for their ability to inhibit topo VI ATPase 
activity revealed that quinacrine appeared to inhibit the ATPase activity of 
the enzyme. However, the IC50 for this inhibition was approximately 400 µM 
which was around forty-fold greater than its IC50 in the gel assay. In 
addition it was shown that this apparent inhibition is likely due to quinacrine 
interfering with the linked assay by inhibiting the activity of pyruvate 
kinase. These data lead to conclude that quinacrine does not target the 
enzymes ATPase activity as part of its mode of action. 
Interestingly, hexylresorcinol appeared to activate the ATPase activity 
of topo VI when present at a concentration of 500 µM (roughly ten-fold its 
IC50 in the gel assay). Since the drug had no effect on the activity of 
pyruvate kinase in the absence of topo VI and possessed no intrinsic ability 
to hydrolyse ATP this activation of topo VI ATPase activity is likely genuine. 
It may be that the drug operates by uncoupling ATP hydrolysis from the 
conformation changes it usually induces. Whether this phenomenon is 
relevant to the mechanism of hexylresorcinol still remains unclear, since the 
concentration at which it manifests strongly is much higher than its IC50 in 
the gel assay. 
Unfortunately since M. mazei topo VI seemed unusually resistant to 
stabilization of the cleavage conditions the ability of the remaining hits to 
stabilize the cleavage complex was difficult to determine as discussed 
above. However, the S. shibatae topo VI proved to be a viable substitute 
 Chapter 5 
 
  171 
 
achieving a good level of cleavage with the ADPNP control, although neither 
hexylresorcinol nor suramin were able to inhibit the enzyme. Although none 
of the hits tested appeared to stabilize the cleavage complex they all 
seemed to reduce the stabilization of the cleavage complex by ADPNP. It 
may be that these compounds operate by directly preventing the cleavage 
of DNA by topo VI. However there was neither the time nor the enzyme to 
explore this further, and these results would greatly benefit from further 
study. Furthermore, it would be superior to repeat the experiment using 
Ca+2 as the cleavage complex stabilizing agent. This would eliminate the 
possibility that the drugs were preventing the binding of ADPNP rather than 
preventing cleavage. 
5.3.7 Hexylresorcinol as an inhibitor of Arabidopsis 
endoreduplication  
Out of the hits from the screen only hexylresorcinol had an effect on the 
growth of Arabidopsis thaliana. Treating plants with 40 µM hexylresorcinol 
resulted in an overall decrease in plant size and caused plants to become 
pale and transparent. At this concentration there appeared to be a range of 
responses to the drug with some plants largely unaffected, some with 
slowed growth and others exhibiting a reduction in overall size and root hair 
size and frequency (the “dwarf” morphology) (Figure 5.42). The 
characteristics of the “dwarf” morphology are similar to those observed in 
topo VI knock-out mutants (Hartung et al, 2002; Sugimoto-Shirasu et al, 
2002). Additionally all plants took on a yellowish colour, which was noted in 
some of the topo VI mutants (Hartung et al, 2002). However, it does 
appear that the trichromes size of these remains largely unaffected, 
whereas they were reduced in the topo VI mutants.  
The difference between slow growing plants was more apparent when 
treated plants were transferred to fresh agar lacking hexylresorcinol. After 
three weeks the plants which had either not been affected or had their 
growth slowed had mostly recovered, growing to full size and regaining 
their pigmentation. Interestingly, a few leaves on these plants turned a 
vivid white and withered. In contrast plants which had exhibited the dwarf 
morphology remained smaller and did not have any withered leaves, 
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although they did grow considerably and retain their pigmentation. These 
observations suggest that the withering of leaves is an immune response to 
the drug, most likely the sequestering of the herbicide into certain leaves. A 
similar response has been reported for weeds resistant to the common 
herbicide glyphosate (Shaner et al, 2011). Plants which are able to 
sequester the drug successfully are able to grow normally or have their 
growth slowed as a stress response, whereas those who can’t exhibit the 
“dwarf” morphology. 
 To discern whether the “dwarf” morphology was due to in vivo 
inhibition of endoreduplication both cyro-SEM and flow cytometry were 
carried out on hexylresorcinol grown seedlings. Since endoreduplication 
results in both increased ploidy and cell size the expected result for its 
 
Figure 5.42 Comparing hexylresorcinol “dwarf” morphology to topo VI knock-out 
mutants. Electronmicrographs of Arbadopsis roots (top left) and trichromes 
(bottom left) in wild-type and topo VI knock-outs from (Sugimoto-Shirasu et al, 
2002) compared to photographs of plants treated with 40 µM hexylresorcinol 
displaying the “dwarf” morphology. The roots of an untreated Arbadopsis hypocotyl 
is shown for comparison. 
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inhibition is a reduction in both of these characteristics. Plants which had 
grown normally or slowly both exhibited a cell size of around 300 µm 
whereas plants exhibiting the “dwarf” phenotype were reduced at around 50 
µm. Furthermore the ploidy of the “dwarf” plants was found to alter with a 
large increase in the 2n peak and a reduction in the 4n and 8n peaks. These 
observations suggest that endoreduplication is indeed decreased in these 
plants. This is different to what was observed with topo VI knock out plants 
where endoreduplication was stopped above 8n. In contrast the “dwarf” 
plants do display a slight reduction in the 16n peak although it is difficult to 
tell if this change is. This difference may have arisen since the original 
studies carried out flow cytometry on the leaves of the plants, whereas the 
whole plant was used in these experiments. Since ploidy varies between 
tissue types this may explain the discrepancy. 
 As to whether this decrease in endoreduplication is due to the 
inhibition of Arabidopsis topo VI in vivo it is difficult to say for certain since 
there is always the possibility that hexylresorcinol just happens to target 
another key enzyme involved in the process. The drug does provoke other 
morphologies (such as reduction in pigmentation) which are not solely 
explainable as the effect of reduced endoreduplication. It is therefore likely 
that it has multiple targets within the plant. Additionally, although the 
“dwarf” morphology shares some of the features with the topo VI knock-out 
mutants (overall size reduction, yellowish colour, altered ploidy, and 
reduced root hair size and frequency) there are some key differences. 
Thrichrome size appears to be unaffected, whereas it was reduced in the 
mutants, and endoreduplication above 8n was observed with the “dwarf” 
plants which was abolished in the knock-out mutants. These differences 
could imply that hexylresorcinol is targeted to specific tissues within the 
plant. 
However, the only way to prove for definite that topo VI is the target 
within the plant would be to express the enzyme from the plant and 
demonstrate that hexylresorcinol inhibited it in vitro. Resistant mutants 
could then be designed and introduced back into the plant. If these mutant 
plants were resistant to the dwarfing effect of hexylresorcinol then one 
could say for definite that topo VI was its target in planta. However, the fact 
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that the drug inhibits M. mazei topo VI in vitro and Arabidopsis 
endoreduplication in planta lends circumstantial evidence to that conclusion. 
5.3.8 Expression of P. falciparum topo VI 
Having read about hypothetical topo VI in the malaria parasite Plasmodium 
falciparum in the literature expression of the two potential A subunits 
(PfT6A1 and PfT6A2) and the B subunit (PfT6B) was attempted. 
Unfortunately none of the proteins were expressed in a non-truncated, 
soluble form in either the E. coli or baculovirus expression systems. 
 The expression of PfT6A1 and A2 in the E. coli system was a success, 
although neither protein was soluble. Expression was best when induction 
was carried out at high a OD600 (~2) or when carried out in auto-induction 
media (which also allows for high densities prior to expression). An 
exploration of expression conditions (such as temperature or expression 
strain) may lead to the production of soluble protein. However a large-scale 
analysis of P. falciparum proteins expressed in a soluble form in E. coli has 
revealed that the pI of the desired protein contributes heavily to the 
chances of successful soluble expression (Mehlin et al, 2006). Solubility was 
found to decrease with increasing pI, with the effect being most pronounced 
with pI >8. The pIs of PfT6A1 and A2 are 8.8 and 9.3 respectively (as 
calculated by the ExPASy Compute pI/MW tool), putting them well above 
this value. It may be more fruitful to search for homologues of these genes 
in other Plasmodia spp. which have more favourable characteristics and 
attempt expression of these genes instead of those from P. falciparum. 
 Expression of the B subunit was successful in the baculovirus system, 
but sequencing and PCR analysis revealed that this was likely a 86 amino 
acid truncation of the proteins C-terminus. This was due to a single base 
pair deletion resulting in a frame-shift. The mutation occurs in a stretch of 
14 A-T repeats with the final pair being deleted (1410 bp). This results in 
the formation of a stop codon 6 codons downstream. It is likely that the 
high number of repeats in this region caused an error with the polymerase. 
In the M. mazei enzyme these residues form the C-terminal domain of the B 
subunit, which are thought to control substrate specificity and localisation of 
the enzyme (Corbett et al, 2007). It was noted that this C-terminal domain 
 Chapter 5 
 
  175 
 
was only found in archaea which also possessed a DNA gyrase, implying 
that it was necessary for regulating the activity of the two enzymes in 
respect to one another. It would therefore make sense for P. falciparum 
topo VI to also posses this domain, since it too has a DNA gyrase. Deletion 
of this domain from the M. mazei enzyme results in a five-fold decrease in 
activity. It is therefore possible that the truncated version of PfT6B would 
retain some activity if purified. However it would be superior to reattempt 
the cloning and alter the codons in that region to reduce the number of A-T 
repeats without changing the amino acid sequence (AAA to AAG, for 
example). This would reduce the chance of a polymerase error, and may be 
worth considering for other such regions in the sequence (although this 
appears to be the longest).  
The failure to express either A subunit in the baculovirus system was 
likely either due to the necessity for dual expression (see below) or purely a 
matter of optimization. Since the expression procedure is very lengthy there 
was only time to trial a few conditions, so a more detailed exploration may 
be fruitful. Our laboratory was not equipped to accurately determine the 
multiplicity of infection (MOI) for the viral stocks, so it was necessary to 
estimate them. The control of the MOI is commonly held to be crucial for 
successful expression. As such further studies should invest in the 
appropriate equipment and training to allow for this. 
 The topo VIs currently successfully expressed in a soluble form (i.e. 
S. shibatae and M. mazei) have only been done so by co-expressing the two 
subunits. This may in fact be the key to their expression and is possibly due 
to the strong interaction between the two subunits. It would be interesting 
to test dual expression of the subunits in both E. coli and baculovirus, since 
suitable vectors are available for both systems. 
 Finally, it was noted that the gene for PfT6A2 has since been 
duplicated in the Plasmodium database: PFL0825c-a and PFL0825c-b. 
PFL0825c-b is the same as the original sequence (which was used in this 
study) whilst PFL0825c-a contains a 20 amino acid deletion towards the C-
terminal end. Which of these two, if any, is the correct gene remains to be 
seen. 
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5.3.9 P. falciparum topo VI as a drug target 
Although we were unable to express the P. falciparum topo VI our results 
with the M. mazei enzyme can allow us to speculate somewhat about its 
possible interactions with the compounds found in the screen. Several of the 
compounds from the screen have been shown to have efficiency against P. 
falciparum: suramin and quinacrine. Since suramin has such a prolific range 
of enzymes it can inhibit (including: topo II, DNA gyrase, topo VI, kinases 
(Hosoi et al, 2004; Lopez-Lopez et al, 1994), malarial surface receptors 
(Fleck et al, 2003) and P2 receptors (Abbracchio et al, 2006)) it is difficult 
to say anything of its target in vivo. Although it may target topo VI in P. 
falciparum, it almost certainly has multiple targets. 
 Quinacrine is a well-established anti-malarial drug (Chauhan & 
Srivastava, 2001) but its mode of action remains elusive. It is a member of 
the acridine class of compounds which includes two other hits: 9-
aminoacridine and amsacrine. Derivatives of amsacrine have been shown to 
have potency against Plasmodium falciparum (Figgitt et al, 1992). 
Quinacrine has been shown to target the erythrocyte stage of the 
Plasmodium life cycle, during which the parasite undergoes schizogony (a 
process similar to endoreduplication). This makes it very tempting to 
imagine that topo VI as its target. Interestingly none of the other anti-
malarial compounds tested had any effect on the activity of M. mazei topo 
VI. This was particularly interesting in the cases where the compound was 
an almost direct analogue of quinacrine but with a different scaffold such as 
chloroquine, MT-IC52 or MT1074 (Figure 5.43). All of these compounds 
have been shown to have anti-malarial activity despite having no activity 
against topo VI, strongly suggesting they have some other target. This 
demonstrates the necessity of the acridine scaffold for the inhibition of topo 
VI by quinacrine, which may be useful for further design of inhibitors 
against the enzyme. 
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 It would be interesting to test some of the other hits from the screen 
against the parasite in vitro. However, making any strong conclusions about 
the Plasmodium enzyme is impossible without having it expressed in a 
soluble form. This would be a step forward to validating topo VI as a target 
in Plasmodium and possibly the development of a whole new range of anti-
malarial compounds. 
 
Figure 5.43 Comparison of various anti-malarial compounds with different 
scaffolds. 
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     Chapter 6 
6 General Discussion 
6.1 Introduction 
DNA topoisomerases are important targets for antimicrobial drugs. With the 
emergence of strains of various pathogens resistant to many clinical 
antibiotics there is a dire need to discover compounds which inhibit 
topoisomerases in novel ways. However, high-throughput screening for 
these compounds has been limited by the traditional assays for 
topoisomerase activity. The initial aims of this project were to validate the 
use of a novel, microtitre plate-based assay for topoisomerase inhibitors 
(Maxwell et al, 2006) in a high-throughput format and use it for the 
discovery of novel DNA gyrase and topoisomerase VI inhibitors. In chapters 
4 and 5 it was shown that it is possible to screen for novel inhibitors of E. 
coli DNA gyrase and M. mazei topo VI with the microtitre plate-based assay. 
Several novel inhibitors were found for each enzyme and their modes of 
action characterised. In chapter 5 the inhibitors of M. mazei topo VI were 
tested against the Arabidopsis thaliana orthologue of the enzyme in planta, 
and one compound was discovered which produced a similar morphology to 
previously documented topo VI knock-out mutants (Hartung et al, 2002; 
Sugimoto-Shirasu et al, 2002).  
 In addition it was observed that M. mazei topo VI produced an 
unusual banding pattern at high concentrations. AFM experiments have 
revealed that this is likely due to protein remaining bound to the DNA even 
after the proteinase digestion and phenol extraction. This and other 
observations may provide an interesting insight into the mechanism of this 
enzyme. 
Finally, the cloning and expression of the hypothetical topo VI from P. 
falciparum was attempted in order to investigate it as a drug target. 
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Unfortunately were unable to obtain soluble protein, so the question 
remains open. 
6.2 Characteristics of M. mazei topo VI 
This work has confirmed many of the already published biochemical 
characteristics of M. mazei topo VI (Corbett et al, 2007). It was also shown 
that although radicicol is less potent against the M. mazei enzyme than the 
S. shibatae orthologue, its mode of action remains the same for both topo 
VI enzymes (inhibition of ATPase activity). 
 In addition it was observed that the M. mazei enzyme appears to bind 
very tightly to DNA in an ATP-dependent manner, possibly resulting in the 
formation of unusual topoisomers. This has not been observed for the S. 
shibatae topo VI, but the thermophilic nature of the enzyme makes it 
difficult to compare the two. The subunits of the enzyme appear tightly 
associated, proving impossible to separate with high salt or ethylene glycol 
buffers in column chromatography. Furthermore the enzyme appeared 
highly resistant to agents which stabilized the cleavage complex such as 
ADPNP. Imaging of M. mazei topo VI-processed DNA molecules by AFM 
revealed that enzyme molecules seemed to remain associate with the DNA 
despite SDS-proteinase K digestion and phenol-chloroform extraction. It is 
possible this indicates that the topo VI-DNA cleavage complex is incredibly 
robust, remaining associated despite these harsh conditions, and that topo 
VI is intrinsically resistant to proteinase K digestion. This makes sense in 
light of the supposed role for the C-terminal gate in type IIA 
topoisomerases in holding the enzyme-DNA complex associated during DNA 
gate opening (Bates et al, 2011) and its absence in topo VI. Further AFM 
experiments and characterisation of the enzyme’s susceptibility to 
proteinase digestion are necessary to confirm this hypothesis. 
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6.3 The suitability of the microtitre plate-
based assay for screening 
One of the main aims of this project was the adaption of the microtitre 
plate-based assay for topoisomerase activity to a high-throughput format 
and to evaluate its viability by screening a relatively small library of 
compounds. In chapters 3 and 4 two successful screens of a 960 compound 
library against E. coli DNA gyrase and M. mazei topo VI were described. The 
assay was able to identify both known and novel inhibitors during these 
screens (Table 6.1). The overall hit rate for the E. coli DNA gyrase screen 
was significantly higher than for the M. mazei topo VI screen (~1.5% 
compared to ~0.6%). Conversely, the novel hit rate was higher for the M. 
mazei screen (~0.5% compared to ~0.2%). These differences are likely due 
to the fact that DNA gyrase is a well established antimicrobial target and the 
library was primarily composed of clinical drugs. 
 Because DNA gyrase has such a large number of well known and 
clinically used inhibitors it was possible to scan the list of compounds in the 
library for known inhibitors which were missed by the screen. Four such 
compounds were found: nalidixic acid, cinoxacin, oxolinic acid and enoxacin. 
Nalidixic acid, cinoxacin and oxolinic acid are among the oldest members of 
the quinolone class of drugs, with comparably high IC50s to the 
fluoroquinolones which may go some way in explaining why they were 
missed. Enoxacin, however, is a more recently developed fluoroquinolone 
which should have activity comparable to the other fluoroquinolones 
identified by the screen. It may be the case that these compounds have 
become degraded during storage, but it is more likely they were missed due 
to well-to-well or plate-to-plate variations within the assay. Although there 
were relatively few such compounds, it was concerning that the assay did 
not pick out all known inhibitors. This may have been due to compounds 
Screen 
against: 
Z' False 
positives 
Known false 
negatives 
Hits Novel 
hits 
Novel hit 
rate (%) 
Gyrase 0.64 9 4 13 2 0.21 
Topo VI 0.69 3 1 6 5 0.52 
Table 6.1 Statistical summary of the two screens. 
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becoming degraded or contaminated during storage, a possibility which 
should be ruled out before firm conclusions on the assay’s ability to pick out 
known inhibitors can be drawn. Since there are few known inhibitors 
described for topoisomerase VI a similar analysis of the M. mazei topo VI hit 
is less informative. Apart from m-amsacrine none of the other previously 
described inhibitors (Bergerat et al, 1994; Gadelle et al, 2005) were present 
in the library. Crosschecking the hits from the DNA gyrase and topo VI 
screens revealed that mitoxanthrone, a hit in the DNA gyrase screen, was 
also an inhibitor of M. mazei topo VI which had been missed in the topo VI 
screen. It was likely mitoxanthrone had been overlooked during the screen 
because of its ability to disrupt triplex formation, which results in a decrease 
of fluorescence signal. Since relaxation activity in the assay is also denoted 
by a decrease in signal the inhibition of topo VI by mitoxanthrone would be 
masked in the assay. 
 The number of false positives was acceptable for these screens but 
may become prohibitive for larger-scale operations. This can be addressed 
by increasing the hit threshold, or adopting different criteria for hit selection 
(such as taking a certain proportion of the most potent hits). 
 The Z' factor for both screens lay within the range associated with 
excellent separation of positive and negative signals, although there was 
variation of this from plate-to-plate. It has been shown that the Z' is only a 
good indicator of an assay’s power to separate positive and negative results 
if the standard deviation of samples does not vary too much with signal (i.e. 
higher signal resulting in higher variation) (Sui & Wu, 2007). To test if this 
was the case for the microtitre plate-based assay the average signals for 
the positive and negative controls from the two screens were plotted 
against their standard deviation (calculated from 192 reactions) (Figure 
6.1). Fortunately the results showed that there was only a small increase in 
standard deviation as signal increased, meaning the Z' values were likely 
good representations of the separation power of the assay (Sui & Wu, 
2007). Interestingly the relationship between signal and standard deviation 
does not appear to be linear, with the standard deviation plateauing at high 
signal levels. 
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6.4 Perspectives on screen hits 
A number of hits were discovered for each of the two enzymes. Since DNA 
gyrase is a type IIA topoisomerase and topo VI is a type IIB topoisomerase, 
cross-testing the hits may provide some insight into the differences in 
mechanism between these two families.  
In chapter 5 the cross-testing of DNA gyrase hits against M. mazei 
and S. shibatae topo VI was described (Table 6.2). Interestingly only two 
compounds appear to be inhibitors of both E. coli DNA gyrase and M. mazei 
topo VI: mitoxanthrone and suramin. Both of these compounds have also 
been reported as inhibitors of eukaryotic topoisomerase II (topo II) 
(Bojanowski et al, 1992; Smith et al, 1990), a type IIA topoisomerase. It 
has been previously described that topo VI appears to be more susceptible 
to topo II inhibitors than it is to specific inhibitors of DNA gyrase (Bergerat 
et al, 1994). This is true for the majority of topo VI hits described in this 
work with m-amsacrine, quinacrine and 9-aminoacridine all being implicated 
in topo II inhibition (Finlay et al, 1989; Nelson et al, 1984). What is 
 
Figure 6.1 Variation of standard deviation with increasing fluorescence signal. The 
data was compiled from the controls of both screens, with each point calculated 
from the values for 192 repeats. 
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interesting about mitoxanthrone and suramin is that they appear to inhibit 
DNA gyrase, topo II and topo VI (although suramin did not inhibit S. 
shibatae topo VI, but this may have been because the drug was not stable 
at the temperature the assay was conducted at). This prolific inhibition 
probably means they target fundamental aspects of type II topoisomerase 
reaction.  
In the case of suramin this appears to relate to the binding of the 
enzymes to DNA, possibly by acting as a DNA mimic. For mitoxanthrone this 
is likely intercalation at the double-strand break in the G-segment DNA, 
since it is able to stabilize the cleavage complex of both DNA gyrase 
(Section 4.2.6) and eukaryotic topo II (Smith et al, 1990). It was therefore 
surprising that DNA cleavage was not detectable with either M. mazei or S. 
shibatae topo VI. In the case of M. mazei topo VI this may be explained by 
the difficulty in revealing the cleavage complex with the enzyme, but this 
does not hold true for the S. shibatae enzyme for which cleavage with 
ADPNP was observed. It may be that mitoxanthrone’s apparent inhibition of 
topo VI arises from its general ability to intercalate with DNA. To rule out 
the second possibility tests like those described for quinacrine and 9-
Compound Inhibits? 
 
E. coli DNA 
gyrase 
M. mazei 
topo VI 
S. shibatae 
topo VI 
Eukaryotic 
topo II 
Mitoxanthrone     
Suramin     
m-Amsacrine     
Hexylresorcinol    ? 
Quinacrine     
9-Aminoacridine     
Purpurin    ? 
Table 6.2 Summary of type II topoisomerase inhibition by screen hits. A tick 
indicated inhibition at least 100 µM by the compound for E. coli DNA gyrase, M. 
mazei topo VI or S. shibatae topo VI. A tick for eukaryotic topo II indicates existing 
literature describing its inhibition by a compound. A question mark indicates no 
such literature was found. 
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aminoacridine in section 5.2.4 should be conducted before firm conclusions 
are drawn. 
For the majority of the M. mazei topo VI inhibitors, except for 
suramin and purpurin which both appeared to prevent G-segment binding, 
it was not possible to conclusively determine mechanisms of action. They 
did not appear to inhibit the ATPase activity of the enzyme, prevent G-
segment binding or stabilize the cleavage complex with M. mazei topo VI. 
Out of those which inhibited S. shibatae topo VI none appeared to stabilize 
the cleavage complex. However mitoxanthrone, quinacrine and 9-
aminoacridine all appeared to prevent ADPNP-induced cleavage of DNA by 
the enzyme. This was interesting since both quinacrine and 9-aminoacridine 
have been reported to prevent the cleavage of DNA by eukaryotic topo II 
(Thielmann et al, 1991). It could be that the mechanism of action for these 
compounds against topo VI is their ability to prevent the formation of the 
cleavage complex. However, this would need to be confirmed by further 
experiments as suggested in Section 5.3.6. 
Very few of the hits are of immediate pharmaceutical or commercial 
interest. The cytotoxicity of mitoxanthrone and suramin make them poor 
candidates for antimicrobials, although derivatives of the compounds may 
have more favourable characteristics. The compounds containing the 
anthraquinone scaffold of mitoxanthrone have already been shown to inhibit 
DNA gyrase meaning this is not a novel class of inhibitors for the enzyme, 
although by no means a highly exploited one (Burckhardt et al, 1998). In 
contrast the inhibition of topo VI by the anthraquinones, such as 
mitoxanthrone and purpurin, has not been previously reported. 
The antimalarial potential of the topo VI inhibitors proved impossible 
to determine since it was not possible to express soluble P. falciparum topo 
VI. Further expression trials with the enzyme, possibly with the two 
subunits expressed in a single vector or with different Plasmodium 
orthologues, may lead to success. Testing of the compounds against 
Plasmodium parasites in cell cultures, and study of any morphologies 
induced may provide circumstantial evidence for the presence of a topo VI 
in Plasmodium and its role as a drug target. However a large number of the 
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hits from the M. mazei topo VI screen have belonged to classes of drugs 
known to have antimalarial activity. These include the aminoacridines (such 
as m-amsacrine, quinacrine and 9-aminoacridine) (Chavalitshewinkoon et 
al, 1993) and the anthraquinones (Sittie et al, 1999; Winter et al, 1995). It 
therefore remains possible that these compounds are targeted against 
Plasmodium topo VI in vivo. 
One M. mazei topo VI screen hit displayed herbicidal properties against 
Arabidopsis thaliana: hexylresorcinol. For hexylresorcinol to be developed 
into an agriculturally useful herbicide its mode of action has to be precisely 
determined in order to design resistance genes for crops. This can be 
approached from either of two directions. The first possibility is to select for 
plants displaying resistance to hexylresorcinol and sequence across the 
topo6 genes. The mutant versions of Arbadopsis topo VI can then be 
expressed and their resistance to hexylresorcinol confirmed in vitro. The 
opposite approach is to generate crystal structures of the drug bound to 
topo VI (preferably the Arbadopsis orthologue) and use these to design 
mutants resistant to the drug. These mutations can then be introduced into 
plants and their resistance to the drug assessed in planta. Both of these 
routes would lead to confirmation of topo VI as the drug’s target in planta 
and allow for the design of resistant crops. The cost, environmental impact 
and spectrum of plants killed by hexylresorcinol would also need to be 
assessed before it could be brought to market. 
6.5 Concluding remarks 
In conclusion we feel that this project has fulfilled its initial aims of 
validating a screening process for novel topoisomerase inhibitors. Although 
none of the compounds which arose from the screening process appear to 
be of immediate pharmaceutical importance they have raised interesting 
questions about the relationships between the inhibitors of type IIA and 
type IIB topoisomerases, as well as probing the mechanism of topo VI. 
Larger-scale screens using this assay with more diverse libraries will 
hopefully lead to the discovery of compounds which lead to novel 
antimicrobials (in fact, one such screen is currently underway).  
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More generally we feel that this project highlights the difficulties of 
antimicrobial screening: although hits against DNA gyrase were found they 
are useless as antimicrobials due to their other unfavourable characteristics. 
On a more positive note, the work here on topoisomerase VI demonstrates 
the value of basic research. Initially topoisomerase VI appeared to be an 
“archaeal curiosity” only of academic interest. However, its potential 
presence in pathogenic protozoa means it may suddenly become very 
medically relevant. We very much hope this turns out to be so, and that 
topo VI becomes another weapon in our arsenal in the “war against 
pestilence”. 
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7.1 High-Throughput Microtitre Plate-Based 
Assay for DNA Topoisomerases 
Functional Genomics: Methods and Protocols (Kaufmann, M. & Klinger, C., 
eds.), In press. Humana Press, New York. 
James A. Taylor, Nicolas P. Burton and Anthony Maxwell 
Abstract 
We have developed a rapid, high-throughput assay for measuring the 
catalytic activity (DNA supercoiling or relaxation) of DNA topoisomerases. 
The assay utilizes intermolecular triplex formation between an immobilized 
Triplex-Forming Oligo (TFO) and a triplex-forming region inserted into the 
plasmid substrate (pNO1), and capitalizes on the observation that 
supercoiled DNA forms triplexes more readily than relaxed DNA. Thus 
supercoiled DNA is preferentially retained by the TFO under triplex-forming 
conditions, whilst relaxed DNA can be washed away. Due to its high speed 
of sample analysis and reduced sample handling over conventional gel-
based techniques, this assay can be used to screen chemical libraries for 
novel inhibitors of topoisomerases. 
 
Keywords: Topoisomerase, DNA gyrase, triplex formation, supercoiling, 
relaxation, high-throughput screening 
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1. Introduction 
 DNA topoisomerases are essential enzymes that control the 
topological state of DNA in all living cells (Bates and Maxwell 2005). The 
crucial nature of their role, plus the fact that they must cleave DNA as part 
of their mechanism, has made them effective targets for antimicrobial and 
anti-cancer drugs as well as potential targets for herbicides, anti-virals and 
anti-protozoal agents. All topoisomerases can relax supercoiled DNA, whilst 
only DNA gyrase is capable of introducing negative supercoils (Nollmann, 
Crisona et al. 2007). Topoisomerases can also catenate/decatenate DNA 
and introduce/remove knots from DNA, to greater or lesser degrees 
(Schoeffler and Berger 2008). 
 The traditional assay for topoisomerase activity is based on the 
principle that different DNA topoisomers have different mobilities on an 
agarose gel. This assay is information-rich, but is also slow and requires 
intensive handling. As such it is not suitable for the high-throughput format 
necessary for large scale screening for novel inhibitors. To address the 
limitations of this assay, a microtitre plate-based assay was developed 
(Maxwell, Burton et al. 2006) (see Note 1), which capitalizes on the fact 
that supercoiled plasmids form DNA triplexes more readily than relaxed 
plasmids (Hanvey, Shimizu et al. 1988; Sakamoto, Akasaka et al. 1996). 
Reactions are carried out in streptavidin-coated microtitre wells, which have 
had a single-stranded biotinylated oligo immobilized on their surfaces. This 
oligo can form triplexes with a target plasmid by the addition of a low pH 
triplex formation buffer, which also stops the topoisomerase reaction. 
Supercoiled DNA will be retained in the wells after washing, whereas 
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relaxed, open circle and linear DNA will be removed. The amount of DNA 
retained can be quantified with a fluorescent dye, and directly correlates 
with the level of enzyme activity (Fig. 1A). 
 
2. Materials 
 The highest purity of materials and ultrapure water with a resistivity 
of ~18 MΩ.cm should be used throughout. Unless otherwise stated, 
materials were purchased from Sigma. The Wash, Triplex Formation (TF) 
and T10E1 buffers should be filtered with a 0.2 μM cellulose nitrate 
membrane before use (see Note 2). 
 
7.1.1 2.1 Buffers and Solutions 
1. DNA Gyrase Dilution buffer: 50 mM Tris·HCl (pH 7.5), 100 mM KCl, 2 mM 
DTT, 1 mM EDTA, 10% (w/v) glycerol. Store at -20°C. 
2. DNA Gyrase Supercoiling buffer: 35 mM Tris·HCl (pH 7.5), 24 mM KCl, 4 
mM MgCl2, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5% (w/v) glycerol, 
0.1 mg/mL bovine serum albumin. The buffer is stored as a 5× concentrate at -
20°C. 
3. PDM media: 7.9 g tryptone, 4.4. g yeast extract, 0.5 g NH4Cl and 0.24 g MgSO4 
in 880 mL of water. After autoclaving add 20 mL 50% w/v glucose and 100 mL 
10x Phosphate buffer (see Note 3). 
4. Phosphate Buffer (10x): 128 g Na2HPO4.7H2O, 30 g KH2PO4 in 1 L of water. 
Autoclave and store at room temperature. 
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5. STEB (x2): 40% sucrose, 100 mM Tris·HCl (pH 8.0), 100 mM EDTA, 0.5 
mg/mL bromophenol blue. 
6. T10E1 buffer: 10 mM Tris·HCl (pH 8.0), 1 mM EDTA. Store at room 
temperature. 
7. TAE: 40 mM Tris·Acetate (pH 8.0), 1 mM EDTA. 
8. Topoisomerase I Dilution buffer: 10 mM Tris·HCl (pH 7.5), 1 mM DTT, 1 mM 
EDTA, 50 % (v/v) glycerol, 100 g/mL bovine serum albumin. 
9. Topoisomerase I Relaxation buffer: 20 mM Tris·HCl (pH 8), 200 mM NaCl, 
0.25 mM EDTA, 5% glycerol. The buffer is stored as a 10× concentrate at -
20°C. 
10.Topoisomerase VI Dilution buffer: 20 mM HEPES pH 7.5, 10% (v/v) 
glycerol. Store at -20°C. 
11.Topoisomerase VI Relaxation buffer: 20 mM bis-tris propane pH 6.5, 
100 mM potassium glutamate, 10 mM MgCl2, 1 mM DTT, and 1 mM 
ATP. The buffer is stored as a 5× concentrate at -20°C. 
12. Triplex Column buffer: 75 mM calcium acetate (pH 4.7). Store at room 
temperature. 
13. Triplex Column Elution buffer: 10 mM Tris·HCl (pH 8.0), 100 mM EGTA. 
Store at room temperature. 
14. Triplex Formation (TF) buffer: 75 mM magnesium acetate (pH 4.7). Store at 
room temperature (see Note 4). 
15. Wash Buffer: 20 mM Tris·HCl (pH 7.6), 137 mM NaCl, 0.01% (w/v) bovine 
serum albumin (acetylated), 0.05% (v/v) Tween-20. Store at 4°C. 
2.2. DNA 
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1. Plasmid pNO1 is a modified version of the high-copy number plasmid pBR322* 
(Boros, Pósfai et al. 1984) containing a triplex-forming insert (Maxwell, Burton 
et al. 2006). It was prepared by ligation of oligos TFO1W and TFO1C (Table 1) 
into the AvaI site of the plasmid. Supercoiled pNO1 is prepared by transforming 
it into competent Escherichia coli cells (e.g. Top10, Invitrogen), growing cells 
overnight in PDM media (Danquaha 2007) (see Note 3) containing 100 μg/ml 
ampicillin (see Note 5) at 37
o
C, 200 rpm. The DNA can then be purified using a 
Qiagen giga-prep kit (or similar) or by a cesium chloride density gradient. 
2. Relaxed pNO1 is prepared by incubating the supercoiled form with chicken 
erythrocyte topoisomerase I (~40-50 μg plasmid with 200 units topoisomerase I 
in 1x Topoisomerase I Relaxation buffer) for 1 h at 37°C. The DNA is extracted 
with two phenol/chloroform extractions and purified by ethanol precipitation. 
3. TFO1 oligo (Table 1) with a 5' biotin tag (e.g. Sigma-Genosys or Bioneer) is 
resuspended to 10 μM in T10E1 buffer and stored at -20°C. 
2.3 Enzymes 
1. E. coli DNA gyrase subunits GyrA and GyrB are expressed in E. coli and 
purified according to established protocols (Maxwell and Howells 1999). The 
subunits are stored separately in DNA Gyrase Dilution Buffer at -80
o
C (see 
Note 6). The complete enzyme is reconstituted by mixing equimolar amounts of 
GyrA and GyrB and stored on ice prior to use. 
2. Chicken erythrocyte topoisomerase I used was a gift from Alison Howells of 
Inspiralis Ltd, and was produced using the published protocol (Tricoli and 
Kowalski 1983). 
2.4 Equipment and DNA Staining 
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1. Black, streptavidin-coated, high binding capacity, 96-well plates (Pierce) are 
used for the screen. Plates should be stored, covered, at 4
o
C. 
2. DNA is stained with SYBR Gold (Invitrogen), which is stored as a 10,000x 
concentrate at 20°C. The dye is diluted 10,000 fold with T10E1 buffer to reach 
the working concentration. This should be prepared fresh each use. 
3. Fluorescence measurements are made using a SPECTRAmax Gemini 
fluorimeter and Softmas Pro Software. Alternative fluorimeters and software can 
be used. 
 
3. Methods  
3.1. DNA Gyrase Microtitre Plate-Based Supercoiling Assay 
1. Wash microtitre plate wells with 3x 200 μL of Wash Buffer (see Note 7). 
2. Load 100 μL 500 nM biotinylated TFO1 oligo (diluted from stock in Wash Buffer) 
into wells and allow immobilization to proceed for 2 min. 
3. Remove oligo solution and wash carefully with 3x 200 μL volumes of Wash buffer 
(see Note 7). 
4. The DNA gyrase supercoiling reaction is performed in the wells in a 30 μL reaction 
volume containing: 1-6 μL reconstituted DNA gyrase (1-2 units (see Note 8); the 
total volume of DNA gyrase is made up to 6 μL with DNA Gyrase Dilution buffer), 
1 μL of 1 μg/μL relaxed pNO1, 6 μL 5x DNA Gyrase Reaction buffer and H2O to 
30 μL (see Note 9). Incubate the reaction at 37°C for 30 min (this can be carried out 
in the plate reader if temperature control is available). 
5. The reaction is stopped with the addition of 100 μL TF buffer, which lowers the pH, 
and the plate is incubated at room temperature for 30 min to allow triplex formation 
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to occur. Supercoiled DNA becomes immobilized on the plate while relaxed DNA 
remains in solution. 
6. Remove unbound relaxed and linear plasmid by washing the wells thoroughly with 
3 x 200 μL volumes of TF buffer. 
7. Remove all the liquid from the wells and stain DNA with 200 μL 1 x SYBR Gold 
(diluted in T10 buffer). The plate is incubated for a further 20 min at room 
temperature. After incubation, mix the contents of the wells and then read the 
fluorescence in a fluorimeter. 
3.2. Screening a Compound Library for DNA Gyrase Inhibitors 
1. Wash the plates and immobilize the TFO1 as described in section 3.1, steps 1 to 3 
(see Note 10). 
2. Add 23.5 μL of a DNA Mix (see Note 11) containing 4.7 μL of 5x DNA Gyrase 
Reaction buffer, 2 μL of 1 μg/μL relaxed pNO1 and H2O to each well by 
multichannel pipette. 
3. Add 3 μL of compound to each well (the assay is tolerant of up to 10% DMSO in 
the reaction). Include a positive control well to which only DMSO is added. 
4. Add 35.5 μL of Control Mix containing 2 μL DMSO, 12 μL DNA Gyrase Dilution 
Buffer, 7.1 μL 5 x DNA Gyrase Supercoiling Buffer and 14.4 μL H2O to the 
negative control wells. 
5. Add 33.5 μL Enzyme Mix containing 1.8 units (where 1 unit is defined as the 
amount of enzyme required to supercoil 1 μg of relaxed pBR322) of DNA Gyrase in 
12 μL DNA Gyrase Dilution buffer, 6.7 μL 5x DNA Gyrase Supercoiling Buffer 
and 14.8 μL H2O to the sample and the positive control wells. 
6. Quickly mix (e.g. using the plate reader if it has such a facility), and incubate at 
37°C for 30 min. 
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7. Follow steps 5 to 7 of section 3.1 to form DNA triplexes and visualize retained 
plasmid. 
3.3. Data Processing and Hit Validation of Hits using Agarose Gel 
Assay 
Once data has been collected from the screen (Figure 1B) the fluorescence 
signals for the duplicates should be averaged and converted into percentage 
inhibition using the positive and negative controls (see Note 10). The 
standard deviation of the controls should also be calculated and converted 
into percentage inhibition. By adding the percentage standard deviations of 
the controls together and multiplying them by three you can obtain the 
95% confidence interval for the screen, which acts as an indicator of 
significance (the majority of hits which give a percentage inhibition over this 
number are likely to be genuine, and not within variance of the 
background). It is also possible to calculate the Z factor for the assay 
(Zhang, Chung et al. 1999) to determine the quality of the data (in our 
hands Z = ~0.75 for E. coli DNA gyrase). Hits obtained from the screen 
should be verified using an independent secondary assay, for example 
agarose gel electrophoresis. It is advisable to use fresh stocks of 
compounds for verification, rather than solutions taken from the library to 
ensure that the inhibition seen is not due to any cross-contamination or 
degradation which may have occurred during library storage. 
1. The supercoiling reaction is conducted in 1.5 mL microcentrifuge 
tubes containing the following: 500 ng of relaxed pNO1, 6 μL 5x DNA 
Gyrase Supercoiling Buffer, 0.5 U of reconstituted DNA gyrase in 6 μL 
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Dilution Buffer, up to 1.5 μL of compound in 100% DMSO at the 
desired concentration and H2O to 30 μL. 
2. Incubate at 37°C for 30 min.  
3. Stop the reaction with an equal volume chloroform:isoamyl alcohol 
(24:1), and an equal volume of 2x STEB, vortex vigorously to form 
an emulsion. Centrifuge at 16,000g for 10 min. 
4. Load 15 μL of the top phase onto a 1% TAE agarose gel. Run the gel 
at 80 V for 2-3 hrs or until the gel has run for at least 7 cm, or 15-30 
V overnight. The further that the gel is run, the better the 
topoisomers will be resolved. 
5. Stain gel with 2 mg/mL ethidium bromide 10 min and visualize under 
UV. 
3.4. Measuring Relaxation Activity with the Microtitre Plate-Based 
Assay 
 The plate assay can also be used to measure the activity of enzymes 
which relax DNA, and consequently used to screen to novel inhibitors for 
them. Below is a sample protocol for using the assay to measure 
Methanosarcina mazei topoisomerase VI, but it is easily adapted for other 
enzymes (such as human topoisomerase I and II, and bacterial 
topoisomerase IV). Likewise the screen protocol described for gyrase above 
can be modified to screen against such enzymes. 
1. Wash the plates and immobilize the TFO1 as described in section 3.1., steps 1 to 
3. 
2. The topoisomerase VI relaxation reaction is performed in the wells in a 30 μL 
reaction volume containing: 1-6 μL reconstituted topoisomerase VI (1-2 units 
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(see Note 8); the total volume of topoisomerase VI is made up to 6 μL with 
Topoisomerase VI Dilution buffer), 1 μL of 1 μg/ μL supercoiled pNO1, 6 μL 5x 
Topoisomerase VI Reaction buffer and H2O to 30 μL (see Note 9). Incubate the 
reaction at 37 °C for 30 min (this can be carried out in the plate reader if 
temperature control is available). 
3. Follow steps 5 to 7 of section 3.1 to form DNA triplexes and visualise retained 
plasmid. Enzyme activity is denoted by a drop in signal as supercoiled substrate 
is converted to relaxed product and lost from the wells during subsequent wash 
steps.  
3.5. Purification of Supercoiled Plasmid via Triplex Affinity Columns 
and Other Applications for the High-Throughput Assay 
 As well as its utility in high-throughput screening, the assay and the 
principles behind it have potential to be exploited in a range of other 
settings. Previously it has been used for the rapid determination of inhibitor 
IC50s (Anderle, Stieger et al. 2008), which is useful for the characterisation 
of hits determined during screening. It is also possible to use the assay for 
measuring the activity (and inhibition) of any enzyme which alters the 
linking number of the plasmid substrate (such as restriction enzymes). In 
addition, the protocol above could be altered to screen for compounds which 
either promote or inhibit the formation of DNA triplexes, simply by omitting 
the enzyme. The compounds should be included in the TF buffer wash steps 
(section 3.1, step 6), as well as in the TF buffer for the triplex formation 
step. Finally the capture of supercoiled DNA plasmids by triplex-forming 
oligos has been utilized to create an affinity column for the specific 
purification of supercoiled plasmid (Schluep and Cooney 1999). 
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1. Add 1 mL of 4% agarose streptavidin coated beads to an empty 
gravity flow column (see Note 12). 
2. Wash three times with 1 mL T10 Buffer. 
3. Stop the flow and add 1 mL of 100 µM TFO1 in T10 buffer. Incubate 
at room temperature for 1 min. 
4. Wash three times with 1 mL T10 Buffer. 
5. Equilibrate the column by washing three times with 1 ml Triplex 
Column buffer. 
6. Add 1 mg of DNA in 1 ml Triplex Column buffer. Retain the flow 
through for subsequent steps. 
7. Elute bound DNA with 2 mls Triplex Column Elution buffer. 
8. Re-equilibrate the column by washing three times with 1 ml Triplex 
Column buffer. 
9. Re-circulate the flow through from step 6.  
10.Repeat steps 6 to 9 until all plasmid is recovered. 
11.Combine eluents and concentrate through ethanol precipitation. 
 
4. Notes 
1. The triplex assay described is protected by patent application WO06/051303. 
Commercial performance of the assay requires a license, available from Plant 
Bioscience Ltd. (Norwich, UK; http://www.pbltechnology.com/). The assay is 
available as a kit from Inspiralis Ltd. (Norwich, UK; http://www.inspiralis.com/) 
who also supply pNO1 and a range of topoisomerase enzymes including several 
bacterial DNA gyrases and topoisomerase IVs, and human topoisomerases I and 
II. 
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2. The presence of suspended particles will result in light scattering, which will 
reduce the quality of data and may introduce variation. It is also recommended 
that the microtitre plates are protected with a cover where possible to prevent 
airborne particles entering the wells.  
3. Alternatively Luria-Bertani (LB) or Terrific Broth (TB) can be used, although 
lower yields and increased amounts of nicked plasmid may be observed. 
4. The assay was originally developed using a TF buffer of 50 mM sodium acetate 
pH 5.0, 50 mM sodium chloride, 50 mM magnesium chloride. However, 75 mM 
magnesium acetate (pH 4.7) was found to give slightly improved results. Certain 
DNA binding compounds can promote or inhibit the formation of triplexes, 
resulting in them appearing either as false negatives or positives in the assay. 
Although the inclusion of proper controls and hit validation should minimize the 
impact of these compounds on the screen results, we have found that substituting 
magnesium with another divalent metal (e.g. calcium) can reduce the effect of 
intercalators upon triplex formation. However, no one metal ion has emerged as 
a panacea for the problem. 
5. Alternatively, carbenicillin can be used, which is broken down more slowly than 
ampicillin, resulting in more sustained selective pressure which may increase 
plasmid yields. 
6. Repeated freeze thaw cycles will reduce enzyme activity, so it is recommended 
that the subunits are aliquoted before freezing. The GyrB subunit can precipitate 
if stored at concentrations higher than 1 mg/mL.  
7. It is essential to wash the wells thoroughly before and after TFO1 addition as 
unbound TFO1 can interfere with triplex formation. Buffer should be thoroughly 
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removed after the final wash to prevent it interfering with subsequent steps. 
Residual buffer can be removed by pipetting or aspiration. 
8. It is highly advisable to calculate the concentration of DNA gyrase equivalent to 
one unit with the triplex assay prior to screening. One unit of supercoiling 
activity is defined as the amount of enzyme required to just fully supercoil 0.5 
μg of relaxed pNO1 at 37°C in 30 min. The extent of supercoiling is determined 
by the inclusion of a control containing 1 μg supercoiled pNO1 without enzyme. 
Conversely, a unit of relaxation activity is defined as the amount of enzyme 
required to just relax 0.5 μg of supercoiled pNO1 at 37°C in 30 min. Units of 
enzyme activity are quantified by performing the reaction over a range of 
enzyme concentrations. For example, to quantify units of DNA gyrase 
supercoiling activity using the triplex assay, supercoiling would be assayed with 
DNA gyrase between 2 and 20 nM in triplicate, and the amount of enzyme 
corresponding to one unit can then be extrapolated from a linear regression of 
these data. 
9. The assay can be carried out with less DNA (e.g. 0.75 μg) and correspondingly 
less enzyme. The enzyme should be added to the reaction mix last. It is possible 
to make a Master Mix of water, Gyrase Supercoiling buffer and relaxed pNO1, 
which is then aliquoted into the microtitre plate wells. The enzyme is then added 
to bring the volume to 30 μl and start the reaction. 
10. A larger reaction volume (60 μl) is suggested here for performing the screen 
since although it uses more materials, it can give more consistent results. When 
designing the screen, the first and last column of each plate should be reserved 
for negative controls (substrate plasmid in identical buffer conditions to sample 
wells but lacking compounds and enzyme) and positive controls (substrate 
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plasmid in identical buffer conditions to sample wells including enzyme but 
without compounds). It is advisable to perform the screen in duplicate to ensure 
confidence in the results. 
11. It is advisable to make both DNA and Enzyme Mixes as single stocks for the 
entire screen; these can be frozen at -20°C in appropriately-sized aliquots if 
necessary. However, the reconstituted DNA gyrase should only be added to the 
Enzyme Mix immediately before use, since repeated freeze/thaw cycles and 
storage at low concentrations can result in loss of activity. The amount of each 
mix required should be calculated on the number of wells required, plus ten 
percent to allow for reservoir dead volume. 
12. Using the protocol provided, 1 mL of streptavidin coated agarose beads with the 
TFO1 oligo immobilized on them can capture ~0.2 mg of supercoiled plasmid. 
By re-circulating the flow-through after elution of the bound plasmid, more 
plasmid can be captured. We have found that five such rounds of elution/re-
circulation result in a yield of ~60% with high purity. Higher yields may be 
obtainable with a matrix with a larger pore size (since it is theorised that 
plasmids are too large to gain access to the binding sites within the pores of 4% 
agarose), larger column volumes or with automated pumping. 
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Figures and Tables 
 
Name Sequence (5'-3') 5' Modification 
TFO1 TCTCTCTCTCTCTCTC Biotin 
TFO1W TCGGAGAGAGAGAGAGAGAG  
TFO1C CCGATCTCTCTCTCTCTCTC  
Table 1: Oligonucleotides used in the high-throughput assay 
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Fig. 1: A. Sample agarose gel assay for increasing units of DNA gyrase with 
a cartoon representation of its equivalence in the high-throughput 
assay. Conversion of relaxed to supercoiled DNA increases the 
amount of DNA retained in the well due to triplex formation and 
subsequently the intensity of the fluorescent signal after SBYR Gold 
staining. B. Sample data for a DNA gyrase inhibitor screen, 
performed in duplicate in a 96-well plate. Each bar represents the 
percentage inhibition of a single compound, calculated from the 
negative and positive controls for enzyme activity (of which there 
were sixteen repeats each). The dotted line denotes the hit threshold, 
as calculated from the standard deviation of the controls. Most of the 
compounds fall well below this threshold whilst three are clearly 
above it. 
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7.2 Screening data 
Below are the plate-by-plate results of the E. coli DNA gyrase and M. mazei 
topo VI screens. Negative control (Neg. control) refers to wells with relaxed 
DNA and no enzyme whilst Positive control (Pos. control) refers to wells 
with DNA and enzyme but no test compound. The values for the controls 
represent the average of 16 repeats, with the error bars calculated from 
their standard deviation. The results for the samples are arranged by plate 
row and column, and represent the average of two repeats. Compounds of 
interest have been annotated. The dotted line indicates the hit threshold. 
7.2.1 E. coli DNA gyrase screen 
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7.2.2 M. mazei topoisomerase VI screen 
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